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Introduction  
 
Flavonoids, probably the most widespread group of polyphenolic secondary metabolites in the 
Plant Kingdom, have long been recognized to play an important role in the prevention and/or 
treatment of many pathological conditions [1] [2]. Their chemical structure allows these 
compounds to participate in various redox reactions, including free radical scavenging, while 
due to their typically phenolic characteristics they can also specifically interact with several 
biochemical processes [3]. The common belief, which considers flavonoids in general as 
beneficial and healthy-to-consume plant metabolites, is certainly based on a large body of 
scientific evidence. Most common members of this compound family are present in fruits and 
vegetables, and they even have been suggested to be vitamins (vitamin P, coming from 
‘‘permeability’’) by the group of the Nobel-laureate Albert Szent-Györgyi [4] . Although they 
finally withdrew this theory, nowadays, more than 75 years later the most typical dietary 
flavonoids have a generally positive impact on human health. One has to note, however, that 
several classes of flavonoids can exert well defined, specific, sometimes strong bioactivities: 
isoflavones and prenylflavones are for example well known from their phytoestrogenic effect 
[5], and certain methoxylated flavones have been identified as potent antiviral agents [6], [3]. 
Many studies have suggested that flavonoids exhibit different biological effects, including 
antioxidant, anti-inflammatory, antiallergic, cytotoxic and antitumor activities. The work 
presented in this Thesis focuses on a rather unusual flavonoid group: protoflavonoids. 
1.1. Protoflavonoids – chemistry and occurrence in Nature 
Protoflavonoids are unusual natural flavonoid derivatives bearing a non-aromatic B-ring and a 
hydroxyl group in the C-1′ position. Several further substituents can be present on the B-ring, 
but a 4′-oxo group, forming a p-quinol ring (that can be partially or fully saturated) is rather 
typical. The nomenclature of these compounds has had some ambiguity in the past. For 
example, the first flavonoid derivative named with a “proto”- prefix, protofarrerol (see below), 
was in fact the 4′,5′-dihydro derivative of what we would call today the protoflavanone analog 
of farrerol (6,8-dimethylnaringenin), and, accordingly, dihydroprotofarrerol has a fully 
saturated B-ring. Herein we will use a nomenclature that appears to be more and more generally 
accepted for the trivial names of protoflavonoids. A protoflavone is named based on the trivial 
name of the corresponding 4'-hydroxyflavone in a way that a “proto-” prefix is added in case a 
4'-hydroxy group is present (as in protogenkwanin), and an additional “-one” ending shows if 
it has been oxidized to an oxo group (as in protogenkwanone). Accordingly, protoflavonoids 
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with a 2,3-saturated basic skeleton are categorized as protoflavanones. This classification is 
presented in Fig. 1. 
 
Figure 1. Types of protoflavonoid basic skeletons in comparison with that of a flavone 
The first protoflavonoid, the protoflavanone type protofarrerol (22)1 and dihydroprotofarrerol 
(26), were isolated from Leptorumohra miqueliana (Aspidiaceae) by Japanese scientists in the 
late 1960s, [7] [8] [9] ;  and the 7-O-β-D-glucoside derivative of protofarrerol (23) was isolated 
from Monachosorum henryi (Pteridaceae) [10]. Further three protoflavanone derivatives were 
isolated from a Western African medicinal plant (Ongokea gore)  [11], and, most recently, two 
more from a Piperaceae species, Piper carniconnectivum [12]. 
The first protoflavone was isolated from the fertile sprouts of Equisetum arvense and 
called protogenkwanin 4'-glucoside (14) [13]. This was soon followed by reporting the isolation 
of its aglycone, protogenkwanin (13), from the same source [14]. The two hydroxyl groups of 
this compound on the B ring at positions 1' and 4' were found to be trans oriented by means of 
X-ray crystallography (15), and similar orientation was found both for the partially [16] and the 
completely saturated B ring containing protogenkwanin analogs [17]. On the other hand, 
existence of the 1',4'-cis form in the dihydroprotogenkwanin series was also argued by Pouny 
et al. (2011) [18]. Structures of the known natural protoflavones are shown in Figure 2. ; 
occurrence of these compounds in plant species is summarized in Table 1 Although the 
biosynthesis of these compounds has not been investigated, a possible way for their production 
was suggested from the corresponding 4'-hydroxyflavone (i.e. apigenin or genkwanin) by 
oxidation. This step would then be followed by reduction of the 4'-oxo group and/or saturation 
of either one or both double bond(s) in the already non-aromatic B-ring [19]. Interestingly, the 
formation of derivatives with further hydroxylation on a partially saturated B-ring seems to 
                                                 
1 As a compromise, a chemical logic was followed in numbering the protoflavonoids (see Fig. 2, page 8) rather 
than considering appearance in the text (i.e. the order of discovery). Accordingly, the best-studied protoflavone 
(protoapigenone), which also served as the „archetype” of many of our compounds, was named as compound 1, 
leading to the not-in-order appearance of compound numbers within the text. 
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occur via a non-specific way: 2'-hydroxy-2',3'-dihydroprotoapigenone (3) was isolated from 
Equisetum fluviatile as a racemate [18], and both enantiomers were also found to be present in 
Thelypteris torresiana [20]; [21]. The possible role of non-specific oxidative processes in the 
formation of protoflavones is also highlighted by a recent study reporting the first protoflavone 
derivative of an isoflavone, daidzeine. Interestingly, this compound, protodaidzeone, was 
obtained by the chlorophyll-catalyzed oxidation of daidzeine upon exposure with visible light 
[22]; similar processes can certainly take place also in living plants. 
As per the above, it is not surprising that protoflavonoids have recently been reported also from 
plant species other than ferns, namely from Apium graveolens  [23] and Piper carniconnectivum 
[24]. Accordingly, there seems to be a high chance that similar compounds can be found in 
several further plant species containing high amounts of flavonoids. Structures of the known 
natural protoflavonoids are presented in Fig. 2, their respective sources are given in Table 1. 
 
Figure 2. Structures of natural protoflavones (1-20) and protoflavanones (21-30) isolated from 
plants. 
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Table 1. Occurrence of protoflavones in plants 
Plant Species Protoflavones and protoflavanones identified a Reference 
Ferns   
Equisetum arvense protogenkwanin 4'-O-β-D-glucoside (14) (25) 
protogenkwanin (13) (26) 
Pseudophegopteris 
hirtirachis 
protogenkwanone (2); tetrahydroprotogenkwanone (10); tetrahydroprotogenkwanin 
(19); protogenkwanin 4'-O-β-D-glucoside (14) 
(17) 
Pseudophegopteris 
subaurita 
protogenkwanone (2); tetrahydroprotogenkwanone (10); protogenkwanin 4'-O-β-D-
glucoside (14); protogenkwanin 4'-O-(2-O-acetyl)-β-D-glucoside (15); 
protogenkwanin 4'-O-(6-O-acetyl)-β-D-glucoside (16) 
(17) 
Pseudophegopteris 
bukoensis 
protogenkwanin 4'-O-β-D-glucoside (14); protogenkwanin 4'-O-(2-O-acetyl)-β-D-
glucoside (15); protogenkwanin 4'-O-(6-O-acetyl)-β-D-glucoside (16) 
(17) 
Equisetum fluviatile protoapigenin 4'-O-β-D-glucoside (12) (27) 
2',3'-dihydroprotogenkwanone (6); (+/-)2'-hydroxy-2',3'-dihydroprotoapigenoneb (3) (18) 
Equisetum debile protoapigenone (1) (18) 
Cyclosorus falcilobus protoapigenin (11); protoapigenin 4'-O-β-D-glucoside (12) (18) 
Cyclosorus parasiticus protoapigenone (1) (18) 
Phegopteris decursive-
pinnata 
protogenkwanone (2); 5',6'-dihydroprotogenkwanone (6);  (18) 
Phegopteris connectilis 5',6'-dihydroprotogenkwanin (8) (16) 
Thelypteris or 
Macrothelypteris 
torresianac 
protoapigenin (11); protoapigenin 4'-O-β-D-glucoside (12); protoapigenone (1); 2'-
methoxy-2',3'-dihydroprotoapigenone (4) 
(28) 
flavotorresin (20) (19) 
2'-hydroxy-2',3'-dihydroprotoapigenone acetonide (7) (29) 
2',6'-dimethoxy-tetrahydroprotoapigenone (9) (30) 
tetrahydroprotoapigenine (17); (+)2'-hydroxy-2',3'-dihydroprotoapigenone (3)b (20) 
(-)2'-hydroxy-2',3'-dihydroprotoapigenone (3) (21) 
Macrothelypteris 
oligophlebia 
protoapigenone (1); protoapigenin 4'-O-β-D-glucoside (12) (31) 
Macrothelypteris 
viridifrons 
protoapigenone (1); protoapigenin (11); protoapigenin 4'-O-β-D-glucoside (12); 2'-
hydroxy-2',3'-dihydroprotoapigenone acetonide (7); 2',6'-dimethoxy-
tetrahydroprotoapigenone (9) 
(32) 
7-ethoxy-2'-hydroxy-2',3'-dihydroprotoapigenone (5) (33) 
tetrahydroprotoapigenin (17); tetrahydroprotoapigenin 4'-O-β-D-glucoside (18); 2'-
hydroxy-2',3'-dihydroprotoapigenone (3); 2'-methoxy-2',3'-dihydroprotoapigenone (4) 
(34) 
Ongokea gore (2S)- 
ongokein-4’-one (25), (2S)-4’,4’-dimethoxy-ongokein (27), 
(2S)-cis-4’-hydroxy-ongokein (28), and (2S)-trans-4’-hydroxy-ongokein (29). 
(36) 
Leptorumohra 
miqueliana 
protofarrerol (22) (8) 
dihydroprotofarrerol (26) (7) 
Monachosorum henryi protofarrerol  7-O-β-D-glucopyranoside (23) (10) 
Steganotaenia 
araliacea 
protosteganoflavanone (30) (37) 
Other Species   
Apium graveolens protoapigenin 4'-O-β-D-glucoside (12) (23) 
Piper carniconnectivum 
C. DC. 
5,4'-Dihydroxy-6,7-dimethoxy-dihydroprotoflavanone (21)  
5,4',2’-Dihydroxy-6,7-dimethoxy-tetrahydroprotoflavanone (24) 
(35) 
a Several compounds listed in this table were reported with their IUPAC names; for a more clear interpretation                                                
here they are presented according to the nomenclature described above 
b OH or OCH3 groups present at C-20 in derivatives with partially saturated B-ring are cis to the 10-OH group 
c Depending on the botanical definition of Thelypteridaceae, the species can be assigned to different genera; both     
names were used in protoflavone related publications  
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1.2. Bioactivity of protoflavones 
Anticancer activity 
In several cases, the isolation of new natural protoflavones was reported together with 
bioactivity data, typically concerning their in vitro cytotoxic or anti-proliferative activity 
against various cancer cell lines. To date, however, protoapigenone (1) is by far the most deeply 
studied protoflavone. This compound and a number of its analogs were shown to exert strong 
cytotoxic activity in a wide variety of cancer cells including breast, ovarian, cervical, prostate, 
lung, liver, etc. ( [28] [19] [38] [39] [40] [41] [42]. Chang and co-authors also showed that 
protoapigenone (1) exerted strong cytotoxicity on ovarian cancer cell lines MDAH-2774 and 
SKOV3 but not on immortalized non-cancer ovarian epithelial cells [39]. Moreover, several 
studies showed that this compound induces apoptosis both in vitro and in vivo, without 
significantly damaging healthy tissues in the latter case [39] [40] [43].  
The mechanism of the anticancer activity 
Concerning the mechanism of action, several pathways were found to be involved in the 
anticancer activity of protoflavones, and mainly of protoapigenone (1) 
Based on the chemical structure of the p-quinol B ring, protoflavones seem to be capable for 
participating in various redox reactions. Indeed, apoptosis induced by protoapigenone (1) and 
other synthetic analogs were shown to be correlated with the induction of oxidative stress within 
the cancer cells by generating reactive oxygen species (ROS) [44] [53] [33] [21]. In connection 
to this, inhibition of the enzyme glutathione S-transferase π was also observed, even though it 
is still to be determined if this was a direct effect on the enzyme or rather a result of the increase 
in ROS within the cell [53]. Studies on breast cancer cells showed that protoapigenone 
treatment led to increased levels of ROS, required for activation of MAPK involved in the 
mitochondria-mediated apoptosis induced by this compound [53]. Similar observations were 
made when other protoflavonoids, WYC0209 [44], DHEC [34] and DEDC [21] were tested for 
their apoptotic effect on DU145 postate cancer, human colon HT-29 cancer and human 
neuroblastoma SH-SY5Y cell lines, respectively. In fact, WYC0209 was shown to increase 
intracellular generation of ROS, followed by DNA damage induction and activation of 
Chk1/Chk2 which led to cell cycle arrest at S and G2/M phases [44], and resulted in a stronger 
cytotoxic effect than that of protoapigenone (1) [39] . Due to the important role of ROS in the 
activity of protoflavones, it is currently hard to make a sound judgment on which of the 
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previously mentioned pathways are subject to specific changes and which would be non-
specifically affected by the oxidative stress; further research will be necessary to clarify this. 
DNA damage in lung [41] and prostate cancer cell lines [44] treated by protoapigenone or one 
of its synthetic analogs (WYC0209, see Fig. 3; page 13) was also observed. Damage of DNA 
is an important and frequent outcome during cancer treatment. In fact, inhibition of DNA 
damage response mechanisms is an attracting novel target for enhancing tumor 
chemosensitivity [45] [46]. Remarkably, a recent study showed that protoapigenone (1) and 
WYC0209 can significantly interact with the ATR-dependent signaling pathways by inhibiting 
the phosphorylation of Chk2 and Chk1 kinases [43] that play a crucial role in DNA damage 
response [47]. According to this, it was shown that these protoflavones themselves apparently 
do not directly damage DNA, the underlying mechanism is rather a specific inhibition of its 
repair. As expected, this inhibition could effectively sensitize the cancer cells to the DNA 
damaging anticancer drug cisplatin, resulting in significantly stronger combined activities as 
compared to those of the compounds administered alone [43]. These results suggest that future 
development of protoflavones might reasonably be re-directed towards the optimization of this 
highly promising chemo-sensitizing activity, in order to obtain valuable new options for 
combination chemotherapy. The synthetic WYC0209 deserves particular attention; this 
compound was as much as 10 times stronger than protoapigenone (1) in some of the 
aforementioned activities. 
 Apoptosis induction was shown to be mitogen-activated protein kinase (MAPK)-dependent in 
both human prostate [39] and breast cancer cells [44], also involving the activation of c-Jun 
NH2-Terminal Kinase (JNK). Related apoptotic pathways were also identified using ovarian 
cancer cell lines [40]: activation of caspase-3, cleavage of PARP and decreasing of Bcl-xL and 
Bcl-2 protein levels were found, accompanied by membrane alterations and nuclear 
fragmentations at different stages of the cell cycle. Protoapigenone (1) was also shown to 
interfere with the cell cycle inducing its arrest at S and G2/M phases [39] [40] [41] Both in 
human ovarian [39] and prostate cancer cells [40], the cell cycle arrest was correlated with 
alterations in the expression level of Cdk2, Cyclin B1 and Cdc25C, well known cell cycle 
regulators that actually lead to a higher cytotoxic effect of protoapigenone (1) at this stages of 
the cell cycle. In human breast cancer cells [44]  loss of the mitochondrial membrane potential 
was also observed and linked with the persistent activation of MAPK upon treatment with 
protoapigenone (1). 
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Other Bioactivities 
Protoapigenone (1) was shown to inhibit the expression of Epstein-Barr virus (EBV) lytic 
proteins in P3HR1 cells, preventing EBV lytic proliferation at doses well below those which 
exerted cytotoxic activity on the host cells [54]. This study also showed that the use of 
protoflavones is not limited to their anticancer activity; these flavonoids apparently represent a 
class of bioactive compounds with several further potential effects yet to be discovered. 
1.3. Synthesis of protoflavones 
The first total synthetic procedure of protoflavones was reported by Lin et al. in 2007 [38]. 
Protoapigenone and several synthetic protoflavones were synthetized by the Taiwanese 
research group as potential antitumor agents. After difficulties in carrying out the direct 
semisynthesis of 1 from apigenin, methoxymethyl-diprotected trihydroxyacetophenones and 4-
benzyloxybenzaldehyde as starting materials were utilized to prevent the A-ring of 2 from 
oxidation, and, after removal of the benzyl protecting group by catalytic hydrogenation, 
oxidative de-aromatization was performed by [bis(trifluoroacetoxy)iodo]benzene (commonly 
referred to as PIFA) in the presence of 0.2 eq. of TEMPO, a commercially available free radical 
catalyst in order to obtain the p-quinol moiety on the B-ring. Finally, 1 was successfully 
obtained after the removal of the methoxymethyl protecting group. The procedure was very 
long and required chromatographic purification at nearly all steps, resulting in as low as 3.3% 
final isolated yield of 1. Scheme 1 shows an outline of this procedure, including reaction times 
and isolated yields of each reaction step. 
Scheme 1. Total synthesis of protoapigenone reported by Lin et al. [28] 
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Scheme 2. Semi synthesis of protoapigenone and its 1-O-alkyl ethers reported by Hunyadi et 
al. [42] 
Despite the difficulties in the total synthesis of 1, the above-referred work also led to the 
discovery of a synthetic derivative much stronger than protoapigenone, WYC0209 [38]. This 
compound, originated from 4'-hydroxy-β-naphthoflavone, was considered as one of the most 
promising lead for further development. Following this, and mostly parallel to the work 
presented here, rational drug design led to the development of related derivatives containing 
various O-linked substituents on the naphthyl ring condensed with the flavonoid skeleton. 
Several of these compounds, and particularly one containing an O-tetrahydrogeranyl moiety, 
were designed and confirmed as both strong cytotoxic agents and potent inhibitors of 
glutathione S-transferase Ω 1 [55] [56]. 
Attempting to find the minimum pharmacophore of protoflavonoids, another research group 
performed the total synthesis of an analog (RY10-4) consisting of the B and C ring of 
protoapigenone. Similarly to the above-mentioned synthetic efforts, the six steps procedure was 
finished with an oxidative de-aromatization catalyzed by PIFA in a solvent mixture of 
acetonitrile and water. Based on their results, the authors concluded that the flavonoid A-ring 
is not necessary for the anticancer effects of protoflavones. An overview of the synthetic 
analogs of protoflavonoids is presented in Fig. 3. 
  
Figure 3. Structures of synthetic protoflavonoid analogs prepared by others 
WYC0209
R: CH3, Ac, Pr, MOM,
RY10-4 Protodaidzeone
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1.4. Direct preliminaries of the PhD work 
As a direct antecedent of the work described here, an optimization of the critical step of the 
total synthesis, namely the oxidative de-aromatization of the B-ring was attempted by A. 
Hunyadi, supervisor of my doctoral studies. During this work, it has been revealed that a semi-
synthetic preparation of protoapigenone (1) is also possible directly from apigenin [42], by 
using PIFA as oxidant and by keeping the concentration of apigenin at a maximum of 1 mg/mL 
in acetonitrile – water (9:1, v/v). This finding allowed a fast and economic synthesis of 1 up to 
the gram scale, representing a breakthrough in studying the bioactivity of this interesting 
flavonoid. Moreover, with the preparation of a set of 1′-alkoxyprotoflavones (Fig. 4), important 
new structure-activity relationships were also revealed. Previously, the presence of a symmetric 
and non-substituted p-quinol B-ring was thought to be an absolute need for a strong pro-
apoptotic activity. Indeed, neither of the partly or completely saturated or the 4'-hydroxy 
compounds, nor the 1′-methoxylated synthetic analogs were found before as potent in this 
regard as protoapigenone (1) [28];  [38]; [20] ; [18]; [33]. In contrast with this, however, when 
a longer, non-branching aliphatic side-chain (n-propyl or n-butyl) was introduced at C-1′ 
instead of a methoxy group, an equivalent or even increased cytotoxic activity was found as 
compared to that of 1 [42].  
 
Figure 4. 1-O’-alkylprotoflavones prepared as direct preliminaries of this work 
At the beginning of my PhD studies I had the chance to be partially involved in this work, which 
then served as the head-start for the studies described hereinafter. 
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2. Objectives 
 
As per the above, the following objectives were set up for this work. 
1. As a primary aim of the work, to prepare new A-ring modified synthetic protoflavones and 
their 1′-O-alkoxy derivatives. 
2. To perform an in vitro and in silico study on the potential formation of protoapigenone (1) 
upon ROS scavenging by apigenin. 
3. To test the cytotoxicity of the newly prepared compounds and to extend related structure-
activity relationships, with a strong focus on multi-drug resistant cancer. 
4. To search for other potential bioactivities of these compounds, which are not related to the 
cytotoxic effect. 
3. Materials and methods 
 
3.1. Reagents and starting materials 
Commercially available 4′-hydroxyflavones (4´-hydroxy-6-methylflavone, 4´-hydroxy-6-
methoxyflavone, 4´-hydroxy-β-naphthoflavone) were purchased from Indofine Chemical 
Company, Inc. (Hillsborough USA). Chemicals were obtained from Aldrich, Inc. (USA). 
Solvents of HPLC grade were from Merck (Darmstadt, Germany). Solvents of analytical grade 
were obtained from Molar (Halásztelek, Hungary). 
3.2. General experimental procedures 
3.2.1. Synthesis 
Synthesis of 5´-ethyl- and 5´-pentyl-2´-hydroxyacetophenone (48 and 49). In the first step, 
4-ethyl- and 4-pentylphenol acetate (46 and 47, respectively) were synthesized by adding 0.1 
mol (10.2 g) of acetic anhydride and one drop of ccH2SO4 to 0.1 mol of 4-ethyl or 4-
pentylphenol and stirring at room temperature for 20 min. The mixture was then poured into 
water and extracted with 3 x 50 ml EtOAc. The organic layer was evaporated under reduced 
pressure, re-dissolved in CH2Cl2 and crystallized anhydrous AlCl3 was added little by little 
under ice bed cooling. The mixture was refluxed for 10 h, then the reaction was stopped by 
adding crushed ice. After filtration, the precipitate was purified on silica to obtain (48) or (49). 
General Procedure for chalchone synthesis. The 5´-substituted 2´-hydroxyacetophenone (48-
51) and 4-benzyloxybenzaldehyde (3.0 g, 14.3 mmol) were dissolved in 50% EtOH, KOH/H2O 
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solution (20 mL). The reaction was stirred at r.t. for 30 h, and then the solvent was evaporated 
under reduced pressure. The mixture was purified on silica gel (isocratic elution, n-
hexane/EtOAc, 6:1) to afford (52-55), respectively. 
General Procedure for Flavone synthesis. 3 mmol of chalchone (52-55) was dissolved in 
DMSO (5 mL), and 1 eq. iodine (76 mg, 0.3 mmol) was added. The solution mixture was stirred 
and heated to 110 °C. After 2 h, 10% Na2S2O3 (50 mL) was added to remove iodine. The 
mixture was extracted with EtOAc (3 X 50 mL) and then purified by column chromatography 
on silica gel to afford compounds 49-52, respectively. 
Synthesis of compound (53) from (52) via Suzuki-coupling. Compound (52) (407.26 mg, 1.0 
mmol), 1.2 eq. phenylboronic acid (146.3 mg, 1.2 mmol) and 2 eq. (276.42mg, 2.0 mmol) 
K2CO3 were dissolved in 7 mL of water, and 25 mL of propanol and 5 mmol of 
Tetrakis(triphenylphosphine)palladium(0) were subsequently added. The reaction was 
performed under N2 gas at 40ºC, to afford (53) as a yellow solid. 
General Procedure for Benzyl Group Removal. A mixture of 0.5 mmol of the 4´-
benzyloxyflavone (49-53), dry Pd/C (10%, 106 mg), and 20 mL of EtOAc was stirred at 25 °C 
under an atmosphere of hydrogen for 10 h. The mixture was filtered, washed with EtOAc, 
concentrated under vacuum and purified by column chromatography on silica gel to afford 
compounds (54-58), respectively. 
General procedure for protoflavone synthesis from 4´-hydroxyflavones. Apigenin, 
genkwanin, 4´-hydroxy-6-methylflavone, 4´-hydroxy-6-methoxyflavone, 4´-hydroxy-β-
naphthoflavone (Indofine, Hillsborough, NJ, USA), or the synthesized 4´-hydroxyflavone (61-
65) was dissolved at 1 mg/mL concentration in a 9:1 v/v ratio mixture of acetonitrile and water 
or the alcohol to be coupled at position C-1´. Two equivalents of 
[bis(trifluoroacetoxy)iodo]benzene were added to the mixture. After stirring at 80 °C for 1 hour, 
the mixture was cooled down, evaporated under reduced pressure and purified by flash 
chromatography to obtain the pure compounds  . 
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3.2.2. Chromatographic techniques 
Thin-layer chromatography (TLC) 
Normal-phase (NP) TLC analyses were performed on Silica gel 60 F254 and reversed-phase (RP) 
TLC on Silica gel 60 RP-18 F254S (E. Merck, Darmstadt, Germany) plates. The plates were 
developed by an ascending technique in a glass chamber (Desaga, Heidelberg, Germany) at 
room temperature. The following NP- and RP-TLC solvent systems were utilized: NP-TLC1: 
hexane-ethyl acetate (90:10, v/v); NP-TLC2: hexane-ethyl acetate (70:30, v/v); NP-TLC3: 
hexane-ethyl acetate (50:50, v/v); NP-TLC4: hexane-ethyl acetate (30:70, v/v); RP-TLC1: 
acetonitrile-water (35:65, v/v); RP-TLC2: methanol-water (60:40, v/v); RP-TLC3: methanol-
water (30:60, v/v); RP-TLC4: tetrahydrofuran-water (50:50, v/v). 
Rotation Planar chromatography (RPC) 
Compounds were purified by rotation planar chromatography on a Chromatothron equipment 
(Harrison Research, USA). The stationary phase for RPC was silica gel 60 GF254. The following 
mobile phases were utilized. 
RPC1: n-hexane/ethyl acetate (11:3, v/v); RPC2: n-hexane/ethyl acetat (9:1, v/v); RPC3: n-
hexane/ethyl acetat (8:2, v/v); RPC4: n-hexane/ethyl acetat (6:3, v/v); RPC5: chloroform-
methanol (97:3, v/v). 
High-perfomance liquid chromatography (HPLC)  
HPLC analyses were performed by a gradient HPLC system of two Jasco PU-2080 pumps 
coupled to a Jasco MD-2010 Plus diode-array detector (DAD) controlled by the ChromNAV 
chromatographic software. The following normal- (NP) and reverse-phase (RP) HPLC columns 
were utilized: 
Analytical - NP-HPLC1: Zorbax-SIL column (5 µm, 250 x 4.6 mm) (DuPont, Paris, France); 
RP-HPLC1: Zorbax SB C18 (5µm, 250 x 4.6 mm) (DuPont, Paris, France); Semi-preparative 
- RP-HPLC2: Zorbax SB C18 (5µm, 250 x 9.4 mm) (DuPont, Paris, France); RP-HPLC3: 
Gemini-NX C18 (5µm, 250 x 10 mm) (Phenomenex, USA). 
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Flash chromatography 
Flash Chromatography (FC) was performed on a Combiflash Rf+ equipment (TELEDYNE 
Isco, USA) on RediSep normal-phase 24 g silica disposable flash columns (40-60 μm; Teledyne 
Isco, USA). The following solvent systems were utilized:  
NP-FC1: Gradient system was 0% Ethyl acetate gradually increasing to 100% in 30 min at a 
flow rate of 30 mL/min; NP-FC2: Gradient system was 0% Methanol gradually increasing to 
5% in 25 min at flow rate of 30 mL/min. 
Centrifugal Partition Chromatography (CPC) 
Centrifugal Partition Chromatography were carried on an Armen SCPC-250-F equipment 
(Armen Instrument, France). The following biphasic solvent systems were utilized: 
CPC1: hexane-ethyl acetate-methanol-water (7:3:7:3, v/v/v/v); CPC2: hexane-ethyl acetate-
methanol-water (6:4:6:4, v/v/v/v) 
Capillary zone electrophoresis (CE) 
Aiming to study the apigenin-protoapigenone transformation during the Fenton reaction, 
capillary zone electrophoresis was performed in collaboration. An Agilent Capillary 
Electrophoresis 3DCE system (Agilent Technologies, Waldbronn, Germany) was used, applying 
bare fused silica capillary having a 64.5 cm total and 56 cm effective length with 50 μm I.D, 
and with a bubble cell detection window (Agilent Technologies, Santa Clara, CA, USA). On-
line absorption at 230 nm and 340 nm was monitored by DAD UV-Vis detector. The capillary 
thermostat was set for 25°C. Between measurements, the capillary was rinsed subsequently 
with 0.1 M HCl, 1.0 M NaOH, 0.1 M NaOH and distilled water for 3 minutes each, and with 
BGE (50 mM sodium tetraborate (pH 9.3) for 5 minutes. Samples were injected by 5×103 Pa 
pressure for 6 sec. Runs were performed in the positive-polarity mode with 27 kV. 
3.2.3. Structure elucidation 
Structure elucidation was carried out by means of nuclear magnetic resonance (NMR) 
spectroscopy and mass spectroscopy (MS). NMR spectra were obtained on a Varian Gemini-
2000 200 MHz or Bruker Avance DRX-500 NMR spectrometer in chloroform-d1, methanol-
d4, acetone-d6, or dimethyl sulfoxide-d6. Mass spectra were taken on an API 2000 triple-
quadrupole (Ab Sciex, USA) or LCMS-IT-TOF (Shimadzu, Japan) with and ESI interface. 
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3.2.4. In silico studies on the formation of protoapigenone from apigenin 
Calculations were achieved in the Gaussian09 software within the DFT (Density Functional 
Theory) formalism. Results were obtained on Intel Xeon Sandy Bridge E5-2620 (CAlcul en 
LImousin, Université de Limoges, Limoges, France). The B3P86 functional was chosen as it 
has shown a very good agreement between theoretical and experimental values of bond 
dissociation enthalpies (BDE). For the phenolic group O-H bond dissociation enthalpies (BDE), 
were calculated as the difference between Fl-OH (the flavonoid) and Fl-O˙+ H˙ (the 
corresponding radicals formed after H-atom abstraction (HAT) from Fl-OH to the free radical. 
The effect of solvent was taken into account by using the integral-equation-formalism 
polarizable continuum model (IEF-PCM). 
3.2.5. Experimental studies on the apigenin-protoapigenone transformation 
10 mg of apigenin was dissolved in 10 ml 50% aqueous MeOH, and the pH was adjusted to 
pH=4 by using H2SO4. 1.02 mg iron catalyst (FeSO4 · 7H2O) was added, followed by the 
slow addition of 0.11 ml of 30% H2O2. After 60 minutes the reaction mixture was purified by 
using SPE on C18 stationary phase, and investigated by HPLC. 
3.2.6. Bioassays 
Cell lines. 
 L5178 mouse T-cell lymphoma cell line (ECACC catalog no. 87111908, U.S. FDA, Silver 
Spring, MD, U.S.), and its sub-cell line L5178B1, derived from L5178 by transfection with pHa 
MDR1/A retrovirus (57), were cultured in McCoy’s 5A media supplemented inactivated horse 
serum. L5178B1 cell line was selected by culturing the infected cells with 60 μg/L colchicine 
(Sigma). Breast cancer cell lines MCF7 and its sub-cell line obtained by adaptation to 
doxorubicin, MCF7Dox (58) were cultured in EMEM media supplemented with non-essential 
amino acids, 1mM Na-pyruvate and 10% inactivated fetal bovine serum (MCF7Dox was cultured 
in presence of 1 μM of doxorubicin each third passage). All cells were cultured at 37°C and 5% 
CO2; all media contained Nystatin, 2 mM of L-glutamine, 100U of penicillin and 0.1mg of 
streptomycin, purchased from Sigma. MES-SA human uterine sarcoma cell line and the 
doxorubicin selected MES-SA/Dx5 were obtained from ATCC. The human cervix carcinoma 
cell line KB-3-1 and its vinblastine selected derivative KB-V1 were a kind gift from Dr. 
Michael M. Gottesman (National Institutes of Health). A431 and the retrovirally transduced 
A431B1 and A431G2 are human skin-derived, epidermoid carcinoma cells were kind gifts from 
Dr. K. Német. MES-SA, KB-3-1, A431 and their derivative cell lines were maintained in 
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DMEM completed with 10% FBS, 5 mM glutamine and 50 units/mL penicillin and 
streptomycin (Life Technologies). 
Cytotoxicity assays. 
In case of mouse lymphoma cell lines, 2x104 cells per well were cultured in 96-wells 
microplates with different concentrations of the tested compound, in McCoy’s 5A media, at 
37ºC and 5% CO2, for 24h. With respect to the MCF-7 and MCF-7Dox, 1x104 cells per well 
were seeded overnight and serial dilutions of the compounds were added the following day and 
incubated for 48h. In all cases, after the incubation time, 10% MTT was added to each well and 
incubated for 4h, when SDS was added to the medium. Results were read after o/n incubation. 
Fifty per cent inhibitory concentrations (IC50) were calculated using nonlinear regression curve 
fitting of log (inhibitor) versus normalized response with a variable slope and least squares 
(ordinary) fit of GraphPad Prism 5 software, for three independent samples. 
In the case of A431 cell lines, MES-SA cell lines, KB-3-1 and KB-V1 cell lines, 5x103 cells 
per well were cultured and incubated overnight in 96-well microplates. Serially diluted drugs 
were then added, and plates were incubated for additional 72 hours. Cytotoxicity was measured 
by Presto Blue cell viability reagent (Invitrogen) in a final dilution of 5%. 
FACS measurements 
Calcein-AM uptake assay was performed as described earlier (59). Briefly, 250.000 cells per 
tube were pre-incubated for 5 minutes in the presence of 50 µM verapamil or the test 
protoflavone compounds. Calcein-AM was added at a final concentration of 250 nM and 
incubated for an additional 10 minutes. Samples were then washed with ice-cold PBS and were 
kept on ice until measured by an Attune® Acoustic Focusing Cytometer. The mitoxantrone 
uptake assay was carried out similarly: tariquidar (1µM) was added to the cells for 5 minutes at 
37C (pre-incubation), and Mitoxantrone was added at 4 µM for an additional 20 minutes at 
37C. The reaction was stopped by adding serum-free DMEM; the samples were immediately 
measured by FACS. 
Xanthine oxidase inhibition assay and determination of the binding mode of (44) 
XO inhibition activity for compounds (31-44) and related data for the dose-effect curves for 
(44), apigenin and allopurinol, were obtained by using commercially available XO activity 
assay kit (Sigma-Aldrich Ltd., USA), following the provided protocol.  
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For determination of the binding mode of (44), the following procedure was applied. The 
activity of XO was determined by measuring the production of uric acid, at 290 nm for 3 min 
in 96-well plates, using a FluoSTAR OPTIMA plate reader (BMG LABTECH). The protocol 
was adapted from that recommended by Sigma-Aldrich for a total volume of the assay of 
300 µL. Stock solutions were prepared as follows: 50 mM potassium buffer, pH 7.5; 0.9 mM 
XO, pH 7.5; 1.5, 0.6, 0.3, 0.15 and 0.075 mM solutions of (44) in DMSO; and 0.04 units/mL 
XO enzyme. From the 0.9 mM xanthine solution further stock solutions were prepared with 
concentrations between 7.5 and 600 µM. A 140 µL buffer solution mixed with a 100 µL 
xanthine solution, at the proper concentration, was added to the wells at final concentrations of 
33 mM (buffer) and 2.5-300 µM (xanthine). A 10 µL solution of (44) was added to the 
respective wells, with final concentrations of 2.5, 5, 10 and 20 µM. The final concentration of 
DMSO in the assay did not exceed 3.3% of the total volume. The reaction was initiated by 
automatic addition of 50 µL XO solution (final concentration of 0.006 units/mL). Allopurinol 
was used as a positive control. For each concentration of xanthine, the four concentrations of 
(44) were tested in five replicates. 
Docking study on protoapigenone 1′-O-propargyl ether to the active center of xanthine 
oxidase 
The 3D structure of (44) was optimized prior to docking, by the Gaussian09 (Gaussian Inc., 
Wallingford, USA) software. The DFT (Density Functional Theory) formalism was used with 
the hybrid B3P86 functional that has been shown accurate enough to assess geometrical and 
energetic features of flavonoids. The 6-31+G(d,p) basis set was sufficient to provide a relevant 
geometry. The optimized structure was subsequently used for the docking study. 
The 3NVY structure, representing 3D structure of bovine XO in complex with quercetin, was 
downloaded from www.pdb.org, and used without modification. Docking study was performed 
by using iGEMDOCK 2.1 (BioXGEM, Hsinchu, Taiwan) at default settings for “accurate 
docking”; population size: 800, generations: 80, number of solutions: 10. Ligand binding site 
was defined with a 15 Å radius around the X-ray position of quercetin. Scoring function was 
left at its default settings with equal preferences to hydrophobic and electrostatic interactions. 
Docking was validated by re-docking the “Que” residue into the macromolecule in mol2 format 
in order to allow flexible docking. RMSD calculations, as well as visualization of the ligand-
residue interactions were achieved with Discovery Studio 3. 
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4. Results 
4.1. Synthesis 
Thirty-seven protoflavones and protoflavone 1´-O-alkyl ethers were synthesized from 
commercially available 4′-hydroxyflavones (apigenin, genkwanin, 4´-hydroxy-6-
methylflavone, 4´-hydroxy-6-methoxyflavone and 4´-hydroxy-β-naphthoflavone) by utilizing 
PIFA-mediated oxidative de-aromatization. 20 of these protoflavone derivatives were prepared 
as new compounds (60) [I,II,VII]. 
Scheme 2. Synthesis of protoflavones from commercially available 4´-hydroxyflavonesa 
 
a Reagents: a) CH3CN/ROH 9/1, PIFA (2 eq). 
Total synthesis of a set of various 6-substituted protoflavones was achieved in 4-6 steps [VII]. 
In order to obtain starting materials (i.e. 5´-ethyl-2´-hydroxyacetophenone, (45); and 5´-pentyl-
2´-hydroxyacetophenone; (42) for our 6-ethyl and 6-pentyl substituted target compounds, the 
appropriate p-substituted phenols were acetylated and subjected to Fries-rearrangement 
reaction under the condition of dry AlCl3 in dichloromethane (61). The resulting 2´-
hydroxyacetophenones and those commercially available with a 5´-ethoxy or -bromo 
substituent ((49) and (50), respectively) were utilized in Claisen-Schmidt condensation 
reactions with p-benzyloxybenzaldehyde to yield chalchones (51-54), which, after performing 
ring closure with iodine in DMSO, yielded the corresponding 6-substituted 4´-
benzyloxyflavones (49-50). The 6-bromo substituted compound (58) was subjected to Suzuki 
coupling in order to obtain the corresponding 6-phenylflavone (59). Debenzylation of the 
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flavonoids obtained this way and subsequent oxidative de-aromatization of the flavones (60-
64) with PIFA, as described above, allowed us to obtain the protoflavones with various 
substituents at positions C-6 and C-1´ (65-79). 9 of the protoflavone derivatives were obtained 
as new compounds. Scheme 3 summarizes the total synthetic procedure. 
Scheme 3. Total synthesis of 6-substituted protoflavone derivativesa 
 
a Reagents: a) (CH3CO)2O, cc H2SO4; b) AlCl3; c) EtOH, 4-benzyloxybenzaldehyde, 50% KOH/H2O; d) I2, 
DMSO; e) Phenylboronic acid, K2CO3, Tetrakis(triphenylphosphine)palladium(0); f) 10% Pd-C/H2; g) 
TFA/CH2Cl2, reflux; h) CH3CN/ROH 9/1, PIFA (2 eq). 
4.2. The role of OH radical scavenging in the formation of 1 from apigenin 
The possible formation of protoapigenone (1) from apigenin was first studied in silico, within 
the DFT (Density Functional Theory) formalism. Bond dissociation enthalpies (BDEs) for the 
4′-OH group of apigenin were calculated in the gas phase or by taking into account the effect 
of solvent (see Materials and Methods, page 15). Electron spin density was calculated for the 
resulting phenoxyl radical in order to have a rough estimation on the likelihood for the position 
where an OH radical could possibly attack this intermediate. Results of these calculations, as 
well as those of the thermodynamic analysis are summarized in Scheme 4 and Figure 5. 
Scheme 4. Possible formation of protoapigenone from apigenin upon •OH radical scavenging. 
BDE: bond dissociation enthalpy in vacuum or in solution. 
 
Apigenin Phenoxyl Radical Protoapigenone
•OH
BDE Gas:  87.411 kcal/mol
BDE Sol.:  87.664 kcal/mol
+ H2O
•OH
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Figure 5. A: Spin density map of the 4′-phenoxyl radical of apigenin, indicating that the 
favorable position for the radical is situated at C-1′ that makes this carbon a potential target for 
further scavenging. B: Thermodynamic analysis of the whole process of forming 
protoapigenone from apigenin through OH radical scavenging. 
Based on the above in silico results, it can be stated that, even though the initiating hydrogen 
atom transfer requires a relatively large energy, such a transformation is indeed possible. In 
order to obtain experimental verification or disproof to this hypothesis, Fenton’s reaction was 
performed on apigenin, and the resulting mixture was analyzed by RP-HPLC-DAD after pre-
purification, or CE-UV with a direct injection. The same reaction was also performed on 
protoapigenone, in order to investigate its possible further decomposition within the reaction 
mixture. Furthermore, the possible reduction of protoapigenone to apigenin was studied by 
incubating it with reduced glutathione (GSH) for 24h. Fig. 6 presents the results of these studies. 
 
Figure 6. Studies on the apigenin-protoapigenone-apigenin redox transformation. Ap: 
apigenin, Pa: protoapigenone (1). A: HPLC-DAD fingerprint on the Fenton reaction mixture of 
Ap (black) in comparison with that of 1 (purple). B: CE studies on the decomposition of Ap 
and the formation of 1 over the time of a Fenton reaction. C: CE study on the decomposition of 
1 in a Fenton reaction. D: HPLC chromatograms of 1 before and after a 24h incubation with 
GSH in comparison with that of Ap. 
ΔG (kcal/mol)
Apigenin
+ 2 ˙OH
Protoapigenone
+ H2O
ΔGGas = -9.89
ΔGSol = -7.96
A B
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As seen from the above figure, the formation of 1 from apigenin does take place in the presence 
of excess amounts of OH radicals (i.e. Fenton reaction). Moreover, despite its much faster 
decomposition (complete disappearance after 40 min; see Fig 6C) as compared to that of 
apigenin (still detectable after 180 min; see Fig 6B, left panel), 1 is continuously present over 
the reaction (see Fig 6B, right panel). This strongly suggests that 1 is in fact a major primary 
product forming when apigenin scavenges OH radicals. 
4.3. Anticancer activity 
The cytotoxicity of compounds (Gen, 6Me) were tested in collaboration with the team of Prof. 
Dr. Fang-Rong Chang (Graduate Institute of Natural Products, Kaohsiung Medical University, 
Kaohsiung, Taiwan) on HepG2, Hep3B, A549 and MDA-MB-231 human cancer cell lines [II]; 
results are summarized in Table 2. 
Table 2. The cytotoxicity of protoflavones 81-94 on HepG2, Hep3B, A549 and MDA-MB-231 
human cancer cell lines. Intervals indicate 95% confidence intervals of the IC50 values as 
calculated by GraphPad Prism 5.0; n=3-4; Dox=doxorubicin. 
 IC50 (µM) 
Compound HepG2 Hep3B A549 MDA-MB-231 
Pa 3.07 (2.83–3.34) 1.21 (1.19–1.24) 11.29 (10.07–12.65) 1.35 (1.17–1.55) 
WYC0209 1.06 (1.04–1.08) 0.25 (0.20–0.30) 2.19 (2.03–2.37) 0.43 (0.41–0.45) 
6-OMe 1.86 (1.85-1.88)  0.64 (0.55-0.73)  1.77 (1.50-2.08)  0.70 (0.64-0.77)  
6-OMe 7.65 (7.44-7.87)  1.88 (1.55-2.28)  12.09 (8.95-16.34)  2.08 (1.96-2.22)  
6-OMe 7.27 (7.05-7.50)  1.82 (1.73-1.91)  10.97 (9.24-13.03)  2.09 (1.99-2.20)  
6-OMe 8.69 (8.05-9.38)  1.83 (1.33-2.52)  10.27 (9.49-11.11)  2.20 (2.05-2.36)  
6-OMe >50 >50 >50 >50 
6-OMe 12.27 (11.70-12.87) 0.65 (0.61-0.68)  11.83 (10.16-13.77)  5.13 (4.52-5.84)  
6-OMe 7.85 (7.66-8.04)  1.65 (1.15-2.36)  5.04 (3.48-7.31)  1.87 (1.74-2.01)  
6-Me 2.02 (1.87-2.18)  0.54 (0.53-0.54)  2.00 (1.82-2.19)  0.61 (0.57-0.65)  
6-Me 9.79 (9.23-10.39) 3.18 (2.64-3.83)  15.47 (13.15-18.20)  5.46 (5.12-5.82)  
6-Me 8.61 (8.46-8.77  2.17 (1.78-2.66)  7.35 (6.86-7.88) 3.20 (3.03-3.39)  
6-Me 14.10 (13.08-15.19)  3.75 (3.12-4.50)  13.45 (11.58-15.61)  5.13  (4.93-5.35)  
6-Me 7.47 (7.28-7.65)  3.69 (2.90-4.70)  5.13 (4.92-5.35)  4.85 (4.56-5.16)  
6-Me 11.09 (10.47-11.75)  2.41 (1.54-3.78)  14.57 (12.54-16.92)  4.37  (4.22-4.52)  
6-Me 9.13 (8.88-9.39)  2.03 (1.50-2.75)  15.30 (14.53-16.12)  4.86 (4.74-4.99)  
Dox 0.79 (0.41-1.55) 1.16 (0.91-1.47) 2.19 (1.76-2.73) 2.60 (2.05-3.30) 
 
In order to evaluate the potential of the newly prepared protoflavone derivatives to overcome 
efflux-mediated multi-drug resistance (MDR), further collaborative studies were performed. 
The cytotoxicity of compounds (1, WYC0209, 31-44, 81-100 and 66-74) were tested in 
collaboration with Prof. Dr. Joseph Molnár and Dr. Ana Martins (Department of Medical 
Microbiology and Immunobiology, University of Szeged, Szeged, Hungary), utilizing two non-
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MDR/MDR cancer cell line pairs (parental L5178 mouse lymphoma cells and L5178B1 cells 
engineered to overexpress the human ABCB1 protein, and parental MCF-7 breast cancer cells 
and the doxorubicin resistant derivative MCF-7Dox, overexpressing P-gp) [II,VII]. The fraction 
of IC50 values obtained in P-gp negative vs. positive cells served as a quantification of the MDR 
selective effect (selectivity ratio, SR). Accordingly, SR ≤ 0.5 indicated that the compound is 
subject to P-gp-mediated resistance, whereas SR ≥ 2 suggested that the P-gp expressing cells 
demonstrate collateral sensitivity against the tested protoflavone derivative. A graphical 
interpretation of the MDR selective cytotoxicity of each compound on the above-mentioned 
two susceptible/MDR cell line pairs is presented in Figure 7; detailed data is available in tabular 
form as Annex, Table A1. 
 
Figure 7. Cytotoxicity of protoflavones (1, WYC0209, 31-44, 81-100 and 66-74) . pIC50 values 
were derived from dose response curves obtained from cell viability experiments on 
L5178/L5178B1 mouse lymphoma cells (A) and MCF-7/MCF-7Dox cells (B). SR=Selectivity 
Ratio, calculated as IC50
nonMDR/IC50
MDR; n=3-4; Dox: doxorubicin. 
 
The above results indicate that the synthesized protoflavone derivatives possess significant 
toxicity in the two cell line pairs. Interestingly, MCF7 cells were in general more resistant. 
Whereas the expression of ABCB1 did not modify the sensitivity of L5178B cells in comparison 
with the parental L5178 cell line, MCF-7Dox cells showed collateral sensitivity to several 
derivatives, with SR values exceeding 5 in the case of compounds (36, 65-68, 70). 
To substantiate the role of ABC transporters in the MDR-selective toxicity of the compounds, 
additional MDR models were included in the study in collaboration with Dr. Gergely Szakács 
(Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of 
Sciences, Budapest Hungary). The cytotoxic activity of compounds (38-44, WYC0209, 31-37, 
68-73 and 73) were tested in four additional MDR/sensitive cell line pairs, including A431, 
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A431B1, A431G2, MES-SA, MES-SA/Dx5, KB-3-1 and KB-V1. The results are shown in 
Figures 8-9; detailed data are available as Annex, Tables A2 and A3). 
The tested protoflavone derivatives were equally toxic to A431, A431G2 or A431B1 cells (IC50 
values ranged from 0.60 µM to 7.27 µM), with the exception of protoapigenone (1), suggesting 
that the compounds tested herein are able to bypass ABCB1 or ABCG2. Resistance of A431G2 
cells to compound 2 was abolished in the presence of tariquidar, confirming that protoapigenone 
is an ABCG2 substrate (Figure 8). 
 
Figure 8. A. Cytotoxic activity of selected protoflavones against A431 (parental) cell line and 
two MDR derivatives engineered to overexpress ABCB1 (A431B1) or ABCG2 (A431G2). 
SR=Selectivity Ratio, calculated as IC50
sensitive/IC50
MDR; n=3-4; Mx: mitoxantrone. B. IC50 
values of 1 (protoapigenone) and mitoxantrone in A431 and A431G2 cell lines in the presence 
and absence of 1 µM tariquidar, an ABCG2 efflux inhibitor. 
 
Figure 9. pIC50 values measured in doxorubicin-selected MES-SA/Dx5
 (77) nd vinblastine-
selected KB-V1 (78) cells compared to the pIC50 values of MES-SA and KB-3-1 cells (A and 
B, respectively). Two compounds were selectively toxic against both MES-SA/Dx5 and KB-
V1 cells (2 and 73), and none of the protoflavones showed substrate-like characteristics; Dox: 
doxorubicin, Vbl: vinblastine. 
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Finally, we tested the interaction of the compounds with P-gp to reveal if any of the compounds 
inhibit drug efflux. ABCB1 function was characterized using the calcein accumulation assay 
[62]. Each derivative was assayed at two concentrations in the presence of the fluorescent 
indicator. Except for the 6-phenylprotoflavone series (66-71), which showed moderate 
inhibition at 20 µM (14-46 %; for details see Annex, Table A4), none of the compounds 
inhibited the efflux of calcein AM by P-gp 
In addition to the above results, an international research collaboration (Dr. Milica Pesic; 
Institute for Biological Research „Sinisa Stankovic”, Belgrade, Serbia) was utilized to test 
selected compounds (PA, PABu, PAPIII, BNFOH, 6MeOH, 6BrOH) on further four non-
MDR/MDR cell line pairs, including NCI-H460 (human non-small cell lung carcinoma), DLD1 
(human colorectal carcinoma), U87 (human glioma), C6 (rat glioma) and MRC-5 (human 
embryonal bronchial epithelial) cell lines, and their MDR counterparts NCI-H460/R (adapted 
to doxorubicin), DLD1-TxR and U87-TxR (adapted to paclitaxel), and RC6 (adapted to 
carmustine), respectively, and toxicity was also tested on HaCaT (normal human keratinocytes) 
and MRC-5 (embryonal bronchial epithelial) cell lines [VI] [63]. In this study, selective 
toxocity towards the MDR cell lines was found to correlate with the altered antioxidant defense 
of these cells: collateral sensitivity vs. cross-resistance to protoflavonoids appeared to be in line 
with that towards H2O2 induced oxidative stress, and several (necessarily adaptation-related, 
evolutionary) changes were evidenced in the redox homeostasis of the MDR cells as compared 
to that of their parental cell lines [VI] [63]. These changes all pointed in the same direction, 
which was, however, not the case for the MCF-7/MCF-7Dox cell line pair (see Fig. 7B and Table 
A1), whose collateral sensitivity was accompanied by resistance to H2O2 mediated oxidative 
stress. 
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4.4. Activity of selected compounds on xanthine oxidase  
Compounds (31-44 and 81-87) were also tested for their ability to inhibit xanthine oxidase 
(XO) [IV]. First, inhibition% was determined at 0.1 mM, followed by taking dose-effect curve 
for compound (44) exerting a significant, nearly complete inhibition. The binding mode of (44) 
to the enzyme was also determined. Fig. 10 summarizes the results of these studies. 
 
Figure 10. Activity of selected compounds 1, 31-44, 81-87 and WYC0209 on xanthine oxidase. 
A: inhibition% of the compounds at 0.1mM; B: dose-effect curves of PA-PIII in comparison 
with Ap and the positive control allopurinol; C: determination of the binding mode of (44) to 
the enzyme. 
 
As seen from Fig. 10A, the genkwanin derivatives (group b) were inactive, whilst weak 
inhibition was found for some of the naphthoflavone derivatives (group c), and weak to 
moderate activity was observed for most of the protoapigenone analogs (group a). However, 
compound (44), protoapigenone 1′-O-propargyl ether, was found to inhibit the enzyme almost 
completely at the tested concentration. The dose–effect curve of this compound revealed a 
significantly stronger IC50 value that that of allopurinol (Fig 10B). The kinetic curve (Fig 10C) 
was found to be characteristic of substrate inhibition, that is, increasing the amounts of the 
substrate (here: xanthine) could also exert mild inhibition. Such a situation has already been 
described for XO (64). Furthermore, a global model with identical Vmax values for each curve 
was found (1.376 nM s-1) at p <0.05, while no solutions were found when curve fitting criterion 
of a common Km value was set for all curves. Based on these thorough analyses, compound 
(44) is strongly suggested to be a competitive inhibitor of the enzyme. 
The binding mode of (44) into the enzyme was investigated by in silico docking, using the 
3NVY structure, corresponding to the crystal structure of XO in complex with quercetin 
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(www.pdb.org). In this structure, quercetin is bound near the active center of the enzyme within 
the channel dedicated to the substrate. Since (44) is described here as a competitive inhibitor 
similar to quercetin, the XO/quercetin complex appears as a relevant model for further docking, 
that is, replacing quercetin by (44) and using the same active site for the docking procedure. 
iGEMDOCK, a docking and virtual screening tool utilizing the GEMDOCK scoring function 
was used,19,20 which combines an automatic preparation of the macromolecule around the 
bound ligands with docking and post-analysis. Re-docking the experimental ligand into the 
binding site resulted in a root mean square deviation (RMSD) value as low as 0.9149 Å for the 
best-fit pose, which represented the most favorable van der Waals interactions. The results of 
this experiment and the best docking pose of (44), as well as its interactions with the enzyme 
are shown in Figure 11. 
 
Figure 11. Results of the docking study. A: Overlapping of the re-docked quercetin residue 
(turquoise) with its experimental position (yellow, interactions shown to this position). B: Best 
docked position of (44) (turquoise) along with the hydrophobicity surface around the ligand at 
a probe radius of 1.1 Å. In A and B, the viewing angles are identical, and H-bonds and p–p 
interactions are shown in green and orange, respectively. C: 2D Interpretation of the ligand–
residue interactions between 3NVY and (44) including the distances of the H-bonds in Å. 
 
Of the ten possible solutions found in the docking study of (44), the best four represented very 
similar positions, with binding energies of -126.88, -126.33, -118.68 and -117.50 kcal/mol, 
respectively. In the case of the fifth best solution, the A and C rings of (44) almost perfectly 
overlapped with those of quercetin within the X-ray structure, resulting in a somewhat less 
favorable binding energy (-95.37 kcal/mol). The remaining five solutions showed much weaker 
binding to 3NVY (-68.11 to -16.73 kcal/mol). 
A CB
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In the most stable orientation of (44) in the XO active site, several H-bonds were observed 
(Fig. 11B), which differed from those existing in the presence of quercetin (Fig. 11A). This 
difference is mainly attributed to the flipped orientation of (44) with respect to that of quercetin, 
which modifies the H-bonding possibilities with residues of the active site. Interestingly, due 
to these flip-flop orientations, the 5-OH and 7-OH groups have inverted roles in quercetin and 
compound (44). Concerning quercetin, the 5-OH group forms a H-bond with the oxygen of the 
molybdopterin (MOS) residue, thus blocking its function. However, the 5-OH group of 
flavonoids is known to form a strong intramolecular H-bond with the keto group at C-4 [65] 
which consequently weakens the intermolecular H-bond with molybdopterine. In the case of 
compound (44), the 7-OH group forms this intermolecular H-bond, which effectively enhances 
the binding to molybdopterin, and therefore the blocking of its function. This highlights the 
crucial role of the 7-OH group, fully rationalizing the dramatic loss of activity, e.g., from (44) 
to (86) (Fig. 10).  
The orientation of (44) in the XO active site is also stabilized by π-π interactions between the 
A and C rings of the flavonoid and the aromatic ring of the Phe914 residue (Fig. 11B); these 
interactions are similarly observed for quercetin (Fig. 11A).  
The most stable orientations found for (44) in the XO active site suggest a reasonable 
explanation for the importance of the propargyl side-chain: it perfectly fits into the hydrophobic 
pocket formed by the Leu648, Phe649, Asp872, Leu873 and His875 residues. Moreover, this 
orientation is also stabilized by a H-bond between the ether oxygen and Ser876. On the other 
hand, when the butyl ether derivative (42) was docked into 3NVY, its docking scores and 
positions could not explain its much lower activity compared to (44). Similar binding energies 
and orientations were found for these two compounds, and even the longer butyl ether side-
chain was able to fit into the aforementioned pocket and form a H-bond with Ser876 at the same 
time. Side-chain length, on the other hand, might still be a limiting factor for these compounds 
to reach the active site through its relatively narrow access channel. This might explain the 
gradually decreasing XO inhibitor activity from the methyl to butyl derivatives (compounds 
38-42) when tested at 0.1 mM. 
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5. Discussion 
5.1. Synthesis 
By utilizing a simple oxidative de-aromatization by a common hypervalent iodine reagent 
similarly to the strategy published as a direct preliminary of this work [42], 15 new 
protoflavones were obtained from genkwanin, 4’-hydroxy-6-methylflavone. Following the 
observation on the apparent MDR selectivity of each derivative of the latter one (see below, 
Chapter 5.2.), the preparation of various 6-substituted derivatives was attempted. 
In order to achieve this goal, the straightforward total-synthetic strategy reported by Lin et al. 
was utilized [38], following the preparation of those acetophenones that were commercially not 
available (46), (47). As an important difference to the reported total synthesis, efforts were 
made to optimize the ring closing step (i.e. chalchone to flavone). Even though related 
publications, including the one mentioned above, typically describe the use of a catalytic 
amount of iodine for the ring closure to obtain the flavone skeleton, utilizing a larger, 1 
equivalent amount was found far more efficient. Following deprotection to obtain the 4′-
hydroxyflavone, the oxidative de-aromatization was achieved by utilizing 2 equivalents of 
PIFA in a 9:1 ratio mixture of acetonitrile and either water or the alcohol to be coupled at 
position 1′ as an ether group. Structure elucidation of the protoflavones obtained this way was 
straightforward based on the mass and 1H NMR spectra. The expected change in the molecular 
mass, and, in case of the 1´-O-alkyl derivatives, the appearance of the characteristic 1H NMR 
signals and coupling pattern of the side chain proved the successful linking of water or alcohol. 
The build-up of the protoflavone type B-ring was evidenced by the change in the coupling 
constant of the two dublets of H-3´/H-5´ and H-2´/H-6´ from ca. 8.8 Hz to ca. 10.0 Hz, together 
with the remaining 3-H singlet and practically unchanged A-ring signals in the 1H NMR 
spectrum. 
5.2. The apigenin – protoapigenone – apigenin redox cycle 
From our in silico and in vitro results it could be evidenced that, when scavenging ROS such 
as OH radicals, the well-known chemo-preventive agent apigenin [66] can yield the potent 
antitumor compound protoapigenone. Moreover, when studying the time-dependency of the 
formation of protoapigenone in the presence of excess OH radicals (i.e. Fenton reaction; see 
Fig. 6 on page 24) by using capillary electrophoresis, it was found that protoapigenone should 
indeed be a major primary product of such a scavenging event, just as it was previously 
predicted in silico. 
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This is a particularly interesting finding that might completely change our understanding of 
how apigenin works in presence of oxidative stress (i.e. when it exerts its free radical 
scavenging antioxidant activity). Indeed, there are similarities between the bioactivities of these 
two compounds [67-68], which can likely be explained through a hypothesis considering 
protoapigenone as the “active form” of apigenin at least in terms of its antitumor and/or anti-
carcinogenic properties. Interestingly, a very similar redox circle was evidenced for estrone by 
Prokai et al. [69]. In this study, the antioxidant activity of estrone was explained through a p-
quinol A-ring containing derivative, which was found to rapidly transform back to estrone by 
enzymatic reduction, hence recovering the original compound able to scavenge further OH 
radicals [69]. Nevertheless, at the time of preparing this dissertation, we have not yet studied 
the enzymatic reduction of protoapigenone to apigenin, making it hard to make a judgment on 
the dynamics of this redox circle. The reaction with reduced glutathione was performed only in 
a test tube, and while this can prove that this reduction can take place in the presence of a 
relatively mild reducing agent, at this time no information is available on the involvement of 
enzymatic processes in this transition. It is also important to mention that only a limited data 
are available on the actual biological relevance of this redox cycle. Our preliminary 
experiments, however, suggest that oxidative stress can in fact modulate (increase) the in vitro 
antitumor activity of apigenin possibly through the formation of protoapigenone; further studies 
are necessary to clarify related biological aspects. 
5.3. Anticancer activity of protoflavones 
Our results on the cytotoxic activity of protoflavone derivatives against a diverse set of drug 
susceptible and MDR cancer cell lines provided a rich set of bioactivity data, and revealed 
several new structure-activity relationships (SAR). According to their B-ring substitution, 
cytotoxicity of the protoflavones on the utilized cell lines typically followed the SAR observed 
at the very beginning of our studies [I]: in most of the cases, 1´-OH substituted compounds 
were more toxic than those with 1´-alkoxy moieties and the isopropyl-ethers were the least 
cytotoxic derivatives. This, however, did not apply for protogenkwanone and its analogs (81-
87): protogenkwanone 1´-O-methylether (82) exerted a stronger activity on the mouse 
lymphoma cells than (81). Moreover, an at least two carbons long side-chain was necessary for 
this series of compounds to be slightly toxic on MCF-7 cells. Presence of a non-branching 
propyl or butyl ether side chain at the C-1´ of protoapigenone (as in compounds 40 and 42) was 
found to be preferable for a strong cytotoxic activity [I]. This was also observed in the present 
study in most cell lines with the exceptions of the L5178 / L5178B1 and the MCF-7 / MCF-7Dox 
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cell line pairs. The introduction of a 1´-benzyloxy moiety (as in compound 45) to 
protoapigenone also resulted in an increased toxicity in the A431 cell line and its MDR sub-
cell lines, as well as in the KB-3-1 and KB-V1 cells. This provides further evidence for the 
importance of the size and/or lipophilicity of the substituent at C-1´ and suggests that a larger 
branching and/or unsaturated alkyl side-chain might also lead to an increased cytotoxicity, 
despite the generally lower activity of the 1´-O-isopropyl substituted derivatives as compared 
to those with linear alkyl chains. 
Studies on the new compounds’ activity against MDR cancer cell lines was initiated by 
investigating a set of compounds (PA, BNF, GEN és 6Me) on the L5178 / L5178B1 cell line 
pair. A mild, yet statistically significant selectivity was observed towards the MDR cancer cell 
line for the 6-methyl substituted derivatives and none of the other compounds. This was a 
particularly interesting and important finding. Multi-drug resistance can emerge as a result of 
reduced uptake or increased efflux of cytostatic agents – the latter is mediated by ATP-binding-
cassette (ABC) proteins, primarily by P-glycoprotein (P-gp; ABCB1) and ABCG2, which 
confer resistance to a wide variety of compounds [7] [71]. There is a constant need for novel 
chemotherapeutics with marked and selective antitumor activity that can overcome resistance 
mediated by these transporters. The unfavorable prognostic impact of P-glycoprotein 
expression in several cancers has prompted overwhelming research efforts aimed at the clinical 
development of high affinity efflux inhibitors that were shown to overcome MDR in in vitro 
models. Unfortunately, even after decades of intensive research, a clinically effective inhibitor 
has not been identified. Recently, the discussion has shifted to alternative strategies, either to 
bypass the transporters or to exploit the collateral sensitivity (CS) of MDR cells [72]. Recent 
discoveries have shown that it is possible to invert the selective advantage of resistant cells to 
reverse the evolution of resistance [73]. 
According to the above, our synthetic efforts have been redirected towards the synthesis of new 
derivatives with various A-ring substituents, with a particular attention to position C-6, and 
investigating the compounds’ in vitro anticancer activity on drug susceptible / MDR cell line 
pairs. In order to set a criterion for CS stricter than statistical significance, we decided to apply 
a two-fold threshold, namely CS was considered relevant if a compound exerted twice as strong 
activity on the MDR cell line than on its drug susceptible counterpart. Similarly, cross-
resistance (CR) to a compound was considered relevant if its activity was two times weaker on 
the resistant cell line than on the parental one. 
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Our attempt to increase the above-mentioned mild selective toxicity of 6-methylprotoflavones 
(88-94) on the ABCB1 transfected L5178 cells [II] by introducing various C-6 substituents 
revealed one single compound reaching our chosen threshold of relevance against the L5178B1 
cells, 6-methoxyprotoflavone 1´-O-allylether (99). On the other hand, while all 6-methoxy 
compounds also showed tendency for such selectivity, other new derivatives showed decreased 
selective cytotoxicity against this cell line (Table A1). Similarly, none of the tested compounds, 
including 6-methylprotoflavone (88), showed (higher than two-fold) selective toxicity against 
ABCB1 transfected cell lines, including A431B1 (Table A2) and MDCK-IIB1 (not shown). 
Despite the equal toxicity of the studied compounds on parental and P-gp transfected cell lines, 
several derivatives proved selectively toxic against MDR cell lines overexpressing P-gp as a 
result of long-term drug selection. In particular, MCF-7Dox cells (adapted to doxorubicin) 
showed collateral sensitivity to most compounds except for (34, 39, WYC0209, 69 and 75-80) 
with structural differences of the A-ring clearly influencing activity (Table A1). Compound 
(72), 6-phenylprotoflavone, for example, showed a remarkable, 13.2 fold selective cytotoxicity, 
while its β-naphthoflavone analog (WYC0209), where a fused aromatic ring is connected to 
the A-ring at the C-5/C-6 position, was non-selective. By comparing the selectivity ratios of 
compounds with different C-6 substituents, a clear SAR of the following order was observed: 
Ph > Me > OMe ≈ Pentyl, while the ethoxy substituted protoflavones (75-80) and the ethyl 
substituted compound (72) were non-selective. No such general SAR could be concluded for 
the C-1´ substituents, except for the lower selectivity observed for the isopropyl ether 
derivatives (41) and (70). Interestingly, in case of the MES-SA / MES-SA/Dx5 cell line pair 
where the MDR sub-cell line was also obtained by adaptation to doxorubicin (74) collateral 
sensitivity was observed only for the classical, 1´-OH containing protoflavones (1, 66, 81 and 
88, but SR was below threshold for 31 and 82) and not for any of the 1´-O-alkylprotoflavones. 
Furthermore, the KB-V1 cell line, obtained from KB-3-1 by adaptation to vinblastine [75], also 
presented marginal CS towards most of the protoflavones, although SR values for several 
compounds fell just below the 2-fold threshold (Figure 3B, Table S3).  
Statistical significance of the SAR was tested from two angles. Compounds were grouped either 
according to their A-rings or their substituents at C-1´, and the SR values of these groups were 
compared by one-way ANOVA2 followed by Bonferroni’s post hoc test. No differences were 
observed for the C-1´ substituents on any of the cell lines, not even when the data were 
                                                 
2 Each group containing at least 7 data points passed the Shapiro-Wilk normality test, suggesting the normal 
distribution of SR values under the influence of the presented chemical variations. Therefore, ANOVA is suitable 
for the statistical evaluation of these datasets. 
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normalized to the average of their corresponding series (i.e. analogs with the same A-ring). 
However, the different A-ring containing protoflavone derivatives showed significant 
differences in their SR values on the MCF-7 / MCF-7Dox cell line pair; results are presented in 
Fig. 5. 
 
Figure 12. Selectivity ratio (SR) values for protoflavone analogs containing the same A-rings 
on the MCF-7 / MCF-7Dox cell line pair. Box-and-whisker plots represent medians, first and 
third quartiles and ranges; SR≥2.0 and SR≤0.5 represent CS and CR, respectively; different 
lower case letters represent datasets with statistically significant differences (i.e. groups with 
overlap in their marking are not significantly different) at p≤0.05 by one-way ANOVA followed 
by Bonferroni’s post-hoc test. 
 
Collateral sensitivity is causally linked to the adaption of MDR cells to a chemotherapeutic and 
may involve metabolic modifications, the up-regulation of receptors [76] or the modulation of 
the redox homeostasis [77]. One limitation of studies relying on MDR cell lines is that the 
contribution of MDR pumps, versus other acquired cellular alterations, cannot be delineated 
[78] [79] [80]. Collateral sensitivity of the MDR cell lines analyzed in this study indicates that 
resistance to doxorubicin or vinblastine may result in cellular alterations that render the cells 
susceptible to the protoflavone derivatives. However, in contrast to MDR-selective compounds 
[81], protoflavone derivatives do not selectively target cells engineered to overexpress P-
glycoprotein, suggesting that the increased toxicity observed in the MDR cells is not conferred 
by the efflux pumps. This was also supported by our observation that selectivity ratios did not 
37 
 
decrease significantly when compounds 1, 81, and 88 were tested on the MES-SA / MES-
SA/Dx5 cell line pair in the presence of tariquidar (data not presented). 
It is important to point out that the lack of cross-resistance to most protoflavones in all MDR 
cell lines studied here indicates that these compounds can overcome MDR through bypassing 
efflux that is mediated by ABCB1 or ABCG2. SAR of the cytotoxic activity concerning the 6-
substituents appears to differ from cell line to cell line, for example an order of Me > Et ≈ Pent 
≈ Ph > Br > OEt > OMe can be recognized on L5178 and L5178B1, Pent > Ph ≈ Me on KB-3-1 
and KB-V1, while similar activities are exerted by 6-pentyl (73), 6-phenyl (66) and 6-methyl 
(88) compounds on MES-SA and MES-SA/Dx5. From a general overview, 6-alkyl substituted 
protoflavones appear to be somewhat more favorable anticancer agents over 6-alkoxy ones, 
even though nearly all compounds presented here can be considered as valuable leads against 
resistant cancers. As an interesting exception to this, however, resistance to protoapigenone (1) 
was observed in the ABCG2 transfected A431G2 cell line, and a tendency for marginal 
resistance appeared also to its 1′-O-alkyl ethers. Resistance of this cell line to protoapigenone 
(1) markedly decreased in the presence of tariquidar, strongly suggesting that compound (1) is 
an ABCG2 substrate. ABCG2 did not confer resistance towards any of the other compounds 
including protogenkwanone (80), which differs from 1 only in its 7-methoxy group. This 
suggests that a non-substituted phenolic OH group at C-7 is necessary for protoflavones to be 
recognized by this transporter. 
5.4. Xanthine oxidase inhibition by protoflavonoids 
Xanthine oxidase (XO), a molybdenum-containing metalloenzyme, is well known for its key 
role in the catabolism of purines, during which hypoxanthine and xanthine are transformed into 
uric acid. Elevated levels of uric acid lead to various pathological events including gout and the 
related formation of kidney stones. Moreover, although uric acid is the most abundant 
antioxidant in the human body, high XO activity makes a major contribution to oxidative stress 
by also producing reactive oxygen species (ROS) such as hydrogen-peroxide and superoxide 
anion radical [82] [83]. Despite their various problematic adverse effects, the purine derivative 
allopurinol and its active metabolite, oxipurinol, have long been nearly the exclusive choices 
for therapeutic XO inhibition. Thanks to the significant efforts on the search for new, non-
purine type XO inhibitors, several different classes of compounds have been revealed as 
possible alternatives: Febuxostat [2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-
carboxylic acid], a non-competitive inhibitor of the enzyme, is probably the most important 
example to mention due to its recent approval by the FDA [84]. 
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Another prospective class of non-purine type XO inhibitors is that of flavonoids, many of which 
have long been described as efficient inhibitors of the enzyme [85]. In accordance with our aim 
to search for non-cytotoxicity related bioactivities of protoflavones, XO inhibitory activity was 
tested for selected compounds. 
A large body of scientific literature on flavonoids as XO inhibitors has previously been 
published. Prior to our study, all established structure-activity relationships (SAR) of these 
compounds were highly consistent with the following conclusions: i. structure of efficient 
inhibitors allows them to take a planar shape (i.e. no sp3 carbons are present; flavones are far 
more active than flavanones), ii. OH-groups at C-5 and C-7 are important for strong activity, 
and iii. flavonols, isoflavones and anthocyanodines are less active than flavones [86] [87] [88] 
[89] [90]. Accordingly, the surprisingly strong XO inhibitory activity observed for compound 
(44), the 1´-propargylether derivative of protoapigenone, allowed us to partially re-write the 
SAR accepted for flavonoids in this regard. Since the enzyme kinetics studies revealed that 
compound (PA-PIII) acts as a competitive inhibitor of XO, in silico docking was expected to 
provide valuable insights as to how this compound can exert its activity at the active center of 
the enzyme. 
The observed interactions (see chapter 4.5) provided a rational explanation how this compound 
can be anchored inside the channel through which the ligand should approach the molybdenum 
active center. Based on our results, the “planar structure” criterion no longer appears as a major 
prerequisite for efficient XO inhibitor activity of flavonoid derivatives; unlike the case of 
flavanones, if loss of the π -conjugation from the B- to the C-ring occurs at C-1′, the activity 
does not necessarily decrease as compared to flavones. Although the structure of 
protoapigenone 1′-O-propargyl ether certainly represents a rather special case among 
flavonoids, revision of this globally accepted structure-activity relationship might open novel 
directions for designing potent and safe XO inhibitors from this compound class. The planarity 
of the A and C moiety appears mandatory to favor intermolecular π- π stacking, but flexibility 
is permitted for the moiety attached to C-2. For example, enhancing the binding to the Leu648-
Phe649-Asp872-Leu873-His875 hydrophobic pocket is a relevant strategy to improve 
selectivity of flavonoid-type XO-inhibitors. 
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6. Summary 
 
By applying a straightforward synthetic strategy, combining semi-synthesis from naturally 
occurring 4ʹ-hydroxyflavones and a 4-7 steps total synthetic approach, fifty-two protoflavone 
derivatives including 50 new compounds were prepared during this study. Chemical diversity 
of these compounds includes various A-ring substitution patterns (5,7-dihydroxy-, 5-hydroxy-
7-methoxy-, 6-methyl-, 6-methoxy-, 6-ethoxy-, 6-ethyl, 6-penthyl-, 6-bromo-, and 6-phenyl-
substituted compounds as well as analogs of β-naphthoflavone) and various substituents at 
position C-1ʹ (OH, O-Me, O-Et, O-Pr, O-iPr, O-Bu, O-allyl, O-propargyl and O-benzyl). 
In silico DFT calculations revealed the possibility of an apigenin-protoapigenone 
transformation upon OH radical scavenging by the well-known antioxidant and 
chemopreventive agent apigenin. This was further supported by HPLC analyses of the reaction 
mixture obtained from the Fenton reaction of apigenin, where traces of protoapigenone were 
identified. By means of direct CE measurements on such mixtures, it can be concluded that 
protoapigenone is likely a major bioactive metabolite of apigenin whenever such a scavenging 
event takes place. Protoapigenone could also be reduced back to apigenin by an overnight 
incubation with reduced glutathione, an abundant intracellular antioxidant, which is evidence 
for the existence of an apigenin-protoapigenone-apigenin redox cycle. Further studies are 
necessary to clarify the biological relevance of this phenomenon. 
The synthesized protoflavones were tested for their in vitro anticancer activity on a diverse set 
of drug susceptible and multi-drug resistant cell lines, and several new structure-activity 
relationships were revealed. The ability of protoflavones to evade efflux-mediated MDR was 
confirmed both in ABCB1 and ABCG2 expressing cell lines, with the exception of 
protoapigenone, which was identified as an ABCG2 substrate. MDR selective cytotoxicity was 
observed for most of the tested protoflavones in a breast cancer cell line adapted to doxorubicin 
(MCF-7Dox) and SAR revealed importance of the A-ring substitution, while in the uterine 
sarcoma MES-SA/Dx5, another doxorubicin-selected cell line, only the 1´-OH containing 
compounds showed relevant selectivity. Since overexpression of neither ABCB1 nor ABCG2 
sensitized the cells, it could be concluded that the MDR-selective cytotoxicity of protoflavones 
is connected to other changes accompanying acquired drug resistance. As an example to this, a 
smaller set of compounds were found to selectively kill drug-adapted MDR cancer cells whose 
antioxidant defense decreased during their evolution, and cross-resistance was observed with a 
cell line that had increased defense in this regard as compared to its parental cell line. 
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Finally, protoapigenone 1ʹ-O-propargylether was identified as an efficient competitive inhibitor 
of xanthine oxidase (XO), a key enzyme of the purine metabolism involved in the 
pathomechanism of gout and many chronical diseases through its role in producing reactive 
oxygen species. This finding revealed for the first time that sp3 configuration is permitted for 
C-1ʹ for a flavonoid-type XO inhibitor, in contrast with the generally accepted SAR stating that 
the ability for adopting a planar structure is a must for such an activity. In silico docking studies 
revealed a flip-flop orientation of this compound as compared to that of quercetin, and provided 
a reasonable explanation for the role of the propargyl side chain, fitting perfectly into the 
hydrophobic pocket formed by the Leu648, Phe649, Asp872, Leu873 and His875 residues. 
Altogether, this work on protoflavonoids provided several new derivatives with a natural 
product-inspired scaffold, provided new insights into their formation, and allowed us to obtain 
rich bioactivity and SAR data related to these compounds. Studies on their bioactivity from 
several angles outlined a number of promising research directions for the future, including, but 
not limited to, the possible use of protoflavone analogs as new lead compounds against multi-
drug resistant cancer. 
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Table A1. Cytotoxic activity of compounds on the L5178 / L5178B1 and MCF-7 / MCF-7Dox 
cell line pairs. A-ring substitutions and O-alkyl groups at C-1′, R and R1 refer to Scheme 2; 
SR=selectivity ratio, n.d.: not determined; n=3-4; Dox=doxorubicin.  
A-ring 
substitution 
R group 
at C-1´ 
 IC50 (µM)  IC50 (µM)  
Compound L5178 L5178B1 SR MCF-7 MCF-7Dox SR 
 
H 1 0.88 ± 0.09 0.76 ± 0.04 1.2 5.56 ± 0.79 1.33 ± 0.37 4.2 
Me 38 4.64 ± 0.43 3.24 ± 0.68 1.4 11.40 ± 0.31 4.20 ± 0.13 2.7 
Et 39 5.16 ± 0.01 5.12 ± 0.18 1.0 6.03 ± 0.14 3.71 ± 0.14 1.6 
Pr 40 6.04 ± 0.15 4.70 ± 0.60 1.3 6.68 ± 0.65 2.42 ± 0.04 2.8 
i-Pr 41 10.91 ± 0.83 8.01 ± 0.59 1.4 > 50 > 50 n.d. 
Bu 42 1.54 ± 0.15 1.32 ± 0.12 1.2 7.43 ± 0.10 2.28 ± 0.03 3.3 
Allyl 43 1.67 ± 0.12 1.52 ± 0.02 1.1 20.42 ± 0.76 5.00 ± 0.11 4.1 
Propargyl 44 2.61 ± 0.12 2.46 ± 0.26 1.1 8.84 ± 0.07 2.64 ± 0.02 3.3 
Bn 45 n.d. n.d.  4.48 ± 0.42 1.82 ± 0.20 2.5 
 
H 81 2.09 ± 0.06 2.05 ± 0.03 1.0 > 50 > 50 n.d. 
Me 82 0.50 ± 0.03 0.59 ± 0.05 0.9 > 50 > 50 n.d. 
Et 83 1.77 ± 0.07 1.66 ± 0.17 1.1 20.17 ± 2.26 4.66 ± 0.59 4.3 
Pr 84 1.41 ± 0.02 1.92 ± 0.13 0.7 9.42  ± 0.71 2.26 ± 0.11 4.2 
Bu 85 3.99 ± 0.04 4.49 ± 0.20 0.9 27.16 ± 1.78 6.80 ± 0.83 4.0 
Allyl 86 1.55 ± 0.04 0.99 ± 0.02 1.6 10.46 ± 0.86 1.94 ± 0.33 5.4 
Propargyl 87 1.53 ± 0.08 0.96 ± 0.09 1.6 12.30 ± 1.60 3.81 ± 0.28 3.2 
R1=Me 
 
H 88 0.26 ± 0.02 0.16 ± 0.02 1.6 4.93 ± 1.27 0.75 ± 0.06 6.6 
Me 89 2.27 ± 0.05 1.45 ± 0.14 1.6 27.12 ± 2.01 4.58 ± 0.10 5.9 
Et 90 3.17 ± 0.26 1.85 ± 0.16 1.7 36.79 ± 1.17 5.34 ± 0.10 6.9 
Pr 91 5.35 ± 0.23 3.03 ± 0.17 1.8 22.80 ± 1.40 2.59 ± 0.05 8.8 
Bu 92 4.07 ± 0.10 2.75 ± 0.14 1.5 17.48 ± 2.23 2.40 ± 0.09 7.2 
Allyl 93 2.91 ± 0.13 1.81 ± 0.09 1.6 20.35 ± 2.07 4.33 ± 0.45 4.7 
Propargyl 94 1.74 ± 0.12 0.97 ± 0.03 1.8 19.32 ± 0.70 4.28 ± 0.30 4.5 
R1=OMe 
 
H 81 n.d. n.d.  3.92 ± 0.73 1.05 ± 0.12 3.7 
Me 82 18.16 ± 0.04 11.75 ± 0.96 1.5 32.84 ± 0.55 12.82 ± 1.11 2.6 
Et 83 26.18 ± 0.28 17.29 ± 0.48 1.5 43.70 ± 1.91 11.85 ± 0.34 3.7 
Bu 85 4.64 ± 0.01 3.30 ± 0.26 1.4 14.14 ± 0.27 3.70 ± 0.06 3.8 
Allyl 86 8.95 ± 0.04 4.42 ± 0.38 2.0 12.94 ± 0.06 4.38 ± 0.09 3.0 
Propargyl 87 9.46 ± 0.07 8.13 ± 0.10 1.2 21.99 ± 0.04 7.28 ± 0.39 3.0 
 
H WYC0209 0.15 ± 0.02 0.13 ± 0.01 1.2a 2.57 ± 0.49 1.96 ± 0.08 1.3 
Me 31 0.98 ± 0.08 0.90 ± 0.11 1.1a 9.18 ± 0.18 2.69 ± 0.07 3.4 
Et 32 1.43 ± 0.17 1.71 ± 0.11 0.8a 8.25 ± 0.09 2.39 ± 0.07 3.5 
Pr 33 2.34 ± 0.24 2.05 ± 0.06 1.1a 8.57 ± 0.44 1.98 ± 0.07 4.3 
iPr 34 11.16 ± 0.33 9.44 ± 0.40 1.2a 13.83 ± 0.63 11.79 ± 0.75 1.2 
Bu 35 1.96 ± 0.11 1.51 ± 0.14 1.3a 8.73 ± 0.35 2.80 ± 0.06 3.1 
Allyl 36 0.97 ± 0.06 0.85 ± 0.04 1.1a 13.84 ± 1.09 1.94 ± 0.08 7.1 
Propargyl 37 0.94 ± 0.14 0.88 ± 0.15 1.1a 10.15 ± 1.83 2.19 ± 0.02 4.6 
R1=OEt 
 
H 75 4.00 ± 0.03 2.98 ± 1.03 1.3 7.35 ± 0.45 7.29 ± 0.08 1.0 
Me 76 7.58 ± 0.81 6.60 ± 0.63 1.1 7.27 ± 0.62 7.87 ± 1.33 0.9 
Et 77 2.79 ± 0.32 3.11 ± 0.42 0.9 4.56 ± 0.25 3.99 ± 0.02 1.1 
Pr 78 1.61 ± 0.12 1.50 ± 0.34 1.1 3.02 ± 0.30 2.03 ± 0.05 1.5 
iPr 79 26.35 ± 1.48 21.71 ± 3.69 1.2 23.60 ± 1.26 23.42 ± 0.76 1.0 
Bu 80 1.30 ± 0.11 0.85 ± 0.26 1.5 1.66 ± 0.24 1.81 ± 0.02 0.9 
R1=Et H 72 0.85 ± 0.09 1.06 ± 0.14 0.8 4.35 ± 0.43 2.68 ± 0.61 1.6 
R1=Pent 
 
H 73 0.68 ± 0.19 1.22 ± 0.21 0.6 1.88 ± 0.23 0.75 ± 0.07 2.5 
R1=Br H 74 3.50 ± 0.20 2.09 ± 0.07 1.7 n.d. n.d. n.d. 
R1=Ph H 66 0.98 ± 0.09 1.14 ± 0.16 0.9 16.20 ± 0.25 1.23 ± 0.12 13.1 
Me 67 4.31 ± 0.15 4.51 ± 0.15 1.0 23.93 ± 0.40 2.73 ± 0.19 8.8 
Et 68 4.62 ± 0.04 4.78 ± 0.19 1.0 24.41 ± 0.32 2.97 ± 0.34 8.2 
Pr 69 7.50 ± 0.40 7.64 ± 0.37 1.0 35.16 ± 0.17 4.61 ± 0.19 7.6 
i-Pr 70 13.88 ± 0.71 13.09 ± 1.09 1.1 30.04 ± 0.71 7.78 ± 1.13 3.9 
Bu 71 5.39 ± 0.41 6.39 ± 0.73 0.8 33.34 ± 1.50 4.14 ± 0.33 8.0 
  Dox 0.23 ± 0.01 3.53 ± 0.44 0.065 2.14 ± 0.30 > 20 < 0.11 
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Table A2. Cytotoxic activity of selected protoflavones on the A431, A431B1 and A431G1 cell 
lines. A-ring substitutions and O-alkyl groups at C-1′ are presented, R and R1 refer to Scheme 
2; SR=selectivity ratio, n.d.: not determined; n=3-4; Mx=mitoxantrone. 
A-ring 
substitution 
R group 
at C-1´ 
 IC50 (µM)  IC50 (µM)  
 A431 A431B1 SRB1 A431G2 SRG2 
 
H 1 2,19 ± 0.63 2.41 ± 0.46 0.9 9.08 ± 1.18 0.2 
Me 38 1.67 ± 0.34 2.77 ± 0.56 0.6 2.69 ± 0.33 0.6 
Et 39 1.35 ± 0.26 1.75 ± 0.16 0.8 2.3 ± 0.41 0.6 
Pr 40 0.66 ± 0.2 0.6 ± 0.01 1.1 1.09 ± 0.1 0.6 
i-Pr 41 3.3 ± 0.93 2.8 ± 1.91 1.2 6.2 ± 2.53 0.5 
Bu 42 0.62 ± 0.14 0.6 ± 0.18 1.0 0.82 ± 0.05 0.8 
Allyl 43 1.05 ± 0.35 1.27 ± 0.18 0.8 1.74 ± 0.32 0.6 
Propargyl 44 1.33 ± 0.36 1.62 ± 0.5 0.8 2.07 ± 0.3 0.6 
Bn 45 0.61 ± 0.11 0.74 ± 0.02 0.8 0.77 ± 0.06 0.8 
 
H 81 7.27 ± 2.29 6.23 ± 1.63 1.2 5.00 ± 0.6 1.5 
R1=Me 
 
H 87 
2.14 ± 0.54 2.12 ± 0.5 1.0 1.85 ± 0.59 1.2 
 
H WYC0209 2.24 ± 0.77 1.99 ± 0.8 1.1 1.68 ± 0.81 1.3 
Me 31 0.62 ± 0.2 0.99 ± 0.49 0.6 0.7 ± 0.28 0.9 
Et 32 1.13 ± 0.41 1.93 ± 0.77 0.6 1.11 ± 0.33 1.0 
Pr 33 1.24 ± 0.38 1.69 ± 0.2 0.7 1.39 ± 0.19 0.9 
i-Pr 34 1.29 ± 0.51 1.77 ± 0.3 0.7 1.36 ± 0.29 0.9 
Bu 35 0.91 ± 0.09 1.33 ± 0.15 0.7 0.96 ± 0.07 0.9 
Allyl 36 1.45 ± 0.7 2.14 ± 0.82 0.7 1.3 ± 0.28 1.1 
Propargyl 37 0.69 ± 0.21 0.82 ± 0.24 0.8 0.8 ± 0.08 0.9 
R1=Pent H 73 1.16 ± 0.58 1.35 ± 0.79 0.9 0.98 ± 0.23 1.2 
R1=Ph H 66 2.5 ± 0.73 2.58 ± 0.27 1.0 2.23 ± 0.8 1.1 
Me 67 1.66 ± 0.12 2.06 ± 0.19 0.8 1.54 ± 0.26 1.1 
Et 68 2.15 ± 0.23 3.22 ± 0.23 0.7 2.08 ± 0.48 1.0 
Pr 69 2.63 ± 0.39 3.32 ± 0.13 0.8 2.46 ± 0.1 1.1 
iPr 70 4.31 ± 0.61 5.4 ± 1.1 0.8 5.3 ± 0.58 0.8 
Bu 71 2.28 ± 0.19 3.27 ± 0.05 0.7 2.14 ± 0.02 1.1 
  Mx 1.22 ± 0.62 5.65 ± 0.57 0.2 6.15 ± 0.63 0.2 
 
  
53 
 
Table A3. Cytotoxic activity of selected protoflavones on the MES-SA / MES-SA/Dx5 and  
KB-3-1 / KB-V1cell line pairs. A-ring substitutions and O-alkyl groups at C-1′ are presented, 
R and R1 refer to Scheme 2; SR=selectivity ratio, n.d.: not determined; n=3-4; 
Dox=doxorubicin, Vbl=vinblastine. 
 
A-ring 
substitution 
R group 
at C-1´ 
 IC50 (µM)  IC50 (µM)  
Compound MES-SA MES-SA/Dx5 SR KB-3-1 KB-V1 SR 
 
H 1 3.68 ± 1.42 1.8 ± 0.54 2.0 5.59 ± 1.00 2.02 ± 0.28 2.8 
Me 38 3.96 ± 0.05 2.94 ± 0.06 1.3 5.56 ± 1.04 2.17 ± 0.2 2.6 
Et 39 3.68 ± 0.19 2.37 ± 0.25 1.6 3.04 ± 0.63 1.67 ± 0.1 1.8 
Pr 40 1.96 ± 0.07 1.32 ± 0.09 1.5 2.2 ± 0.61 0.81 ± 0.07 2.7 
i-Pr 41 6.7 ± 2.58 4.5 ± 1.84 1.5 8.52 ± 0.94 4.55 ± 0.48 1.9 
Bu 42 1.52 ± 0.22 0.99 ± 0.08 1.5 1.52 ± 0.01 0.69 ± 0.2 2.2 
Allyl 43 2.79 ± 0.12 2.03 ± 0.12 1.4 3.22 ± 0.47 1.32 ± 0.28 2.4 
Propargyl 44 1.96 ± 0.23 1.73 ± 0.02 1.1 3.51 ± 1.19 1.82 ± 0.26 1.9 
Bn 45 1.92 ± 0.13 1.3 ± 0.16 1.5 1.48 ± 0.51 0.65 ± 0.08 2.3 
 
H 81 7.78 ± 1.56 3.84 ± 1.26 2.0 14.52 ± 5.88 7.53 ± 0.54 1.9 
R1=Me H 87 1.83 ± 0.23 0.82 ± 0.04 2.2 3.37 ± 1.77 1.82 ± 0.29 1.9 
 
H WYC0209 1.66 ± 0.69 1.00 ± 0.63 1.7 2.72 ± 0.93 1.46 ± 0.2 1.9 
Me 31 2.02 ± 0.31 1.45 ± 0.57 1.4 3.77 ± 1.64 0.99 ± 0.34 3.8 
Et 32 3.7 ± 0.41 2.43 ± 0.48 1.5 4.83 ± 1.16 1.49 ± 0.51 3.2 
Pr 33 4.87 ± 1.18 3.32 ± 0.62 1.5 2.65 ± 0.26 1.07 ± 0.24 2.5 
i-Pr 34 2.63 ± 0.22 2.3 ± 0.36 1.1 3.03 ± 0.02 1.39 ± 0.23 2.2 
Bu 35 2.46 ± 0.71 2.25 ± 0.8 1.1 1.42 ± 0.06 0.6 ± 0.17 2.4 
Allyl 36 3.39 ± 1.42 2.91 ± 1.26 1.2 6.93 ± 2.48 2.34 ± 0.66 3.0 
Propargyl 37 1.53 ± 0.04 1.31 ± 0.08 1.2 2.6 ± 0.07 1.14 ± 0.26 2.3 
R1=Pent H 73 1.86 ± 0.87 0.92 ± 0.24 2.0 1.76 ± 0.48 0.83 ± 0.1 2.1 
R1=Ph H 68 2.21 ± 0.38 1.2 ± 0.15 1.8 3.14 ± 0.11 1.48 ± 0.06 2.1 
Me 69 2.02 ± 0.4 1.51 ± 0.14 1.3 4.31 ± 0.57 1.42 ± 0.34 3.0 
Et 70 3.17 ± 0.22 2.53 ± 0.36 1.3 3.64 ± 0.08 1.2 ± 0.31 3.0 
Pr 71 4.02 ± 0.25 2.9 ± 0.3 1.4 4.6 ± 1.14 1.82 ± 0.35 2.5 
iPr 72 5.46 ± 0.88 4.37 ± 0.44 1.2 6.16 ± 2.13 2.81 ± 0.58 2.2 
Bu 73 3.98 ± 0.15 3.16 ± 0.11 1.3 4.18 ± 0.63 1.75 ± 0.13 2.4 
  Dox 0.36 ± 0.11 4.15 ± 0.38 0.1 n.d. n.d.  
  Vbl n.d. n.d.  0.012 ± 0.007 0.80 ± 0.19 0.01 
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Table A4. Relative inhibition values calculated from the calcein uptake assay. 
 
Compound Relative inhibition 
 2 μM 20 μM 
69 1% 3% 
88 6% 7% 
77 13% 7% 
66 7% 45% 
WYC0209 8% 11% 
81 1% 1% 
1 4% 7% 
73 1% 14% 
74 2% 27% 
66 3% 32% 
67 2% 47% 
68 5% 36% 
31 1% 7% 
32 1% 6% 
33 0% 6% 
34 0% 13% 
36 0% 25% 
37 1% 28% 
Verapamil   100% 
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Introduction
Flavonoids are among the most widespread secondary plant
metabolites and play a significant role in the prevention of several
chronic diseases, including cancer [1–3]. Due to their numerous
anticancer functions, including antiproliferative, cell cycle arrest-
ing and pro-apoptotic effects, certain members of this chemical
group are believed to have potential not only in chemoprevention
but also as future chemotherapy agents for treating cancer [4,5].
Protoapigenone (1) was first isolated by our group from the
Formosan fern Thelypteris torresiana [6]. This compound has a close
structural and likely biosynthetic relationship with apigenin (2), a
common 49-hydroxy-flavone (Figure 1) that is abundantly present
in fruits and vegetables and is considered a particularly potent
cancer chemopreventive flavonoid, according to a growing body of
data [7,8].
In vitro, 1 exhibits significant antitumor activities toward HepG2,
Hep3B, MCF-7, A549 and MDA-MB-231 tumor cell lines (IC50
0.27–3.88 mg/mL). The compound was also found to induce
apoptosis in human prostate cancer cells [9] and to selectively
inhibit ovarian cancer cell growth both in vitro and in vivo in nude
mice while causing no major side effects in the latter case [10]. In a
recent study, 1 was shown to exert dose-dependent DNA damage,
apoptosis, and G2/M arrest at micromolar concentrations in a
lung cancer cell line (H1299) [11]. Based on its potent pro-
apoptotic activity and apparent low toxicity, 1 was chosen by the
National Science Council of Taiwan as the lead compound for the
development of a new class of anticancer drugs. Presently, in vivo
toxicology studies are being performed as part of the preclinical
phase, which have created a need for an economical way to
drastically increase the production of 1.
Figure 1. Structures of protoapigenone (1) and apigenin (2).
doi:10.1371/journal.pone.0023922.g001
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In 2007, a six-step total synthesis of 1 was reported by our group
[12]. After difficulties in carrying out the direct semisynthesis of 1
from 2, we used methoxymethyl-diprotected trihydroxyacetophe-
nones and 4-benzyloxybenzaldehyde as starting materials to
prevent the A-ring of 2 from oxidation, and we applied a
hypervalent iodine reaction to the 7-protected apigenin skeleton in
the second-to-last step to obtain the p-quinol moiety on the B-ring.
Finally, 1 was successfully obtained after the removal of the
protecting group. To carry out the key oxidation step that formed
the pharmacophore on the B-ring, we applied 2 equivalent (eq.) of
[bis(trifluoroacetoxy)iodo]benzene (commonly referred to as PIFA)
in the presence of 0.2 eq. of TEMPO, a commercially available
free radical catalyst. Although in some related oxidative
dearomatization reactions phenyliodine diacetate (PIDA) was
found to give higher yield of product as compared to when PIFA
was used [13], PIDA was less effective in our case. This was also in
accordance with the results of Wells et al. [14], who found the use
of PIFA and TEMPO advantegous over PIDA. Based on these,
PIFA was kept as the only oxidizing agent when the methodology
reported here was developed. The reaction was originally
performed by stirring at 25uC for 90 min in acetonitrile:water
(9:1, v/v) at a concentration of 18 mg/mL of 7-protected 2, and,
after deprotection, 1 was successfully obtained. Figure 2 shows an
outline of this procedure, including reaction times and isolated
yields of the reaction steps.
The procedure resulted in the synthesis of protoapigenone as
well as several of its derivatives which allowed SAR data to be
gathered. However, due to the long reaction times and the slow
chromatographic purifications, the procedure took approximately
one to two months to complete, and resulted in only a 3.3%
overall yield of 1. Because this means of production was unable to
satisfy the high material needs for the extensive preclinical
pharmacological investigation, the improvement of the synthetic
route has become an urgent need and a primary objective of our
research program.
Results and Discussion
Synthesis
Our attempt to improve the yield of the original method began
with the optimization of the oxidation of 7-MOM-apigenin but led
to the surprising observation that with appropriate reaction
conditions, 1 could be directly synthesized from 2 without the
need for protecting groups. Optimization of the direct semisynth-
esis provided the following insights:
– By decreasing the concentration of the starting material to
1 mg/mL, the yield could be improved significantly; further
decreases of concentration did not provide further increases in
the yield.
– TEMPO significantly decreases the yield, and the formation of
1 may be prevented completely by increasing the amount of
TEMPO used. Thus, it should be omitted from the reaction.
– The reaction is highly dependent on the solvent used. For
success, the majority of the solvent should be a non-
nucleophilic polar solvent, preferably acetonitrile. When using
acetone:water (9:1, v/v) and THF:water (9:1, v/v), the reaction
failed. EtOAc saturated with water gave traces of 1, while
1,1,1,3,3,3-hexafluoro-isopropanol:water (9:1, v/v) resulted in
about half the yield of that obtained using the ACN:water
mixture.
– Low energy microwave heating (70uC, 1 min, 500 W) can
increase the yield by more than two-fold, compared to when
the reaction is performed at room temperature.
– The TFA (trifluoroacetic acid) derived from the PIFA in the
reaction significantly decreases the pH. Compound 1 does not
suffer quick decomposition, but it is slightly sensitive to acidic
environments, so it is recommended that it be purified as soon
as possible. On the other hand, neutralizing the TFA is not
favorable, as the remaining ionizable phenolic hydroxyl groups
may lead to a less complete separation at the purification
process.
As mentioned above, we performed the reaction via a quick,
microwave-assisted oxidation of 2 (1 mg/mL in acetonitrile:water
9:1, v/v) with 2 eq. of PIFA, which resulted in a 31% isolated yield
for 100 mg of starting material. This was a great improvement
over the previous method [12]. The purification consisted of a
solid phase extraction followed by gel chromatography on
Sephadex LH-20, which also resulted in the isolation of two
side-products, 19 and 10. Based on its NMR spectra and chroma-
tographic properties in comparison with available testcompound
and literature data, 19 was identified as luteolin, a common flavone
and an expected side-product of the performed reaction [15]. By
means of ESI-MS and HRMS data, 10 was found to have a
molecular mass of 554 and a constitution of C30H18O11 corres-
ponding to an apigenin-protoapigenone dimer. The 1H NMR
spectrum suggested, that a ring corresponding to the B-ring of
apigenin is present (2H at both 7.38 and 6.77 ppm, J=8.8 Hz).
Interestingly, four separate hydrogens were shown as doublet-
Figure 2. The total-synthesis of protoapigenone as reported previously [12]. Reaction times and isolated yields are shown for each reaction
step. Purification of each intermediate product was performed by column chromatography on silica.
doi:10.1371/journal.pone.0023922.g002
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doublets with the larger coupling constant of 10.0 Hz. This
coupling would be characteristic to the two doublets, two
hydrogens each, of the B-ring of protoapigenone. Based on the
1H-1H COSY spectrum, these four hydrogens were also on the
same ring, suggesting a cyclohexadienone ring, as in protoapigen-
one, also to be present. Differences between the pairs of
corresponding protons on this ring are suggested to arise from
the effect of the close aromatic B-ring of the apigenin part, which
was also shown by NOESY correlations between hydrogens of
these two rings. The number of non-OH hydrogens and the
presence of only two meta-coupling doublets accompanied by two
singlets in the 1H spectrum suggested a C-C bond between parts of
the dimer. Further assignments were made based on the HMQC
and HMBC spectra, and an 8-30 junction was suggested.
Structure, numbering and key HMBC and NOESY correlations
of 10 are shown in Figure 3.
Hypervalent iodine reagents are widely used for the oxidative
dearomatization of 4-substituted phenols in the presence of an
appropriate nucleophile to obtain 4,4-disubstituted cyclohexadie-
nones [15–16], and reaction mechanisms involving carbocation
[13] and/or cation-radical [17] intermediates have been suggested
in the literature. Considering the structures of our isolated
products we suggest the mechanism shown in Figure 4.
The presence of 10 as a side-product also provides a possible
explanation for the failure of the previous conditions, which most
likely failed due to the much higher concentration of starting
material and thus the more favorable dimerization or even
oligomer formation via C-C coupling side-reactions. Considering
the large variety of other side-reactions also available in this
system, the 31% yield of 1 shows an unexpectedly good selectivity
of PIFA for the 49-OH group. This selectivity may arise from two
phenomena: (1) the greater acidity of the 7-OH group compared
to that of the 49-OH group (in a mixture of MeOH:water (1:2, v/v)
pKa = 6.9 and 8.6, respectively [18]) causes 2 to mostly exist in the
7-mono-anionic form at the neutral pH of the reaction’s start, and
(2) the intramolecular hydrogen-bond to the 5-OH group makes it
more stable than the 49-OH.
According to our main purpose of establishing a useful method
for larger scale production of 1, we scaled-up the procedure by
oxidizing 800.0 mg, 2.0 g and 5.0 g of 2, which provided
251.3 mg (29.6%), 546.2 mg (25.8%) and 1.18 g (22.3%) of 1,
respectively (see Materials and Methods section). Due to the large
volumes of solvent required (in order to prevent excessive side-
reactions, as mentioned above), further increases in the amount of
starting material used would have been difficult under laboratory
conditions. On the other hand, the solvent volume increase was
the most probable reason for the slight decrease of the yield on
larger scales, because it resulted in slower cooling after the reaction
was finished and a much longer evaporation process. This level of
productivity should, however, be suitable to obtain appropriate
amounts of 1 for the remaining preclinical studies.
The optimized reaction was also performed on 50.0 mg of b-
naphthoflavone (10), which served as the basis for the most active
synthetic derivative to date. This reaction yielded a remarkable
59% of the corresponding analog (11), compared to the 16% yield
reported previously [12].
For both starting materials 2 and 10, further derivatives were
also synthesized by replacing water with various alcohols to obtain
the corresponding 19-O-alkyl ethers, as shown in Figure 5.
In vitro activity
The cytotoxic activities of all protoapigenone analogs obtained
were tested on six human cancer cell lines, including HepG2 and
Hep3B (hepatic), Ca9-22 (oral), A549 (lung), as well as MCF-7
and MDA-MB-231 (breast) cancer cells, with doxorubicin as a
positive control. IC50 values and 95% confidence intervals of the
best fit values obtained by nonlinear regression are presented in
Table 1.
To elaborate on the findings of the previous investigation,
which showed that 19-O-methyl substitution decreases the activity
of 1 [12], the present results demonstrated that increasing the
length of a 19-O-alkyl side-chain on the protoapigenone skeletone
typically increases the activity comparing to that of the methyl-
substituted derivative (compound 3). As a result of this tendency,
several analogs were found to exert practically the same, or, as in
case of the butyl-substituted compound 7 against the Hep3B,
MCF-7 and MDA-MB-231 cell lines, even higher in vitro
cytotoxic activities comparing to that of the non-substituted
compound 1. On the other hand, a 20 to 30 unsaturated side-
chain (allyl, propargyl derivatives; 8, 9) decreased the activity on
the A549 cell line comparing to that of compound 5 bearing a
saturated propyl side-chain (p,0.05 and 0.001, respectively). In
addition to this, presence of a branching side-chain (isopropyl
derivative; 6) strongly decreased the activity on each cell line as
compared to that of 5 (p,0.01 in case of Ca9-22 and p,0.001 in
case of all other cell lines), resulting in low activities comparable
to those of the methyl-substituted compound 3. Figure 6 shows
the activities of all protoapigenone analogs on the Hep3B (A),
MCF-7 (B), and MDA-MB-231 (C) cell lines, where 7 was found
to exert significantly stronger activity than that of the lead
compound 1.
Interestingly, the activity of the b-naphthoflavone derivatives
(12–18) does not seem to follow the same trend, except for the
effect of the side-chain branching (isopropyl; 15, compared to the
Figure 3. Structure, numbering and key HMBC (A) and NOESY (B) correlations of 10.
doi:10.1371/journal.pone.0023922.g003
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propyl; 14) on most of the cell lines with the exception of A-549,
and all of these derivatives showed a marked decrease in the
activity as compared to that of 11.
These results may underline the importance of lipophilicity in
the activity of these compounds, which would also explain why
derivatives of the more lipophilic b-naphthoflavone as compared
to those of apigenin did not show a similar increase in activity
when length of the lipophilic side-chain was increased.
The fact, that a 19-O substitution of protoapigenone by a longer,
3 to 4 carbon aliphatic side-chain can restore, or, in case of some
cell lines, even increase the in vitro activity comparing to that of the
non-substituted compound, makes these derivatives, and particu-
larly compound 7, very interesting new candidates for in vivo
studies. Not only their increased lipophilicity will result in
significantly different pharmacokinetical properties and conse-
quential activity change, but we can also assume, that the 19-O-
alkylation may increase the stability of the pharmacophore B-ring
by protecting it from decomposition and/or metabolic conversion
via re-aromatization to the original flavone, apigenin in this case.
Conclusions
Our results can be summarized as the following:
1. The first economical method to obtain gram scale amounts of
protoapigenone was developed via its direct semisynthesis from
apigenin. This achievement is a great step forward for research
on this promising anticancer compound, considering the need
for large amounts of material to carry out toxicological studies.
2. Several new 19-O-alkyl-protoapigenone as well as the corre-
sponding b-naphthoflavone derivatives were synthesized. The
in vitro cytotoxicity assay of these compounds revealed, that in
case of the protoapigenone derivatives a longer aliphatic side-
Figure 4. Suggested reaction mechanism for the synthesis of 1 from 2 and product structures obtained.
doi:10.1371/journal.pone.0023922.g004
Figure 5. The reaction of 2 and 10 with PIFA in presence of water or various alcohols.
doi:10.1371/journal.pone.0023922.g005
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chain can be beneficial on the activity comparing to that of the
non-substituted protoapigenone, while this is not true in case of
the naphthoflavone derivatives.
3. Based on these findings, new candidates for further studies
were discovered, among which protoapigenone 19-O-butyl
ether (7) is the most promising one. The in vivo study of this
compound is planned in the near future, and the synthesis of
further derivatives is currently in progress.
Materials and Methods
General
Solvents, reagents and chromatographic stationary phases were
purchased from the following companies: solvents and octadecyl
silica from Merck Chemicals, PIFA and Sephadex LH-20 gel from
Sigma and b-naphthoflavone from Indofine Chemical Company
Ltd. (NJ, USA). Apigenin was synthesized from naringenine
(Indofine Ltd.) by Chuang DW in previous experiments (not
discussed here). All compounds tested possessed a purity of over
95%, except for 10 (89.1%), 3 (94.8%) and 6 (94.8%). Compound
purities were checked using HPLC-UV with one of the solvent
systems described below at 245 nm using a gradient system
consisting of two Jasco PU2080 LC pump and a Jasco UV2075
ultraviolet detector connected to a Hercule 2000 chromatographic
interface. Columns used: Agilent Zorbax XDB-C8, 5 mm,
15064.6 mm (RP-HPLC), and Agilent Zorbax-sil 5 mm, 2506
4.6 mm (NP-HPLC). Solvent systems: RP-HPLC1: 55% aqueous
MeOH increasing to 80% in 10 minutes; RP-HPLC2: 35% v/v
aqueous MeOH increasing to 80% in 10 minutes; NP-HPLC: 5%
Table 1. In vitro cytotoxic activities of the compounds obtained.
Compound IC50 (mM)
HepG2 Hep3B Ca9-22 A549 MCF-7 MDA-MB-231
1 3.07 (2.83–3.34) 1.21 (1.19–1.24) 0.78 0.49–1.24) 11.29 (10.07–12.65) 1.70 (1.58–1.82) 1.35 (1.17–1.55)
10 ,19.73 .36 16.89 (14.58–19.57) .36 .36 ,18.38
3 8.99 (6.12–13.21) 3.36 (3.19–3.54) 2.02 1.64–2.49) 21.78 (20.41–23.24) 6.76 (6.07–7.53) 2.82 (2.61–3.04)
4 8.27 (8.03–8.51) 1.73 (1.68–1.78) 1.00 (0.81–1.24) 13.45 (12.01–15.07) 3.15 (2.23–4.45) 1.57 (1.45–1.71)
5 ,6.90 1.66 (1.65–1.68) 0.81 (0.80–0.82) 12.39 (11.04–13.91) 2.36 (2.06–2.69) 1.26 (1.04–1.53)
6 ,19.70 3.59 (3.08–4.19) 1.80 (0.89–3.65) 20.06 (16.22–24.80) 11.43 (10.81–12.09) 2.30 (2.06–2.56)
7 8.78 (8.10–9.51) 0.82(*) (0.80–0.83) ,0.70 10.76 (9.25–12.51) 1.38(*) (1.32–1.44) 0.62(***) (0.47–0.81)
8 7.92 (7.74–8.10) 1.61 (1.54–1.67) 0.93 (0.88–0.98) 17.02 (16.14–17.94) 2.47 (2.26–2.70) 1.53 (1.41–1.66)
9 ,7.81 1.20 (1.19–1.21) 0.89 (0.83–0.96) 20.35 (17.33–23.91) 2.32 (2.14–2.54) 1.75 (1.58–1.93)
11 1.06 (1.04–1.08) 0.25 (0.20–0.30) 0.23 (0.16–0.33) 2.19 (2.03–2.37) ,0.61 0.43 (0.41–0.45)
12 19.48 (17.02–22.30) 0.98 (0.90–1.06) 0.82 (0.73–0.92) 23.17 (20.91–25.68) 2.03 (1.78–2.32) 1.32 (1.18–1.46)
13 9.96 (8.64–11.49) 0.85 (0.83–0.86) 1.03 (0.94–1.21) 17.88 (15.26–20.95) 3.45 (3.10–3.83) 1.68 (1.55–1.81)
14 10.53 (8.68–12.77) 0.88 (0.85–0.91) 0.79 (0.77–0.81) 21.72 (16.81–28.07) 2.92 (2.49–3.44) 1.46 (1.34–1.59)
15 19.21 (17.00–21.71) 2.48 (1.98–3.11) 2.18 (1.73–2.73) 20.66 (18.00–23.72) 2.33 (2.10–2.59) 2.97 (2.66–3.31)
16 7.96 (7.85–8.06) 0.94 0.85–1.03) 1.01 (0.89–1.15) 15.66 (14.90–16.45) 3.05 (2.50–3.72) 1.70 (1.56–1.84)
17 9.43 (9.32–9.55) 0.85 (0.81–0.90) 0.83 (0.81–0.86) 15.38 (14.00–16.90) 2.28 (2.14–2.43) 1.46 (1.37–1.56)
18 8.14 (7.82–8.47) 0.88 (0.73–1.05) 0.86 (0.85–0.87) 19.30 (17.10–21.79) 2.24 (2.10–2.40) 1.89 (1.68–2.12)
D 0.83 0.49–1.39 1.14 (0.78–1.69) 0.60 (0.47–0.76) ,1.86 1.24 (0.76–2.00) ,1.73
Individual IC50 values were compared to those of 1 (in case of 3–9) or 11 (in case of 12–18) by one way ANOVA and Dunnet’s Multiple Comparison Test and by
unpaired T-tests in case of compounds 7 and 1 (Hep3B and MCF7 only). Significantly stronger activities than that of the reference compound are only marked. n = 3;
*: p,0.05 by unpaired T-test, while variances were not significantly different;
***: p,0.001 by ANOVA;
,: ambiguous fitting, very wide confidence intervals; D: doxorubicin.
doi:10.1371/journal.pone.0023922.t001
Figure 6. In vitro cytotoxic activities of the protoapigenone
analogs against the Hep3B, MCF-7 and MDA-MB-231 cell lines.
Numbers on the abscissa represent the corresponding compounds,
while charts A, B and C represent activities against Hep3B, MCF-7 and
MDA-MB-231 cell lines, respectively. Error bars represent the 95%
confidence intervals of the IC50 values; doxorubicin: ambiguous fitting,
no confidence interval available. Significantly stronger activities
comparing to that of 1 are marked; *: p,0.05 by unpaired T-test; ***:
p,0.001 by ANOVA.
doi:10.1371/journal.pone.0023922.g006
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v/v isopropanol in dichloromethane increasing to 17% in 12 min-
utes and flow rate was 1 mL/min in each case. Chromatograms are
shown in Figures S4–S20. 1H NMR spectra were taken using a
Varian Gemini-2000 200 MHz FT-NMR, and 13C and 2D NMR
spectra were taken using a Varian Mercury-plus 400 MHz FT-
NMR spectrometer. Shifts are given in ppm downfield of TMS and
were referenced to internal residual protosolvent. 1H NMR spectra
of all new compounds are shown in Figures S21–S60. These spectra
were taken prior to crystallization, while activity assays and HPLC
were done with the pure crystals obtained for all compounds, except
for 10 which could not be crystallized. Hence, Figures S22–S60. do
not represent final purity and are only shown to assist interpretation
of NMR data. Mass spectra were measured on a PECIEX API 3000
instrument with a turbo ion spray source, Agilent-1100, LC/MSD-
Trap, or Shimadzu LCMS-IT-TOF with an ESI interface.
Crystallographic data for structural analysis have been deposited
with the Cambridge Crystallographic Data Centre (deposition
numbers CCDC 762721–762723). These data sets can be obtained
free of charge via www.ccdc.cam.ac.uk/conts/retrieving html, email:
(or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK;
fax: +44 1223 336 033; e-mail: deposit@ccdc.camac.uk). The
melting points were measured on VEBWagetechnik Rapido PHNK
melt microscope (upper limit: 360uC). The structures of 1, 19, 11 and
12 were determined based on literature data [6,12,19], their melting
points were found 183–184uC (lit. for 1 of natural origin: 180–181uC
[6]), 328–330 (lit. for 19 of natural origin: 328–330uC [20]), 197–
198uC and 171–183uC, respectively. HPLC and purity data for the
known compounds 1, 11 and 12 are as follows. 1. RP-HPLC1:
7.057 min (Figure S4), purity: 95.9%. 11. NP-HPLC: 9.733 min
(Figure S13), purity: 98.8%. 12. NP-HPLC: 10.580 min (Figure
S14), purity: 99.5%. Yields given represent isolated yields.
Assay for Cytotoxicity
Human breast (MCF-7 and MDA-MB-231), liver (HepG2 and
Hep3B), and lung (A549) cancer cell lines were obtained from the
American Type Culture Collection. The human oral squamous
cell carcinoma Ca9-22 was a kind gift from Dr. Jeff Yi-Fu Chen,
Kaohsiung Medical University, Kaohsiung, Taiwan. All cell lines
were propagated in RPMI-1640 medium supplemented with 10%
(v/v) FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin at
37uC in a humidified atmosphere of 5% CO2 and 95% air. Cell
viability was measured by the MTT colorimetric method [21].
Cells were seeded at densities of 5,000 to 10,000 cells/well in 96-
well tissue culture plates. On day two, cells were treated with the
test compounds for another 72 h. After drug treatment, attached
cells were incubated with MTT (0.5 mg/mL, 1 h) and subse-
quently solubilized in DMSO. The absorbtion at 550 nm was then
measured using a microplate reader. The IC50 was recorded as the
concentration of the agent that reduced cell viability by 50%
under the experimental conditions, and it was determined by
applying variable slope nonlinear regression with automatic outlier
elimination at Q=1.0% by using GraphPad Prism 5.0 (GraphPad
Software Inc.). Statistical evaluation of the individual IC50 values
was done by one way ANOVA with Dunnet’s Multiple
Comparison Test by choosing compounds 1 and 11 as references
to their corresponding 19-O-alkylated analogs. To reveal structure-
activity relationships, the activites of each compound were
compared by Bonferroni tests, and, in case of comparing the
activities of 1 and 7, unpaired T-tests were also performed.
General procedure for 1
Compound 2 (100.0 mg) was dissolved in ACN:water (9:1, v/v;
100 mL). A quantity of PIFA (318.0 mg, 2 eq.) was added to the
container, and microwave heating was applied (70uC, max. power
500 W, 1 min) with continuous stirring. The resulting mixture was
evaporated, adsorbed onto 2.0 g of octadecyl silica, layered on the
top of 2.0 g of octadecyl silica, washed with 10 mL of 20%
aqueous MeOH and eluted with 20 mL of 60% aq. MeOH. The
latter fraction was evaporated, redissolved in MeOH, and purified
on a Sephadex LH-20 column (385620 mm; eluent: MeOH).
Fractions of 10 mL were collected, and fractions 11 through 14
gave protoapigenone (33.0 mg, 31.2%). The side-products 19 and
10 were isolated from fractions 15 through 18 and 19 through 21,
respectively, with repeated purification on the same Sephadex LH-
20 column.
Scale-up procedure for 1
Different quantities of 2 (800.0 mg, 2.0 g, and 5.0 g) were
dissolved in ACN:water (9:1, v/v; 800 mL, 2 L and 5 L) in
staunch containers that were then pre-heated to 70uC. After
releasing the pressure, PIFA (2 eq.; 2.55 g, 6.37 g and 15.93 g)
was added to each solution in a careful manner to prevent sudden
explosive boiling, and after re-sealing the containers, microwave
heating was applied (70uC, max. 500 W, 3 min) with continuous
stirring. The samples obtained were cooled under a stream of
water and subsequently with an ice bath. Each sample was
immediately evaporated in a 10 L roundbottom flask using a
Bu¨chi Rotavapor R-220 at 50uC. After redissolving them, the
samples were adsorbed onto octadecyl silica (16.0 g, 40.0 g or
100.0 g) that was layered on top of the same amount of octadecyl
silica. SPE was performed by eluting with 15% aqueous MeOH
(80 mL, 200 mL or 500 mL) followed by 50% aqueous MeOH
(200 mL, 500 mL and 1200 mL. The fractions containing 50%
MeOH were purified on silica gel with CH2Cl2-MeOH (20:1, v/v)
to give 251.3 mg (29.6%), 546.2 mg (25.8%) and 1.18 g (22.3%) of
protoapigenone, respectively.
General procedure for 3 through 9 and 11 through 18
A total of 50.0 mg of 2 or 10 was dissolved in 50 mL of a 9:1 v/
v mixture of acetonitrile and the corresponding alcohol (MeOH,
EtOH, PrOH, iPrOH, BuOH, allyl alcohol or propargyl alcohol)
or water in the case of 11 and reacted with PIFA (159 mg or
150 mg, 2 eq.) under the same conditions used to obtain 1. To
purify the products, flash chromatography (Biotage Flash+) on
silica columns (Biotage Si 24+M 2758-1; 116150 mm) was
performed using a dry-loading technique and n-hexane:EtOAc:a-
cetone solvent systems (all ratios are given in v/v/v; 7:3:1 for 3–5,
9:3:1 for 6, 8 and 9, and 11:3:1 for 7 each containing 0.01% TFA,
as well as 16:3:1 for 11 and 12, 27:3:1 for 13, 36:3:1 for 14, 15, 17
and 18, and 44:3:1 for 16 (no added acid was used)) at flow rates of
24 mL/min. Finally, 3 through 9 and 12 were crystallized from
hexane:acetone (1:1, v/v), while 13 through 18 were crystallized
from hexane:CH2Cl2 (1:1, v/v).
Experimental
Protoapigenone-(8-30)-apigenin (10). Yield: 4% (8.2 mg) as
a side-product of the reaction of 2 into 1; RP-HPLC2: 6.843 min
(Figure S5), purity: 89.1%; yellow solid, mp: .360uC, 1H NMR
(acetone-d6) d 12.87 (1H, s, OH-50), 12.65 (1H, s, OH-5), 7.38
(2H, d, J=8.8 Hz, H-209 and H-309), 6.81 (1H, dd, J=10.0,
3.2 Hz, H-29 or H-69), 6.78 (2H, d, J=8.8 Hz, H-309 and H-509),
6.76 (1H, dd, J=9.6, 3.2 Hz, H-69 or H-29), 6.57 (1H, s, H-3),
6.50 (1H, d, J=2.0 Hz, H-80), 6.30 (1H, s, H-6), 6.29 (1H, d,
J=2.0 Hz, H-60), 6.08 (1H, dd, J=10.0, 2.0 Hz, H-39 or H-59),
5.85 (1H, dd, J=10.0, 1.6 Hz, H-59 or H-39) (Figures S21 and
S22); 13C NMR (acetone-d6) d 185.2 (C-49), 184.1 (C-4), 182.5 (C-
40), 168.8 (C-2), 165.8 (C-70), 165.4 (C-20), 164.0 (C-8a), 163.9 (C-
7, C-50), 163.5 (C-5), 161.4 (C-409), 159.5 (C-8a0), 148.1 (C-29 or
Economic Synthesis of Protoapigenone & Derivatives
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23922
C-69), 148.0 (C-69 or C-29), 131.6 (C-209, C-609), 130.6 (C-39 or C-
59), 130.5 (C-59 or C-39), 125.3 (C-109), 116.7 (C-309, C-509), 111.3
(C-30), 108.0 (C-3), 106.1 (C-4a), 105.3 (C-4a0), 101.3 (C-8), 100.5
(C-6), 100.3 (C-60), 95.4 (C-80), 71.3 (C-19); ESI-MS (m/z, %): 555
(M++H, 100), 577 (M++Na, 92); HRMS: C30H18O11Na,
calculated 577.0747; found 577.0750.
Protoapigenone 19-O-methylether (3). Yield: 42% (23.3
mg); RP-HPLC1: 3.860 min (Figure S6), purity: 94.8%; white
crystals, mp: 153–155uC, 1H NMR (acetone-d6) d 12.59 (1H, br,
OH-5), 6.99 (2H, d, J=10.2 Hz, H-29 and H-69), 6.55 (2H, d,
J=10.2 Hz, H-39 and H-59), 6.50 (1H, s, H-3), 6.29 (1H, d,
J=2.0 Hz, H-8), 6.24 (1H, d, J=2.0 Hz, H-6), 3.42 (3H, s,
OCH3-19) (Figures S23 and S24);
13C NMR (acetone-d6) d 183.4
(C-49), 181.6 (C-4), 164.7 (C-2), 164.0 (C-7), 162.0 (C-5), 157.5 (C-
8a), 144.8 (C-29 and C-69), 132.4 (C-39 and C-59), 106.9 (C-3),
104.3 (C-4a), 98.8 (C-6), 93.5 (C-8), 74.2 (C-19), 51.6 (C-10); ESI-
MS (m/z, %): 323 (M++Na, 100), 301(M++H, 82); HRMS:
C16H12O6Na, calculated 323.0532; found 323.0530.
Protoapigenone 19-O-ethylether (4). Yield: 33% (19.2 mg);
RP-HPLC1: 5.157 min (Figure S7), purity: 96.7%; white crystals,
mp: 170–172uC, 1H NMR (acetone-d6) d 12.59 (1H, br, OH-5),
7.01 (2H, d, J=10.2 Hz, H-29 and H-69), 6.56 (1H, s, H-3), 6.51
(2H, d, J=10.0 Hz, H-39 and H-59), 6.28 (1H, br, H-8), 6.24 (1H,
br, H-6), 3.63 (2H, q, J=3.5 Hz, H-10), 1.27 (3H, s, H-20) (Figures
S25, S26 and S27); 13C NMR (acetone-d6) d 183.6 (C-49), 181.7
(C-4), 164.9 (C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.3 (C-
29 and C-69), 131.9 (C-39 and C-59), 106.9 (C-3), 104.3 (C-4a),
98.7 (C-6), 93.4 (C-8), 74.0 (C-19), 60.0 (C-10), 14.6 (C-20); ESI-
MS (m/z, %): 337 (M++Na, 100), 315 (M++H, 96); HRMS
C17H14O6Na, calculated 337.0688; found 337.0686.
Protoapigenone 19-O-propylether (5). Yield: 36%
(21.9 mg); RP-HPLC1: 8.240 min (Figure S8), purity: 97.8%;
white crystals, mp: 181–182uC, 1H NMR (acetone-d6) d 12.59
(1H, br, OH-5), 7.01 (2H, d, J=10.2 Hz, H-29 andH-69), 6.56 (1H,
s, H-3), 6.52 (2H, d, J=10.2 Hz, H-39 and H-59), 6.28 (1H, d,
J=2 Hz, H-8), 6.24 (1H, d, J=2 Hz, H-6), 3.54 (2H, t, J=6.3 Hz,
H-10), 1.68 (2H, m, H-20), 0.98 (3H, t, J=7.3 Hz, H-30) (Figures
S28, S29 and S30); 13C NMR (acetone-d6) d 183.6 (C-49), 181.7 (C-
4), 164.8 (C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.4 (C-29
and C-69), 131.9 (C-39 and C-59), 106.9 (C-3), 104.3 (C-4a), 98.7 (C-
6), 93.5 (C-8), 74.0 (C-19), 65.9 (C-10), 22.7 (C-20), 9.6 (C-30); ESI-
MS (m/z, %): 329 (M++H, 100), 351 (M++Na, 80); HRMS
C18H16O6Na, calculated 351.0845; found 351.0846.
Protoapigenone 19-O-isopropylether (6). Yield: 26%
(15.8 mg); RP-HPLC1: 7.637 min (Figure S9), purity: 94.9%;
light-brownish crystals, mp: 138–140uC, 1H NMR (acetone-d6) d
12.59 (1H, br, OH-5), 7.07 (2H, d, J=9.8 Hz, H-29 and H-69),
6.56 (1H, s, H-3), 6.50 (2H, d, J=9.8 Hz, H-39 and H-59), 6.28
(1H, br, H-8), 6.24 (1H, br, H-6), 3.94 (1H, m, J=6.1 Hz, H-10),
1.24 (6H, d, J=6.2 Hz, H-20 and H-30) (Figures S31, S32, S33
and S34); 13C NMR (acetone-d6) d 162.0 (C-5), 145.7 (C-29 and
C-69), 131.3 (C-39 and C-59), 107.0 (C-3), 104.2 (C-4a), 98.7 (C-6),
93.4 (C-8), 68.0 (C-10), 23.5 (C-20 and C-30); ESI-MS (m/z, %):
329 (M++H, 100), 351 (M++Na, 84), 270 (M++H – OC3H6, 16);
HRMS C18H16O6Na, calculated 351.0845; found 351.0844.
Protoapigenone 19-O-butylether (7). Yield: 44% (27.9 mg);
RP-HPLC1: 9.437 min (Figure S10), purity: 96.1%; white crystals,
mp: 167–168uC, 1H NMR (acetone-d6) d 12.60 (1H, br, OH-5),
7.01 (2H, d, J=10.8 Hz, H-29 and H-69), 6.55 (1H, s, H-3), 6.52
(2H, d, J=10.8 Hz, H-39 and H-59), 6.28 (1H, br, H-8), 6.25 (1H,
br, H-6), 3.58 (2H, t, J=6.0 Hz, H-10), 1.63 (2H, m, br, H-20), 1.44
(2H, m, br, H-30), 0.93 (3H, t, J=7.2 Hz, H-40) (Figures S35, S36
and S37); 13C NMR (acetone-d6) d 183.6 (C-49), 181.7 (C-4), 164.9
(C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.4 (C-29 and C-69),
132.0 (C-39 and C-59), 106.9 (C-3), 104.3 (C-4a), 98.7 (C-6), 93.4 (C-
8), 74.0 (C-19), 64.1 (C-10), 31.5 (C-20), 18.6 (C-30), 12.8 (C-40);
HRMS C19H18O6Na, calculated 365.1001; found 365.1000.
Protoapigenone 19-O-allylether (8). Yield: 29% (17.5 mg);
RP-HPLC1: 8.283 min (Figure S11), purity: 97.2%; transparent
crystals, 1H NMR (acetone-d6) d 12.59 (1H, br, OH-5), 7.04 (2H,
d, J=10.2 Hz, H-29 and H-69), 6.57 (1H, s, H-3), 6.53 (2H, d,
J=10.4 Hz, H-39 and H-59), 6.29 (1H, d, J=2.2 Hz, H-8), 6.24
(1H, J=2.2 Hz, H-6), 6.00 (1H, m, J=5.4 Hz, H-20), 5.37 (1H, d,
J=17.2 Hz, H-30, cis), 5.20 (1H, d, J=10.4 Hz, H-30, trans), 4.14
(2H, J=5.2 Hz, H-10) (Figures S38 and S39); 13C NMR (acetone-
d6) d 164.9 (C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.4 (C-
29 and C-69), 132.0 (C-39 and C-59), 106.9 (C-3), 98.7 (C-6), 93.4
(C-8), 72.9 (C-19), 65.9 (C-10); ESI-MS (m/z, %): 349 (M++Na,
100), 327 (M++H, 85); HRMS C18H14O6Na, calculated 349.0688;
found 349.0690; X-ray data are shown in Figure S1.
Protoapigenone 19-O-propargylether (9). Yield: 36%
(21.6 mg); RP-HPLC1: 4.180 min (Figure S12), purity: 97.4%;
yellow crystalline powder, mp: 205–207uC, 1H NMR (acetone-d6)
d 12.55 (1H, s, OH-5), 7.08 (2H, d, J=10.0 Hz, H-29 and H-69),
6.55 (2H, d, J=10.2 Hz, H-39 and H-59), 6.53 (1H, s, H-3), 6.30
(1H, d, J=2.2 Hz, H-8), 6.24 (1H, d, J=2.0 Hz, H-6), 4.34 (2H,
d, J=2.4 Hz, H-10), 3.11 (1H, t, J=2.4 Hz, H-30) (Figures S40
and S41, 400 MHz 1H spectrum is also provided in Figure S42);
13C NMR (acetone-d6) d 185.4 (C-49), 183.5 (C-4), 166.1 (C-2),
166.0 (C-7), 163.9 (C-5), 159.4 (C-8a), 145.9 (C-29 and C-69),
134.3 (C-39 and C-59), 109.0 (C-3), 106.2 (C-4a), 100.8 (C-6), 95.4
(C-8), 81.3 (C-19), 78.0 (C-30), 76.4 (C-20), 54.8 (C-10); HRMS
C18H12O6Na, calculated 347.0532; found 347.0535.
3-(1-Ethoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (13). Yield: 65% (37.5 mg); NP-HPLC: 7.507
min (Figure S15), purity: 99.8%; white crystals, mp: 158–160uC,
1H NMR (CDCl3) d 9.97 (1H, d, J=8.4 Hz, H-5), 8.04 (1H, d,
J=8.8 Hz, H-9), 7.87 (1H, dd, J=7.6, 1.0 Hz, H-8), 7.74 (1H, td,
J=8.4, 1.4 Hz, H-7), 7.60 (1H, td, J=8.0, 1.0 Hz, H-6), 7.36
(1H, d, J=9.2 Hz, H-10), 6.95 (1H, s, H-3), 6.89 (2H, d,
J=10.2 Hz, H-29 and H-69), 6.55 (2H, d, J=10.4 Hz, H-39 and
H-59), 3.61 (2H, q, J=7.0 Hz, H-10), 1.307 (3H, t, J=7.0 Hz, H-
20) (Figures S43, S44 and S45); 13C NMR (CDCl3) d 184.2 (C-49),
179.5 (C-4), 160.9 (C-2), 156.9 (C-10a), 145.8 (C-29 and C-69),
132.2 (C-39 and C-59), 135.3, 130.2, 129.9, 129.0, 127.8, 126.6,
126.4 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9), 116.9 (C-10), 116.9
(C-4a), 112.1 (C-3), 73.9 (C-19), 60.5 (C-10), 15,3 (C-20); ESI-MS
(m/z, %): 355 (M++Na, 100), 333 (M++H, 79); HRMS
C21H16O4Na, calculated 355.0946; found 355.0945.
3-(1-Propoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (14). Yield: 64% (38.4 mg); NP-HPLC: 5.977
min (Figure S16), purity: 98.9%; transparent crystals, 1H NMR
(CDCl3) d 9.96 (1H, d, J=8.8 Hz, H-5), 8.01 (1H, d, J=9.0 Hz, H-
9), 7.85 (1H, d, br, J=8.0 Hz, H-8), 7.73 (1H, td, J=7.0, 1.6 Hz, H-
7), 7.58 (1H, td, J=8.0, 1.2 Hz, H-6), 7.33 (1H, d, J=9.2 Hz, H-
10), 6.92 (1H, s, H-3), 6.87 (2H, d, J=9.8 Hz, H-29 and H-69), 6.55
(2H, d, J=10.2 Hz, H-39 and H-59), 3.50 (2H, t, J=6.2 Hz, H-10),
1.68 (2H, sextet, J=7.0 Hz, H-20), 0.99 (3H, t, J=7.3 Hz, H-30)
(Figures S46, S47 and S48); 13C NMR (CDCl3) d 145.8 (C-29 and C-
69), 132.2 (C-39 and C-59), 135.3, 129.0, 127.8, 126.6, 126.4 (C-4b,
C-7, C-8, C-8a, C-9), 116.9 (C-10), 116.9 (C-4a), 112.1 (C-3), 73.9
(C-19), 66.5 (C-10), 23.0 (C-20), 10.2 (C-30); ESI-MS (m/z, %): 369
(M++Na, 100), 347 (M++H, 60); HRMS C22H18O4Na, calculated
369.1103; found 369.1105; X-ray data are shown in Figure S2.
3-(1-Isopropoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (15). Yield: 52% (31.2 mg); NP-HPLC:
6.307 min (Figure S17), purity: 99.0%; transparent crystals, 1H
NMR (CDCl3) d 9.97 (1H, d, J=8.8 Hz, H-5), 8.03 (1H, d,
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J=9.0 Hz, H-9), 7.94 (1H, d, br, J=8.2 Hz, H-8), 7.74 (1H, td,
J=7.8, 1.0 Hz, H-7), 7.60 (1H, td, J=7.6, 1.0 Hz, H-6), 7.35
(1H, d, J=9.2 Hz, H-10), 6.94 (1H, s, H-3), 6.91 (2H, d,
J=10.6 Hz, H-29 and H-69), 6.53 (2H, d, J=9.8 Hz, H-39 and
H-59), 3.89 (1H, septet, J=6.2 Hz, H-10), 1.24 (6H, d, J=6.2 Hz,
H-20 and H-30) (Figures S49, S50 and S51); 13C NMR (CDCl3) d
184.5 (C-49), 179.6 (C-4), 161.2 (C-2), 156.9 (C-10a), 146.2 (C-29
and C-69), 131.5 (C-39,C-59), 135.3, 130.2, 129.9, 129.0, 127.7,
126.6, 126.4 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9), 116.9 (C-10),
116.9 (C-4a), 112.2 (C-3), 74.1 (C-19), 68.5 (C-10), 24.3 (C-20 and
C-30); ESI-MS (m/z, %): 369 (M++Na, 100), 347 (M++H, 54);
HRMS C22H18O4Na, calculated 369.1103; found 369.1104.
3-(1-Butoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (16). Yield: 54% (33.8 mg); NP-HPLC:
5.230 min (Figure S18), purity: 95.8%; transparent crystals, mp:
72–73uC, 1H NMR (CDCl3) d 9.97 (1H, d, J=8.8 Hz, H-5), 8.03
(1H, d, J=9.2 Hz, H-9), 7.86 (1H, d, br, J=8.0 Hz, H-8), 7.74 (1H,
td, J=8.4, 1.6 Hz, H-7), 7.59 (1H, td, J=7.6, 1.6 Hz, H-6), 7.34
(1H, d, J=9.0 Hz, H-10), 6.92 (1H, s, H-3), 6.87 (2H, d,
J=10.2 Hz, H-29 and H-69), 6.55 (2H, d, J=10.4 Hz, H-39 and
H-59), 3.54 (2H, t, J=6.2 Hz, H-10), 1.65 (2H, m, J=7.0 Hz, H-20),
1.45 (2H, m, J=7.3 Hz, H-30), 0.95 (3H, t, J=7.4 Hz, H-40)
(Figures S52, S53 and S54); 13C NMR (CDCl3) d 184.3 (C-49), 179.5
(C-4), 160.1 (C-2), 156.9 (C-10a), 145.9 (C-29 and C-69), 132.2 (C-39
and C-59), 135.3, 130.2, 129.9, 129.0, 127.8, 126.6, 126.4 (C-4b, C-
5, C-6, C-7, C-8, C-8a, C-9), 116.9 (C-10), 116.9 (C-4a), 112.1 (C-3),
73.8 (C-19), 64.6 (C-10), 31.7 (C-20), 18.8 (C-30), 13.4 (C-40); ESI-MS
(m/z, %): 383 (M++Na, 100), 361 (M++H, 65); HRMSC23H20O4Na,
calculated 383.1259; found 383.1258.
3-(1-Allyloxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (17). Yield: 51% (30.5 mg); NP-HPLC:
6.650 min (Figure S19), purity: 98.0%; transparent crystals, mp:
148–150uC, 1H NMR (CDCl3) d 9.96 (1H, d, J=8.2 Hz, H-5),
8.03 (1H, d, J=8.8 Hz, H-9), 7.86 (1H, d, br, J=8.2 Hz, H-8),
7.74 (1H, td, J=8.4, 1.4 Hz, H-7), 7.60 (1H, td, J=7.6, 1.0 Hz,
H-6), 7.35 (1H, d, J=9.2 Hz, H-10), 6.94 (1H, s, H-3), 6.91 (2H,
d, J=11.0 Hz, H-29 and H-69), 6.57 (2H, d, J=10.2 Hz, H-39
and H-59), 5.95 (1H, m, J=5.0 Hz, H-20), 5.38 (1H, dd, J=18.8,
1.6 Hz, H-30, cis), 5.25 (1H, dd, J=10.4, 1.6 Hz, H-30, trans),
4.09 (2H, J=5.6 Hz, H-10) (Figures S55, S56 and S57); 13C NMR
(CDCl3) d 184.1 (C-49), 179.4 (C-4), 160.6 (C-2), 156.9 (C-10a),
145.3 (C-29 and C-69), 132.4 (C-39 and C-59), 135.3, 130.2, 129.9,
129.0, 127.8, 126.6, 126.4 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9),
116.9 (C-10), 116.9 (C-4a), 112.2 (C-3), 74.1 (C-19), 65.7(C-10),
133.2 (C-20), 117.2 (C-30); ESI-MS (m/z, %): 367 (M++Na, 100),
345 (M++H, 65); HRMS C22H16O4Na, calculated 367.0946;
found 367.0949; X-ray data are shown in Figure S3.
3-(1-(Prop-2-ynoxy)-4-oxocyclohexa-2,5-dienyl)-1H-benzo
[f]chromen-1-one (18). Yield: 45% (26.7 mg), NP-HPLC:
9.527 min (Figure S20), purity: 99.6%; transparent crystals, mp:
142–145uC, 1H NMR (CDCl3) d 9.95 (1H, d, J=7.4 Hz, H-5),
8.04 (1H, d, J=9.2 Hz, H-9), 7.87 (1H, d, br, J=8.0 Hz, H-8),
7.74 (1H, td, J=8.4, 1.6 Hz, H-7), 7.60 (1H, td, J=8.2, 1.0 Hz,
H-6), 7.37 (1H, d, J=9.2 Hz, H-10), 6.97 (2H, d, J=10.4 Hz,
H-29 and H-69), 6.91 (1H, s, H-3), 6.59 (2H, d, J=10.4 Hz, H-39
and H-59), 4.26 (2H, d, J=2.6 Hz, H-10), 2.55 (1H, t, J=2.4 Hz,
H-30) (Figures S58, S59 and S60); 13C NMR (CDCl3) d 183.9 (C-
49), 179.3 (C-4), 159.9 (C-2), 156.9 (C-10a), 144.2 (C-29 and C-
69), 132.6 (C-39 and C-59), 135.4, 130.2, 129.8, 129.1, 127.8,
126.6, 126.5 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9), 116.8 (C-10),
116.8 (C-4a), 112.2 (C-3), 74.6 (C-19), 53.2 (C-10), 75.7 (C-
30),79.0 (C-20); ESI-MS (m/z, %): 365 (M++Na, 100), 343
(M++H, 52); HRMS C22H14O4Na, calculated 365.0790; found
365.0788.
Supporting Information
Figure S1 X-ray diffraction data for compound 8. CCDC
762721; formula: C18H14O6; unit cell parameters: a 6.9461(20) b
30.2804(66) c 7.6340(13) beta 93.752(19) space group P21/c.
(TIF)
Figure S2 X-ray diffraction data for compound 14.
CCDC 762722; formula: C22H18O4; unit cell parameters: a
7.8452(8) b 25.285(5) c 18.144(2) beta 96.096(9) space group P21/c.
(TIF)
Figure S3 X-ray diffraction data for compound 17.
CCDC 762723; formula: C22H16O4; unit cell parameters: a
7.9122(8) b 24.817(5) c 17.8259(16) beta 96.380(8) space group P21/c.
(TIF)
Figure S4 RP-HPLC chromatogram of compound 1.
Solvent: 35% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 35%; flow rate: 1 mL/min,
l=245 nm
(TIF)
Figure S5 RP-HPLC chromatogram of compound 10.
Solvent: 35% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 35%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S6 RP-HPLC chromatogram of compound 3.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S7 RP-HPLC chromatogram of compound 4.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S8 RP-HPLC chromatogram of compound 5.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S9 RP-HPLC chromatogram of compound 6.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S10 RP-HPLC chromatogram of compound 7.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S11 RP-HPLC chromatogram of compound 8.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S12 RP-HPLC chromatogram of compound 9.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Economic Synthesis of Protoapigenone & Derivatives
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23922
Figure S13 NP-HPLC chromatogram of compound 11.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S14 NP-HPLC chromatogram of compound 12.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S15 NP-HPLC chromatogram of compound 13.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S16 NP-HPLC chromatogram of compound 14.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S17 NP-HPLC chromatogram of compound 15.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S18 NP-HPLC chromatogram of compound 16.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S19 NP-HPLC chromatogram of compound 17.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S20 NP-HPLC chromatogram of compound 18.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S21 400 MHz 1H NMR spectrum of compound 10.
(TIF)
Figure S22 Zoom of 400 MHz 1H NMR spectrum of
compound 10.
(TIF)
Figure S23 200 MHz 1H NMR spectrum of compound 3
before crystallization.
(TIF)
Figure S24 Zoom of 200 MHz 1H NMR spectrum of
compound 3 before crystallization.
(TIF)
Figure S25 200 MHz 1H NMR spectrum of compound 4
before crystallization.
(TIF)
Figure S26 Zoom of 200 MHz 1H NMR spectrum of
compound 4 before crystallization.
(TIF)
Figure S27 Zoom of 200 MHz 1H NMR spectrum of
compound 4 before crystallization.
(TIF)
Figure S28 200 MHz 1H NMR spectrum of compound 5
before crystallization.
(TIF)
Figure S29 Zoom of 200 MHz 1H NMR spectrum of
compound 5 before crystallization.
(TIF)
Figure S30 Zoom of 200 MHz 1H NMR spectrum of
compound 5 before crystallization.
(TIF)
Figure S31 200 MHz 1H NMR spectrum of compound 6
before crystallization.
(TIF)
Figure S32 Zoom of 200 MHz 1H NMR spectrum of
compound 6 before crystallization.
(TIF)
Figure S33 Zoom of 200 MHz 1H NMR spectrum of
compound 6 before crystallization.
(TIF)
Figure S34 Zoom of 200 MHz 1H NMR spectrum of
compound 6 before crystallization.
(TIF)
Figure S35 200 MHz 1H NMR spectrum of compound 7
before crystallization.
(TIF)
Figure S36 Zoom of 200 MHz 1H NMR spectrum of
compound 7 before crystallization.
(TIF)
Figure S37 Zoom of 200 MHz 1H NMR spectrum of
compound 7 before crystallization.
(TIF)
Figure S38 200 MHz 1H NMR spectrum of compound 8
before crystallization.
(TIF)
Figure S39 Zoom of 200 MHz 1H NMR spectrum of
compound 8 before crystallization.
(TIF)
Figure S40 200 MHz 1H NMR spectrum of compound 9
before crystallization.
(TIF)
Figure S41 Zoom of 200 MHz 1H NMR spectrum of
compound 9 before crystallization.
(TIF)
Figure S42 400 MHz 1H NMR spectrum of compound 9
before crystallization.
(TIF)
Figure S43 200 MHz 1H NMR spectrum of compound 13
before crystallization.
(TIF)
Figure S44 Zoom of 200 MHz 1H NMR spectrum of
compound 13 before crystallization.
(TIF)
Figure S45 Zoom of 200 MHz 1H NMR spectrum of
compound 13 before crystallization.
(TIF)
Figure S46 200 MHz 1H NMR spectrum of compound 14
before crystallization.
(TIF)
Figure S47 Zoom of 200 MHz 1H NMR spectrum of
compound 14 before crystallization.
(TIF)
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Figure S48 Zoom of 200 MHz 1H NMR spectrum of
compound 14 before crystallization.
(TIF)
Figure S49 200 MHz 1H NMR spectrum of compound 15
before crystallization.
(TIF)
Figure S50 Zoom of 200 MHz 1H NMR spectrum of
compound 15 before crystallization.
(TIF)
Figure S51 Zoom of 200 MHz 1H NMR spectrum of
compound 15 before crystallization.
(TIF)
Figure S52 200 MHz 1H NMR spectrum of compound 16
before crystallization.
(TIF)
Figure S53 Zoom of 200 MHz 1H NMR spectrum of
compound 16 before crystallization.
(TIF)
Figure S54 Zoom of 200 MHz 1H NMR spectrum of
compound 16 before crystallization.
(TIF)
Figure S55 200 MHz 1H NMR spectrum of compound 17
before crystallization.
(TIF)
Figure S56 Zoom of 200 MHz 1H NMR spectrum of
compound 17 before crystallization.
(TIF)
Figure S57 Zoom 200 MHz 1H NMR spectrum of
compound 17 before crystallization.
(TIF)
Figure S58 200 MHz 1H NMR spectrum of compound 18
before crystallization.
(TIF)
Figure S59 Zoom of 200 MHz 1H NMR spectrum of
compound 18 before crystallization.
(TIF)
Figure S60 Zoom of 200 MHz 1H NMR spectrum of
compound 18 before crystallization.
(TIF)
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Abstract. Background: Protoapigenone (PA), a natural
flavonoid possessing an unusual p-quinol moiety on its B ring,
is a prospective novel lead compound against cancer currently
in development, together with WYC0209, a potent synthetic PA
analog. Structure activity relationships (SAR) concerning
different 1’-O-alkyl side-chains were also studied on two sets
of derivatives. Materials and Methods: Fifteen 1’-O-alkyl
protoflavone derivatives were synthesized from genkwanin or
4’-hydroxy-6-methylflavone, thirteen of which are new
compounds. All compounds were tested for their cytotoxic
effect on four human cancer cell lines, such as HepG2 and
Hep3B (hepatic), A549 (lung) and MDA-MB-231 (breast) cell
lines, with doxorubicin as a positive control. All compounds,
as well as PA, WYC0209 and fourteen of their previously
reported analogs were also tested on a multidrug-resistant
(MDR) sub-cell line of L5178 mouse T-cell lymphoma and on
its parental counterpart (PAR). Results: In general, derivatives
bearing a free hydroxyl group at C-1’ exerted the strongest
activities, while C-1’-substituted compounds were found to be
much weaker. Derivatives of 6-methylflavone exhibited mild,
but statistically significant selectivity towards the MDR cell
line. Conclusion: The results are in agreement with our
previous findings for fundamental SAR of protoflavones. 6-
Methylated protoflavones may serve as valuable leads for
developing selective compounds against MDR cancer.
Identical activity of other derivatives on the PAR and MDR
cell lines suggests that cancer cells cannot exhibit resistance
to protoflavones by ABCB1 efflux pump overexpression.
Flavonoids have long been proposed to exert various
bioactivities interfering with cancer cells on several levels,
including those connected to their antioxidant and
chemopreventive effects, and, for certain derivatives, specific
anticancer activities have also been described (1-4).
Protoapigenone is an oxidized derivative of the common
flavonoid apigenin, expressing an unusual p-quinol moiety
in its B-ring; the structures of these two compounds as well
as that of WYC0209, the strongest synthetic derivative of
protoapigenone obtained to date, are shown in Figure 1.
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Isolated for the first time from the fern Thelypteris
torresiana, protoapigenone was recently discovered as a
promising, natural anticancer agent (5) based on its strong
antitumor activity against several cancer cell lines of
different origin both in vitro and in vivo (5, 6). It induces
apoptosis through the activation of p38 mitogen-activated
protein kinase and c-Jun NH2-terminal kinase 1/2 (7)
resulting in a G(2)/m cell cycle arrest (8), in which the role
of oxidative stress and glutathione-S-transferase π inhibition
was also suggested (9). Most recently, a unique mechanism
was found for the anticancer action of protoapigenone and
WYC0209: these flavonoids were found to affect the ataxia
telangiectasia-mutated and Rad3-related (ATR) signaling
pathway both in vitro and in vivo (10). This pathway plays
an essential role in maintaining genomic integrity, and it is
considered an attractive target for the development of a new
class of anticancer drugs (11). Interestingly, as well as its
cancer-related effects, protoapigenone was also found to
inhibit the lytic cycle of Epstein-Barr virus (12), a well-
known risk factor for several malignant diseases.
After the successful total synthesis of protoapigenone and
several of its derivatives (13), a very simple semi-synthetic
way to obtain this compound directly from apigenin was also
reported by our group (14). This work also resulted in the
production of several 1’-O-alkyl derivatives of both
protoapigenone and WYC0209, revealing new side-chain-
dependent structure activity relationships within the
protoapigenone derivatives but not within those of the
WYC0209. Although a 1’-OCH3 group markedly reduced
the cytotoxic activity, increasing the length of an aliphatic
side chain restored, or even increased the activity. This effect
did not occur in the presence of a branching or unsaturated
side chain (14). As a direct continuation of this work, here
we report the synthesis and cytotoxicity evaluation of several
new protoflavones towards various human cancer cell lines
and two mouse lymphoma cell lines: a parental (susceptible,
PAR) cell line and its multidrug resistant (MDR) sub-cell
line expressing the human ATP Biding Cassette (ABC) B1
efflux pump, which, as the most prevalent ABC transporter,
is among the major reasons for failure of cancer
chemotherapy (15). 
Materials and Methods
Protoflavones. Compounds 1-15 were synthesized from 4’-
hydroxyflavones (genkwanin, 4’-hydroxy-6-methylflavone and 4’-
hydroxy-6-methoxyflavone) obtained from Indofine Chemical
Company Ltd. (Hillsborough, NJ, USA), as reported previously (14).
Briefly, the starting material was dissolved in a 9:1 (v/v) mixture of
acetonitrile and water or the alcohol to be coupled to C-1’ as an O-
alkyl side chain, at a concentration of 1 mg/ml. After this, two
equivalents of [bis(trifluoroacetoxy)iodo]benzene (Sigma Aldrich,
Munich, Germany) were added to the mixture, the container was
sealed and 1-min microwave heating was applied at 300 W in a
standard domestic microwave oven. After cooling, the reaction
mixture was evaporated, re-dissolved in acetone and purified by
rotational planar chromatography on a Chromatothron equipment
(Harrison Research, Palo Alto, California, USA) with adequately
chosen eluents consisting of n-hexane–ethyl acetate–acetone on
silica. Solvents and silica were purchased from Merck (Darmstadt,
Germany). Protoflavones obtained were re-crystallized from solvent
mixtures similar to the eluents. Synthesis, bioactivity on the human
cancer cell lines and compound characterization data for compounds
16-29, were reported previously (14).
Structure elucidation carried out by means of electrospray
ionization tandem mass spectrometry (ESI-MS/MS) and nuclear
magnetic resonance (NMR) spectroscopy. MS and MS/MS spectra
were taken on an API 2000 triple-quadrupole tandem mass
spectrometer (AB SCIEX, Foster City, CA, USA) in ESI+ mode.
NMR spectra were obtained on a Bruker Avance DRX-500
spectrometer in acetone-d6, methanol-d4, or chloroform-d1.
Cell lines. Human cell lines: Human liver (HepG2 and Hep3B),
lung (A549) and breast (MDA-MB-231) cancer cell lines were
obtained from the American Type Culture Collection. All cell lines
were propagated in RPMI-1640 medium, supplemented with 10%
(v/v) fetal bovine serum (FBS), 100 U/ml of penicillin, and 100
μg/ml of streptomycin at 37˚C in a humidified atmosphere of 5%
CO2 and 95% air.
Mouse lymphoma cell lines. PAR and MDR cell lines were L5178
mouse T-cell lymphoma cells and the L5178 cells transfected with
pHa MDR1/A retrovirus, respectively. MDR cell lines were selected
by culturing the infected cells with 60 μg/l of colchicine (16). Both
cell lines were cultured in McCoy’s 5A medium, supplemented with
10% heat-inactivated horse serum, L-glutamine and antibiotics
(penicillin and streptomycin), at 37˚C and in an atmosphere with
5% CO2.
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Figure 1. Structures of apigenin (A), protoapigenone (B) and WYC0209, currently the strongest synthetic protoflavone derivative known (C).
Cytotoxicity assay. Cell viability was measured by the 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
colorimetric method (17). Human cancer cells were seeded at
densities of 5,000 to 10,000 cells/well in 96-well tissue culture plates.
On the next day, cells were treated with 10 μl of the test compounds
dissolved at different concentrations for another 72 h. After drug
treatment, attached cells were incubated with MTT (0.5 mg/ml, for 1
h) and subsequently solubilized in dimethyl sulfoxide (DMSO). The
absorption at 550 nm was then measured using a microplate reader. 
In contrast to these, the non-adherent PAR and MDR cell lines
were used at 20,000 cells/well without being seeded but treated
immediately. The cells were incubated for 24 h, after which MTT
was added to a final concentration of 10% per well. After 4 h of
incubation, sodium dodecyl sulfate (SDS) 10% was also added to a
final concentration of 5% per well and cells were incubated
overnight. Absorption was read at 540 and 630 nm using an ELISA
reader (Multiskan EX, Lab Systems, USA).
Each assay was performed in triplicate. In both protocols, the
IC50 was recorded as the concentration of the agent that reduced cell
viability by 50% under the experimental conditions, as determined
by applying log (concentration) vs. inhibition variable slope
nonlinear regression with automatic outlier elimination at Q=1.0%,
by using GraphPad Prism 5.0 (GraphPad Software Inc., California,
USA), and 95% confidence intervals of the IC50 values were
obtained from the curve fitting. Statistical evaluation of data
obtained for the PAR and MDR cell lines was performed by using
one-way ANOVA followed by Bonferroni’s multiple comparison
test; in those cases where variances were not significantly different,
unpaired t-tests were also performed in order to test for occasional
differences under less strict statistical conditions.
Results and Discussion
With a microwave-assisted oxidative de-aromatization by a
common hypervalent iodine reagent, 15 protoflavones were
obtained from genkwanin, 4’-hydroxy-6-methylflavone. The
structure elucidation of the synthesized compounds was
performed according to the following: As a first step, by
means of the ESI-MS and MS/MS spectra, the expected
molecular mass of each compound was confirmed. After this,
analyzing the 1H-NMR spectrum was sufficient to
unambiguously prove successful transformation: the
characteristic coupling constants of 8.8 Hz of the two
doublets present in the aromatic B-ring of the starting
material (representing H-2’/H-6’ and H-3’/H-5’) changed to
~10.0 Hz, suggesting the formation of a symmetric
cyclohexadien-1-one, and aliphatic proton signals, and their
multiplicity, together with the practically unchanged A-ring
signals and H-3 singlet, proved the presence of the expected
side-chain at position C-1’; detailed data are presented in the
Experimental section. Structures of the obtained compounds,
as well as those of the ones previously reported (14), are
presented in Figure 2. Compounds 3-15 are described here
for the first time.
All derivatives were tested for their cytotoxicity towards
HepG2, Hep3B, A549 and MDA-MB-231 human cancer cell
lines; results are summarized in Table I.
Structure activity relationships previously reported by our
group (14) were confirmed by the present experiments. The
presence of 1-O-alkyl side-chain increases the IC50 in the
case of derivatives of the less polar 4’-hydroxyflavones. The
cytotoxic activities of compounds 10-15 were significantly
weaker than that of compound 9. Interestingly, derivatives of
genkwanin had a similar behavior, and cytotoxicity of these
compounds was generally also not restored or increased
when a 3-4 carbon aliphatic O-alkyl side-chain was
introduced to C-1’ [as found for protoapigenone (14)] with
one single exception: compound 6 (1’-O-butyl ether) was as
Danko et al: Cytotoxicity and MDR Selectivity of Novel Protoflavones
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Figure 2. Structures of the novel protoflavone derivatives 1-15 obtained (A), and those of the analogs of protoapigenone (16-22) and WYC0209 (23-
29) reported previously (14) (B). Substituents at position 1’ for the individual compounds are presented next to their corresponding core structures.
potent as compound 1 in the case of the Hep3B cell line. The
overall tendency, however, suggests the importance of a free
7-OH group in order to have stronger activity when a longer
aliphatic side-chain is present at C-1’.
Compounds (1-15), as well as protoapigenone, WYC0209
and their corresponding analogs (16-29) were also tested for
their cytotoxic activity towards MDR mouse lymphoma cell
line expressing the human ABCB1 pump, and against its
parental cell line; results are shown in Table II.
The fact that none of the tested compounds exerted weaker
activity on the MDR cell line than on the PAR cell line
suggests that cancer cells cannot exhibit resistance to
protoflavone derivatives by overexpressing the ABCB1 efflux
pump. Moreover, for derivatives of 6-methylflavone,
selective killing of the ABCB1 overexpressing MDR cancer
cells takes place with a rather small (~1.5 fold), yet
statistically significant, selectivity. Some selectivity against
MDR cell lines overexpressing energy-consuming efflux
pump systems could be due to a generally higher
susceptibility of these cells whenever they encounter
cytotoxic agents that are not ligands of the pumps. However,
as from all tested compounds only the 6-methylflavone
derivatives were found to be selective towards the MDR cell
line, more specific reasons are to be suspected, in which
presence of a 6-methyl group seems to be important.
Interestingly, such a functional group (although connected to
a non-aromatic A-ring) is also present in the unique flavone
desmosdumotin B, which was found to exert selective
cytotoxic activity towards the ABCB1 expressing MDR cell
line KB-VIN, with an IC50 value of 2.0 μg/ml in contrast to
the >40 μg/ml found towards the parental cell line (19). 
In view of our results, 6-methylated protoflavone derivatives
may serve as valuable leads toward the development of a
potent and selective agent against MDR cancer cells
overexpressing the ABCB1 transporter; design and synthesis
of further analogs with the aim of exploring relevant structure
activity relationships is currently in progress.
Experimental
Chemical characterization data for compounds 1-15 are
presented below.
5-Hydroxy-2-(1-hydroxy-4-oxocyclohexa-2,5-dienyl)-7-
methoxy-4H-chromen-4-one (1)
Yield: 57%; 1H NMR (500 MHz, acetone-d6) δ 12.6 (1H, s,
OH-8), 7.03 (2H, d, J=10 Hz, H-2’ and H-6’), 6.62 (1H, s,
H-3), 6.45 (1H, s, J=2.1 Hz, H-8), 6.34 (2H, d, J=10.0 Hz,
H-3’ and H-5’), 6.31 (d, J=1.85 Hz, H-6), 3.87 (3H, s, OMe-
7); ESI-MS (m/z): 301 (M++H); ESI-MS-MS (m/z, %): 83.3
(14), 223.3 (27), 256.0 (7), 284.1 (14), 301.2 (100).
5-Hydroxy-7-methoxy-2-(1-methoxy-4-oxocyclohexa-2,5-
dienyl)-4H-chromen-4-one (2)
Yield: 62%; 1H NMR (500 MHz, chloroform-d1) δ 12.43
(1H, s, OH-8), 6.77 (2H, d, J=10.0 Hz, H-2’ and H-6’), 6.61
(1H, s, 1H, s, H-3), 6.56 (2H, d, J=10.0 Hz, H-3’ and H-5’),
6.32 (1H, d, J=1.8 Hz, H-8), 6.25 (1H, d, J=1.8 Hz, H-6),
3.82 (3H, s, OMe-7), 3.39 (3H, s, OMe”); ESI-MS (m/z):
315 (M++H); ESI-MS-MS (m/z, %): 243.3 (2), 256.3 (16),
284.2 (100), 315.2 (47).
2-(1-Ethoxy-4-oxocyclohexa-2,5-dienyl)-5-hydroxy-7-
methoxy-4H-chromen-4-one (3)
Yield: 59.2%; 1H NMR (500 MHz, chloroform-d1) δ12.53
(1H, s, OH-8), 6.79 (2H, d, J=10.1 Hz, H-2’ and H-6’), 6.67
(1H, s, H-3), 6.52 (2H, d, J=10.1 Hz, H-3’ and H-5’), 6.32
(1H, d, J=2.1 Hz, H-8), 6.23 (1H, d, J=2.1 Hz, H-6), 3.81
(3H, s, OMe), 3.57 (2H, q, J=6.9 Hz, H-1”), 1.27 (3H, t,
J=6.5 Hz, H-2”); ESI-MS (m/z, %): 329.1 (M++H); ESI-MS-
ANTICANCER RESEARCH 32: 2863-2870 (2012)
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Table I. Inhibition concentration (IC50) values of 1-15 and, in
parenthesis, the corresponding 95% confidence intervals for the six
cancer cell lines.
HepG2 Hep3B A549 MDA-MB-231 
PA 3.07a 1.21a 11.29a 1.35a
(2.83-3.34) (1.19-1.24) (10.07-12.65) (1.17-1.55)
WYC0209 1.06a 0.25a 2.19a 0.43a
(1.04-1.08) (0.20-0.30) (2.03-2.37) (0.41-0.45)
1 1.86 0.64 1.77 0.70
(1.85-1.88) (0.55-0.73) (1.50-2.08) (0.64-0.77) 
2 7.65 1.88 12.09 2.08
(7.44-7.87) (1.55-2.28) (8.95-16.34) (1.96-2.22) 
3 7.27 1.82 10.97 2.09
(7.05-7.50) (1.73-1.91) (9.24-13.03) (1.99-2.20) 
4 8.69 1.83 10.27 2.20
(8.05-9.38) (1.33-2.52) (9.49-11.11) (2.05-2.36) 
5 >50 >50 >50 >50
6 12.27 0.65 11.83 5.13
(11.70-12.87) (0.61-0.68) (10.16-13.77) (4.52-5.84) 
7 7.85 1.65 5.04 1.87
(7.66-8.04) (1.15-2.36) (3.48-7.31) (1.74-2.01) 
8 n. d. n. d. n. d. n. d.
9 2.02 0.54 2.00 0.61
(1.87-2.18) (0.53-0.54) (1.82-2.19) (0.57-0.65) 
10 9.79 3.18 15.47 5.46
(9.23-10.39) (2.64-3.83) (13.15-18.20) (5.12-5.82) 
11 8.61 2.17 7.35 3.20
(8.46-8.77) (1.78-2.66) (6.86-7.88) (3.03-3.39) 
12 14.10 3.75 13.45 5.13
(13.08-15.19) (3.12-4.50) (11.58-15.61) (4.93-5.35) 
13 7.47 3.69 5.13 4.85
(7.28-7.65) (2.90-4.70) (4.92-5.35) (4.56-5.16) 
14 11.09 2.41 14.57 4.37
(10.47-11.75) (1.54-3.78) (12.54-16.92) (4.22-4.52) 
15 9.13 2.03 15.30 4.86
(8.88-9.39) (1.50-2.75) (14.53-16.12) (4.74-4.99) 
D 0.79 1.16 2.19 2.60
(0.41-1.55) (0.91-1.47) (1.76-2.73) (2.05-3.30)
aPreviously published data (14). PA: Protoapigenone; D: doxorubicin,
n.d.: not determined; n=3.
MS (m/z, %): 54.1 (3), 86.3 (4), 243.2 (4), 256.2 (14), 284
(100), 301.1 (4), 329.3 (52).
5-Hydroxy-7-methoxy-2-(4-oxo-1-propoxycyclohexa-2,5-
dienyl)-4H-chromen-4-one (4)
Yield: 68.8%; 1H NMR (500 MHz, chloroform-d1) δ 12.41
(1H, s, OH-8) 6.76 (2H, d, J=10.0 Hz, H-2’ and H-6’), 6.66
(1H, s, H-3), 6.52 (2H, d, J=10.0 Hz, H-3’ and H-5’), 6.32
(1H, d, J=1.6 Hz, H-8), 6.23 (1H, d, J=1.4 Hz, H-6), 3.81
(3H,s, OMe), 3.45 (2H, t, J=6.4 Hz, H-1”), 1.65 (3H, m, H-
2”), 0.96 (3H, t, J=7.4 Hz, H-3”); ESI-MS (m/z, %): 343.3
(M++H); ESI-MS-MS (m/z, %): 54.4 (6), 86.5(10), 243.2 (5),
257.1 (12), 273.1 (2), 284.3 (100), 301.3 (2), 343.2 (40) 
5-Hydroxy-2-(1-isopropoxy-4-oxocyclohexa-2,5-dienyl)-7-
methoxy-4H-chromen-4-one (5)
Yield: 49.4%; 1H NMR (500 MHz, chloroform-d1) δ 12.42
(1H, s, H-8), 6.80 (2H, d, J=9.9 Hz, H-2’ and H-6’), 6.67
(1H, s, H-3), 6.49 (2H, d, J=10.0 Hz, H-3’ and H-5’), 6.30
(1H, d, J=1.8 Hz, H-8), 6.21 (1H, d, J=2.0 Hz, H-6), 3.83
(1H, dd, J=12.2, 6.1 Hz, H-1”), 3.80 (3H, s, OMe), 1.21
(6H, d, J=6.1 Hz, H-2” and H-3”); ESI-MS (m/z): 343.0
(M++H); ESI-MS-MS (m/z, %): 54.3 (6), 86.3(9), 242.5 (4),
256 (13), 272.9 (6), 284.3 (100), 301.3 (8), 343.1 (68). 
2-(1-Ethoxy-4-oxocyclohexa-2,5-dienyl)-5-hydroxy-7-
methoxy-4H-chromen-4-one (6)
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Table II. Cytotoxic activity of protoapigenone, WYC0209 and compounds 1-29 towards the multidrug resistant cell line (MDR) and its parental cell
line (PAR).
IC50 (μM) IC50 (μM)
Compound PAR MDR Selectivitya Compound PAR MDR Selectivitya
1 1.72 1.51 n.s. PA 0.76 0.79 n.s.
(1.57-1.90) (1.28-1.78) (0.66-0.88) (0.71-0.88)
2 0.55 0.57 n.s. 16 3.24 2.50 n.s.
(0.45-0.67) (0.50-0.65) (2.71-3.87) (2.04-3.08)
3 1.36 1.41 n.s. 17 3.72 3.43 n.s.
(1.20-1.54) (1.21-1.64) (3.11-4.46) (2.83-4.16)
4 1.47 1.63 n.s. 18 4.66 3.69 n.s.
(1.26-1.73) (1.41-1.87) (3.50-6.21) (2.57-5.31)
5 n.d. n.d. n.d. 19 7.07 8.16 n.s.
(4.89-10.23) (3.41-19.55)
6 3.95 3.98 n.s. 20 1.29 1.11 n.s.
(3.17-4.93) (3.58-4.42) (1.10-1.53) (0.92-1.33)
7 1.17 1.00 n.s. 21 1.27 1.20 n.s.
(1.00-1.36) (0.87-1.15) (1.08-1.49) (1.09-1.33)
8 1.18 0.97 n.s. 22 1.96 1.91 n.s.
(0.96-1.45) (0.83-1.12) (1.64-2.35) (1.62-2.26)
9 0.26 0.16*(T) 1.63 WYC0209 0.15 0.13 n.s.
(0.23-0.29) (0.15-0.18) (0.14-0.16) (0.11-0.14)
10 1.85 1.35** 1.37 23 0.95 0.82 n.s.
(1.64-2.07) (1.15-1.59) (0.81-1.13) (0.70-0.95)
11 2.38 1.75** 1.36 24 1.46 1.34 n.s.
(2.08-2.73) (1.50-2.05) (1.22-1.75) (1.16-1.55)
12 4.61 2.94*** 1.57 25 1.71 1.79 n.s.
(3.83-5.56) (2.46-3.53) (1.53-1.92) (1.60-2.01)
13 3.71 2.71*** 1.37 26 ~6.79 8.49 n.s.
(3.33-4.14) (2.29-3.21) (4.66-15.46)
14 2.27 1.73** 1.31 27 1.44 1.26 n.s.
(1.94-2.66) (1.50-1.98) (1.25-1.66) (1.12-1.43)
15 1.45 0.98* 1.48 28 0.82 0.74 n.s.
(1.29-1.63) (0.88-1.08) (0.70-0.96) (0.63-0.87)
D 0.61 8.60*** 0.071 29 0.76 0.81 n.s.
(0.51-0.74) (7.80-9.47) (0.67-0.85) (0.65-1.01)
aSelectivity was calculated for those compounds which showed significant differences in the IC50 values towards the two cells lines. 95% Confidence
intervals are presented for each curve fitting result, ~: ambiguous fitting, no confidence interval available. Selectivity=IC50(PAR)/IC50(MDR). Statistical
comparisons were made between values in columns PAR and MDR. *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA followed by Bonferroni’s
multiple comparison test; *(T): p<0.05 by unpaired t-test, variances are not significantly different; D: doxorubicin, n.d.: not determined, n.s.: no
selectivity, n=3.
Yield: 33%; 1H NMR (500 MHz, chloroform-d1) δ12.44
(1H, s, H-8), 6.77 (2H, d, J=10 Hz, H-2’ and H-6’), 6.68
(1H, s, H-3), 6.54 (2H, d, J=10Hz, H-3’ and H-5’), 6.33 (1H,
d, J=1.85 Hz, H-8), 6.25 (1H, d, J=2.0 Hz, H-6). 3.83 (3H,
s, OMe), 3.51 (2H, s, H-1”), 1.62 (2H, m , H-2”), 1.43 (2H,
m, H-3”), 0.92 (3H, t, J=7.4 Hz, H-4”); ESI-MS (m/z): 357
(M++H); ESI-MS-MS (m/z, %): 100.5 (1), 243.1 (5), 257.2
(14),273.2 (4), 284.2 (100), 301.1 (8), 329.3 (1), 357.1 (72).
2-(1-(Allyloxy)-4-oxocyclohexa-2,5-dienyl)-5-hydroxy-7-
methoxy-4H-chromen-4-one (7)
Yield: 43.6%; 1H NMR (500 MHz, chloroform-d1) δ12.39
(1H, s, H-8), 6.79 (2H, d, J=10.1 Hz, H-2’ and H-6’), 6.67
(1H, s, H-3), 6.53 (2H, d, J=10.1 Hz, H-3’ and H-5’), 6.31
(1H, d, J=2.1 Hz, H-8), 6.23 (1H, d, J=1.8 Hz, H-6), 5.91
(1H, m, J=5.2 Hz, H-2”), 5.33 (1H, d, J=17.2 Hz, H-3”,
cisz), 5.22 (1H, d, J=10.4 Hz, H-3” , trans), 4.04 (1H, m, H-
1”), 3.81 (3H, s, OMe); ESI-MS (m/z): 341.3 (M++H); ESI-
MS-MS (m/z, %): 243.2 (6), 257.2 (16), 272.3 (2), 284.1
(100), 300.1 (2), 341.3 (42).
5-Hydroxy-7-methoxy-2-(4-oxo-1-(prop-2-ynyloxy)
cyclohexa-2,5-dienyl)-4H-chromen-4-one (8)
Yield: 37.2%; 1H NMR (500 MHz, chloroform-d1) δ 12.38
(1H, s, H-8), 6.85 (2H, d, J=9.9 Hz, H-2’ and H-6’), 6.66
(1H, s, H-3), 6.55 (2H, d, J=9.9 Hz, H-3’ and H-5’), 6.32
(1H, d, J=1.8 Hz, H-8), 6.24 (1H, d, J=1.8 Hz, H-6), 4.21
(2H, d, J=2.1 Hz, H1”), 3.81 (3H, s, OMe), 2.52 (1H, t,
J=2.4 Hz, H-3”); ESI-MS (m/z, %): 339.3 (M++H,); ESI-
MS-MS (m/z, %): 49.2 (4), 243.3 (6), 256.2 (18), 271.2 (3),
284.3 (100), 300.3 (2), 339.2 (42).
2-(1-Hydroxy-4-oxocyclohexa-2,5-dienyl)-6-methyl-4H-
chromen-4-one (9)
Yield: 48.2%; 1H NMR (500 MHz, chloroform-d1) δ 7.93
(1H, s, H-7), 7.47 (1H, d, J=8.5 Hz, H-8), 7.27 (1H, d, J=8.6
Hz, H-5), 6.94 (2H, d, J=9.5 Hz, H-2’ and H-6’), 6.84 (1H,
s, H-3), 6.41 (2H, d, J=9.5 Hz, H-3’ and H-5’), 2.43 (3H s,
CH3-6); ESI-MS (m/z): 269.1 (M++H,); ESI-MS-MS (m/z,
%): 83.5 (1), 92.4 (5), 107.6 (6), 120.7 (11), 134 (30), 147
(14), 224.2 (1), 241.1 (16), 252 (16), 269.2 (100).
2-(1-Methoxy-4-oxocyclohexa-2,5-dienyl)-6-methyl-4H-
chromen-4-one (10)
Yield: 59.7%; 1H NMR (500 MHz, methanol-d4) δ 7.87 (1H,
s, H-7), 7.57 (1H, d, J=8.5 Hz, H-8), 7.33 (1H, d, J=8.6 Hz,
H-5), 6.97 (2H, d, J=9.9 Hz, H-2’ and H-6’), 6.71 (1H, s, H-
3), 6.57 (2H, d, J=9.9 Hz, H-3’ and H-5’), 3.44 (3H s, H-
1”), 2.43 (3H s, CH3-6); ESI-MS (m/z): 283.2 (M++H,); ESI-
MS-MS (m/z, %): 133.8 (1), 146.9 (3), 224.2 (20), 252.2
(100), 283.1 (25).
2-(1-Ethoxy-4-oxocyclohexa-2,5-dienyl)-6-methyl-4H-
chromen-4-one (11)
Yield: 20%; 1H NMR (500 MHz, methanol-d4)) δ 7.88 (1H,
s, H-7), 7.59 (1H, d, J=8.6 Hz, H-8), 7.33 (1H, d, J=8.6 Hz,
H-5), 7.00 (2H, d, J=10.1 Hz, H-2’ and H-6’), 6.75 (1H, s,
H-3), 6.54 (2H, d, J=10,0 Hz, H-3’ and H-5’), 3.64 (2H q ,
J=6.9 Hz, H-1”), 2.44 (3H s, CH3-6), 1.30 (3H, t, J=7.0 Hz,
H-2”); ESI-MS (m/z): 296. 8 (M++H,); ESI-MS-MS (m/z,
%): 224.2 (18), 241 (2), 252.1 (100), 269.2 (3), 297.3 (28). 
6-Methyl-2-(4-oxo-1-propoxycyclohexa-2,5-dienyl)-4H-
chromen-4-one (12)
Yield: 36%; 1H NMR (500 MHz, methanol-d4)) δ 7.89 (1H,
s, H-7), 7.59 (1H, d, J=8.5 Hz, H-8), 7.34 (1H, d, J=8.6 Hz,
H-5), 7.00 (2H, d, J=10.1 Hz, H-2’ and H-6’), 6.75 (1H, s,
H-3), 6.54 (2H, d, J=10,0 Hz, H-3’ and H-5’), 3.54 (2H q ,
J=6.3 Hz, H-1”), 2.45 (3H s, CH3-6), 1.75 (sextet, J=6.8 Hz
H-2”), 1.01 (3H, t, J=7.3 Hz, H-3”); ESI-MS (m/z): 311. 3
(M++H,); ESI-MS-MS (m/z, %): 54.4 (12), 86.6 (11), 224.1
(20), 241.1 (7), 252.3 (100), 268.8 (3), 311 (28).
2-(1-Butoxy-4-oxocyclohexa-2,5-dienyl)-6-methyl-4H-
chromen-4-one (13)
Yield: 35%; 1H NMR (500 MHz, methanol-d4)) δ 7.89 (1H,
s, H-7), 7.59 (1H, d, J=8.5 Hz, H-8), 7.34 (1H, d, J=8.6 Hz,
H-5), 6.99 (2H, d, J=10.0 Hz, H-2’ and H-6’), 6.75 (1H, s,
H-3), 6.55 (2H, d, J=10,0 Hz, H-3’ and H-5’), 3.59 (2H, t ,
J=6.2 Hz, H-1”), 2.45 (3H s, CH3-6), 1.66 (2H, m , H-2”),
1.48 (2H, m, H-3”), 0.97 (3H, t, J=7.4 Hz, H-4”); ESI-MS
(m/z): 325. 3 (M++H,); ESI-MS-MS (m/z, %): 225.2 (18),
241.2 (7), 252.2 (100), 269 (9), 325 (4). 
2-(1-(Allyloxy)-4-oxocyclohexa-2,5-dienyl)-6-methyl-4H-
chromen-4-one (14)
Yield: 73%; 1H NMR (500 MHz, methanol-d4)) δ 7.77 (1H,
s, H-7), 7.47 (1H, d, J=8.5 Hz, H-8), 7.23 (1H, d, J=8.6 Hz,
H-5), 6.91 (2H, d, J=10.0 Hz, H-2’ and H-6’), 6.66 (1H, s,
H-3), 6.45 (2H, d, J=9,9 Hz, H-3’ and H-5’), 5.90 (1H, m,
J=5.3 Hz, H-2”), 5.27 (1H, d, J=17.2 Hz, H-3”, cisz), 5.12
(1H, d, J=10.4 Hz, H-3”, trans) 4.02 (2H, d , J=5.2 Hz, H-
1”), 2.33 (3H s, CH3-6); ESI-MS (m/z): 309.1 (M++H,); ESI-
MS-MS (m/z, %): 224.1 (14), 240 (18), 252 (7), 268.2 (19),
281.1 (21), 309.1 (100).
6-Methyl-2-(4-oxo-1-(prop-2-ynyloxy)cyclohexa-2,5-dienyl)-
4H-chromen-4-one (15)
Yield: 63%; 1H NMR (500 MHz, methanol-d4)) δ 7.77 (1H, s,
H-7), 7.48 (1H, d, J=8.4 Hz, H-8), 7.23 (1H, d, J=8.6 Hz, H-
5), 6.95 (2H, d, J=10.1 Hz, H-2’ and H-6’), 6.62 (1H, s, H-
3), 6.46 (2H, d, J=10,1 Hz, H-3’ and H-5’, 4.21 (2H, d, J=2.2
Hz, H-1”), 2.89 (t, J=2.3 Hz, 2H, H-3”), 2.34 (3H s, CH3-6);
ESI-MS (m/z): 306.9 (M++H,); ESI-MS-MS (m/z, %): 49.2
(1), 224.2 (23), 252.3 (100), 268 (2), 279 (1), 307.2 (37).
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a b s t r a c t
Protoapigenone (Pa) is a flavone aglycone with a p-quinol structure in its B-ring. It was first discovered in
Thelypteris torresiana, a native fern in Taiwan. Recent studies highlighted that protoapigenone and some
of its derivatives show very potent anticancer activity against several types of tumors, using both in vitro
and in vivo models. Despite the growing body of evidence on the selective anticancer potential of pro-
toapigenone and its derivatives, no data are available on their pharmacokinetical properties. In our pres-
ent research, albumin binding properties of Pa and seven different 10-O-alkyl protoapigenone derivatives
were analyzed as well as their biochemical effects on HepG2 tumor cell line in comparison with the fla-
vone apigenin. Our results are in good accordance with the data of previous investigations of 10-O-alkyl-
ated derivatives of protoapigenone (with the exception of isopropyl and allyl derivatives) showing similar
or higher antitumor effects than Pa. Furthermore structural changes in Pa cause a very remarkable influ-
ence on plasma albumin binding affinity of the derivatives. Our investigation proves that parallel with
changes of lipophilic character and extent of plasma protein binding properties of Pa derivatives a con-
sequent alteration occurs in their pharmacokinetic behavior without losing the pharmacodynamic effect.
Based on our study a better understanding of the structural and biochemical behavior of different chem-
ically modified flavonoid derivatives could be achieved making further design of in vivo experiments
feasible.
 2013 Elsevier B.V. All rights reserved.
1. Introduction
Flavonoids are well-known natural polyphenols typically with
significant free-radical scavenging and antioxidant properties [1].
In addition to the widespread knowledge on the molecular actions
of flavonoids, recent publications have revealed the ability of these
compounds to act via novel pathways influencing several biochem-
ical systems: flavonoids have impact on different enzymes and
transporters [1,2], they can modulate numerous cell signaling
pathways [3,4] and several members of this molecule family show
very strong albumin binding capacity [5,6]. Protoapigenone (Fig. 1),
a less common flavone aglycone with a non-aromatic, p-quinol
structure in its B-ring, was first discovered in Thelypteris torresiana,
a native fern in Taiwan [7]. Recent studies suggest that protoapige-
none and some of its derivatives show very promising selective
anticancer activity against several types of tumors, both in vitro
and in vivo [8–16]. The mechanism of action seems to be complex:
induction of oxidative stress, inhibition of glutathione S-transfer-
ase, S and G2/M phase cell cycle arrest, and induction of apoptotic
cell death were also described [8–10]. Furthermore, selective tox-
icity against a multidrug resistant (MDR) cancer cell line [11] and
antiviral activity against Ebstein–Barr virus (EBV) [12] was pub-
lished. During the last 2 years the biochemical effectiveness of
two further, synthetic protoapigenone analogs RY10-4 and
WYC0209 has been also verified [13–15]. Probably the most inter-
esting, recent finding concerning the mode of action of protoapige-
none and WYC0209 is that they can inhibit ataxia telangiectasia-
mutated and Rad3-related (ATR) signaling both in vitro and
in vivo [16]. As this pathway is known to play a crucial role in
DNA damage response, these compounds are valuable leads for
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development of a combination therapy to be used with common
DNA damaging chemotherapeutics, such as for example cisplatin
[16]. Despite the growing body of evidence on the anticancer po-
tential of protoapigenone and its derivatives, no data are available
on their pharmacokinetic properties.
In the present study our main goal was the investigation of
structure related biological differences between chemically modi-
fied Pa-derivatives. Therefore albumin binding properties of pro-
toapigenone and seven different 10-O-alkyl protoapigenone
derivatives (Fig. 1) were analyzed as well as their antitumor effects
on HepG2 tumor cell line in comparison with those of the
40-hydroxyflavone apigenin (Fig. 1) using fluorescence and
luminescence spectroscopy. Plasma albumin binding properties
of biologically active molecules is a very important parameter be-
cause it plays a key role in the pharmacokinetic behavior of drugs
and xenobiotics. Furthermore, data on the albumin binding charac-
teristics of protoapigenone derivatives provide additional informa-
tion on how albumin binding could be influenced by the chemical
modification of native flavonoid aglycones. In order to investigate
the cellular impacts of Pa-derivatives changes in cell cycle distribu-
tion and effects on cell viability (intracellular esterase activity, ATP
and total protein levels) were examined.
2. Materials and methods
2.1. Reagents
All reagents and solvents were of analytical grade. Protoapige-
none (Pa) and its 10-O-alkyl derivatives: protoapigenone
10-O-methylether (Pa-Me), protoapigenone 10-O-ethylether
(Pa-Et), protoapigenone 10-O-propylether (Pa-Pro), protoapigenone
10-O-isopropylether (Pa-iPro), protoapigenone 10-O-butylether
(Pa-But), protoapigenone 10-O-allylether (Pa-All) and protoapige-
none 10-O-propargylether (Pa-PIII) were synthesized as previously
described by Hunyadi et al. [17]. Human serum albumin (HSA), bo-
vine serum albumin (BSA), Ochratoxin A (OTA), DMEM (Dulbecco’s
Modified Eagle’s Medium) – high glucose (4500 mg/L), fetal bovine
serum (FBS), penicillin/streptomycin solution, adenosine 50-tri-
phosphate (ATP), propidium iodide (PI) (all from Sigma–Aldrich),
FITC-Annexin V (from BD Pharmingen), apigenin (Api; from Fluka),
ATP Bioluminescent Assay Kit CLS II (luciferine–luciferase; from
Roche), fluorescamine (Fluram; from Serva), phenylmethylsulfonyl
fluoride (PMSF; from Serva), calcein acetomethoxy ester (CAM;
from Invitrogen) were used as received.
2000 lM stock solutions of flavonoid derivatives were prepared
in dimethyl sulfoxide (DMSO; from Reanal, spectroscopic grade)
and kept at 4 C, protected from light.
Phosphate buffered saline (PBS) containing NaCl (137 mM), KCl
(2.7 mM), NaH2PO4 (8 mM), K2HPO4 (1.5 mM) in tridistilled water
(pH 7.4) was used to approximate physiological conditions.
2.2. Instrumentation
Fluorescence emission spectra and intensities were determined
by a Hitachi F-4500 fluorescence spectrophotometer. A Berthold
Lumat LB9507 luminometer was applied to quantify ATP concen-
trations. All analyses were performed in the presence of air at
+25 C. Flow cytometry measurements were performed on Beck-
man-Coulter FC500 flow cytometer, data analysis was done using
CXP software.
2.3. Determination of binding constants of flavonoid–HSA complexes
Binding constants (K) of protoapigenone derivative – HSA com-
plexes were determined by fluorescence quenching method.
Increasing flavonoid concentrations (0, 1, 2, 3, 4, 5, 7.5, 10, 12.5,
15, 20, 30, and 50 lM) were added to standard amounts of HSA
(5 lM) in PBS (pH 7.4). Fluorescence emission spectra were re-
corded (kexc = 295 nm), K values of albumin–ligand complexes
were evaluated with Hyperquad2006 software (Protonic Software)
using the following equation, in which a 1:1 model is involved:
I ¼ I0 þ ðIHG  I0Þ2  ½H0
 ½H0 þ ½G0 þ
1
K

ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
½H0 þ ½G0 þ
1
K
 2
 4  ½H0  ½G0
s0
@
1
A
where I denotes the fluorescence emission intensity of HSA at
336 nm in the presence of flavonoid; I0 denotes the fluorescence
emission intensity of HSA at 336 nm in the absence of flavonoid;
IHG denotes the fluorescence emission intensity of pure flavonoid–
HSA complex (which is calculated by the Hyperquard2006); K
denotes the binding constant; [H]0 and [G]0 denote the total concen-
trations of HSA and flavonoid, respectively.
Furthermore fluorescence quenching data were also evaluated
using Stern–Volmer equation:
F0
F
¼ 1þ KSV  ½Q 
where F0 and F denote the steady-state fluorescence intensities of
HSA in the absence and in the presence of the quencher, respec-
tively. KSV (with the unit of L mol1) is the Stern–Volmer quenching
constant and [Q] is the concentration of the quencher (with the unit
of mol L1). Stern–Volmer equation was applied for the determina-
tion of KSV by linear regression of F0/F against [Q].
Fig. 1. Chemical structure of apigenin, protoapigenone and its 10-O-alkyl derivatives.
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2.4. Investigation of competing capacity
Competing capacity of protoapigenone derivatives for HSA
binding were quantified using the previously published fluores-
cence polarization based method [6,18,19]. Ochratoxin A (OTA) is
a mycotoxin that binds to albumin with a very high affinity (the
binding site is the same as seen for warfarin, being located in sub-
domain IIA, Site I) [20]. 25 lM flavonoid concentrations were
added to saturating OTA concentrations in the OTA-albumin model
(1 lM OTA and 1.7 lM HSA in PBS, pH 7.4; kexc = 393 nm,
kem = 446 nm). HSA and Pa derivatives did not show any fluores-
cence signal at the applied wavelengths under these circum-
stances. The degree of fluorescence polarization was calculated as:
P ¼ ðIvv  G  IvhÞ=ðIvv þ G  IvhÞ
where Ivv and Ivh are fluorescence intensities measured at vertical
excitation polarizer setting and at vertical and horizontal emission
polarizer settings respectively, while G is the actually measured
optical correction factor. For calculating the degree of polarization
30 measuring points were averaged.
2.5. Tissue cultures
HepG2 (human liver cancer tissue, ATCC: HB-8065) adhering
cells were cultured in DMEM (high glucose) with 10% FBS plus pen-
icillin (100 U/mL) and streptomycin (100 lg/mL) in 25 cm2 sterile
flasks (VWR), in 96-well and in 6-well sterile plastic plates
(VWR). Cells were grown at 37 C in the presence of 5% CO2 in
humidified atmosphere. Cells were pre-cultured for 2 days in the
flasks then trypsinized and resuspended in fresh medium after
having been counted in a Bürker type counting chamber. 1  104
cells per well in 96-well (150 lL cell suspension in medium/well)
plates and 1  105 cells per well in 6-well plates (for flow cytome-
try; 2000 lL cell suspension in medium/well) were plated. After
16 h the medium was replaced with fresh one and cells were trea-
ted with 10 lM flavonoids. Measurements were done after 24-h
incubation in the presence of flavonoids. All sterile work was car-
ried out in an Aireguard-126300 (Nuaire) vertical laminar box.
2.6. Cell number determination
After subjecting cells to the appropriate treatment the medium
was removed and cells were washed twice with 150 lL PBS. Then
cells were trypsinized using 50 lL trypsin solution per well (2.5 g/L
trypsin, 2.96 g/L sodium citrate, 6 g/L sodium chloride, 0.2 g/L so-
dium EDTA). After 3 min incubation cells were counted in a stan-
dard Bürker-type counting chamber and data obtained for 9
readings were averaged.
2.7. Calcein cell viability assay
Calcein acetomethoxy ester (CAM) is transported into living cells
where intracellular esterases cleave the ester bond resulting in the
formation of the highly fluorescent calcein molecule that stays in-
side the cell [23]. After the removal of the medium cells were
washed twice with 150 lL PBS and treated with the dye (150 lL/
well, 1.6 lM CAM in PBS) for 60 min at 37 C in the dark. Then cells
werewashedwith PBS and 150 lL lysis buffer (0.1% SDS in PBS) was
added to each well. After 10 min treatment at room temperature
100 lL cell lysates were added to 2000 lL PBS and fluorescence
emission intensities were measured (kexc = 480 nm, kem = 515 nm).
2.8. Determination of intracellular ATP concentrations
ATP concentrations were quantified using the firefly luciferin–
luciferase reaction. Sample preparation, measurements and data
analyses were carried out by the method of K}oszegi et al. [21]. After
twowashing stepswith PBS 150 lL lysis buffer (0.2 M borate buffer,
10 mM MgSO4, 0.1% Triton X 100, pH 9.2) was added to the wells
and the plates were kept at room temperature for 15 min 50 lL cell
Fig. 2. Fluorescence emission spectra and intensities of HSA (5 lM) in the absence
and in the presence of increasing Pa-iPro concentrations (in PBS, pH 7.4;
kexc = 295 nm, kem = 336 nm).
Fig. 3. Fluorescence polarization values ± SD of OTA-HSA complex (OTA 1 lM, HSA
1.7 lM) in the absence and in the presence of 25 lM of flavonoid derivatives. The
decrease of fluorescence polarization data represents well the displacement of OTA
from HSA by apigenin and protoapigenone derivatives (kexc = 393 nm, kem = 446 -
nm; n = 5).
Table 1
Binding constants calculated by Hyperquad2006 software (K) with corresponding
standard deviations (SDs) and Stern–Volmer quenching constants (KSV) of flavonoid-
HSA complexes.
Substance K (L mol1) KSV (L mol1)
Pa 2.08  104 (±0.22  104) 2.09  104 (R2 = 0.991)
Pa-All 3.56  104 (±0.28  104) 3.49  104 (R2 = 0.991)
Pa-Me 3.89  104 (±0.30  104) 3.96  104 (R2 = 0.990)
Pa-Et 4.26  104 (±0.26  104) 4.31  104 (R2 = 0.992)
Pa-But 5.14  104 (±0.18  104) 4.86  104 (R2 = 0.998)
Pa-PIII 5.34  104 (±0.25  104) 5.03  104 (R2 = 0.996)
Pa-Pro 6.19  104 (±0.39  104) 6.28  104 (R2 = 0.990)
Pa-iPro 1.70  105 (±0.59  104) 1.34  105 (R2 = 0.992)
Api 2.08  105 (±1.94  104) 1.46  105 (R2 = 0.991)
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lysates were pipetted into disposable 75  12 mm plastic cuvettes
(Sarstedt) containing 100 lL luciferin–luciferase reagent and
850 lL ATP measuring buffer (0.1 M TRIS–acetate buffer, 10 mM
MgSO4, 2 mMNa2EDTA, 0.1% Triton X 100, pH 7.75). ATP concentra-
tions were determined with internal standardization [21].
2.9. Determination of total protein concentrations
Fluorescamine (Fluram) reacts selectively with primary amines
and forms a highly fluorescent product therefore it is used to deter-
mine total protein levels [22]. Protein determination was done
from the same samples that were applied for ATP detection (lysis
with Triton–borate buffer). To prevent proteolysis the lysis buffer
contained 0.2 mM PMSF (serine protease inhibitor). 75 lL lysates
were added to 2000 lL borate buffer (0.2 M, pH 9.2) thereafter
50 lL fluorescamine solutions (10 mM; in DMSO) were vigorously
mixed with the system. Then BSA-related protein concentrations
were calculated from fluorescence emission intensities (kexc = 394
nm, kem = 475 nm).
2.10. Annexin V and propidium iodide staining assay
After subjecting cells to the appropriate treatment the medium
containing any detached cells was carefully removed and spared
for later analysis. Attached cells were rinsed with PBS and trypsin-
ized then combined with the previously removed medium. After
pulse centrifugation for 3 s at 14,000 rpm, cell pellet was resus-
pended in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2, pH 7.4) and incubated for 15 min, at room temperature, in
the dark with 5 lL of FITC-Annexin V reagent and 10 lL of PI solu-
tion (50 lg/mL). Then cells were analyzed by flow cytometry.
2.11. Cell cycle analyses
Cells were washed with 1 mL cold PBS then trypsinized and
centrifuged for 3 s at 14,000 rpm. The supernatant was removed
and after a washing step with PBS the pellet was resuspended in
90% ethanol. After an additional washing step with PBS the cells
were treated with 500 lL PI solution (50 lg/mL propidium iodide,
1 mg/mL RNase A, 0.1% Triton X 100 in PBS) for 30 min, at room
temperature, in the dark. 1  104 cells were analyzed by flow
cytometry.
2.12. Statistics
The data represent mean ± SD from minimum of 3 independent
experiments. Statistical analysis was performed by One-Way
Fig. 4. Cellular total protein levels (left above), ATP concentrations (right above), number of living cells per well (counted in a Bürker chamber; left below) and fluorescence
emission intensity of intracellular calcein (right below) ± SD (expressed as percentage of the data measured for the control samples) in the absence and in the presence of
10 lM apigenin or protoapigenone derivatives (P < 0.05).
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ANOVA test using IBM SPSS Statistics (Version 20). The level of sig-
nificance was set at P < 0.05.
3. Results
3.1. Albumin binding and competing capacity of flavonoids
The high quenching effect on tryptophan residue (Fig. 2) caused
by the flavonoid derivatives and their ability to displace OTA from
the surface of HSA (Fig. 3) strongly support our hypothesis that
protoapigenone derivatives – similarly to other flavonoid agly-
cones – also occupy subdomain IIA on human albumin. Deter-
mined binding constants (Table 1) show that protoapigenone
binds with a significantly lower affinity to HSA than apigenin.
10-O-alkyl substitution of protoapigenone results in the increase
of K values. Pa-iPro represents similar degree in binding affinity
as compared to that of apigenin, suggesting that not only the lipo-
philicity but also the steric properties are important factors for
albumin binding. Interestingly, the allyl derivative shows the
weakest interaction, while isopropyl, propyl and propargyl deriva-
tives show the strongest binding capacities.
In the next series of experiments displacing ability of Pa deriv-
atives were investigated against ochratoxin A using fluorescence
polarization technique. Measurements were done at the fluores-
cence excitation and emission wavelength maxima of the albu-
min-bound OTA. Since the wavelength maxima of free and
albumin-bound OTA are very similar [6,19] we can determine only
the sum of their fluorescence signal and an average degree of
polarization of the system. Whereas fluorescence polarization (P)
values are based on the rotational freedom of the molecule, the
free form has a very low (P = 0.012) and the albumin-bound form
has a high (P = 0.325) P value. Therefore a decrease in the fluores-
cence polarization data indicates the desorption of OTA from the
surface of HSA. Displacement investigations (Fig. 3) suggest similar
results then stability constants: Pa is the weakest competitor while
Pa-iPro is characterized to have the most potent displacing ability.
On the other hand Pa-All represents similar efficiency to Pa-Pro
and Pa-PIII as a competitor.
3.2. Influence on ATP and protein levels
Significant changes of intracellular ATP concentrations were ob-
served after 24-h treatment with Pa (Fig. 4). Api, Pa-iPro and Pa-All
did not cause considerable changes in ATP levels (compared to the
control). Other protoapigenone derivatives show similar or slightly
weaker effect than Pa.
Total protein level falls to 46% of the initial value after Pa treat-
ment. Api, Pa-iPro and Pa-All represent again their weaker impact
but all other derivatives show similar results (there are no signifi-
cant differences; P < 0.05) compared to Pa (Fig. 4).
3.3. Influence on cell viability
In order to determine the effect of protoapigenone derivatives
on cell viability, cells were counted in a Bürker chamber further-
more calcein and Annexin V/PI viability assays were also per-
formed. After 24-h treatment with 10 lM of Pa, the number of
living cells was less than 50% of the control (Fig. 4). Api and Pa-iPro
did not cause significant changes (compared to the control), and
the decrease exerted by Pa-All was considerably milder than that
Fig. 5. Apoptotic and necrotic effects of apigenin and Pa-derivatives on HepG2 cells. Growing cells were treated with 10 lM flavonoid concentrations for 24 h and then
stained with Annexin V/PI for flow cytometry analysis (SD values did not exceed 5%).
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of the other derivatives. In other cases treatment with 10-O-alkyl-
ated Pa derivatives resulted in a stronger (but not significant;
P < 0.05) negative effect (cytotoxicity) on cell viability than Pa.
Calcein data show similar tendency when compared to cell
count measurements (Fig. 4). Api and Pa-iPro exert a significantly
weaker toxic effect than Pa; but in contrast to the previous cell
count results both agents caused significant decrease in cell via-
bility compared to the control. Pa-All represents lower, while
other derivatives indicate higher impact on viability of HepG2
cells, nevertheless only Pa-But caused significant decrease of cal-
cein intensity compared to Pa (P < 0.05). Fig. 4 shows that 10-O-
alkylation (with the exception of Pa-iPro and Pa-All) causes
detectable decrease in cell viability, suggesting that an increase
in the length of the carbon chain slightly elevates the cytotoxic
phenomenon.
In the next series of experiments Annexin V/PI staining assay
was applied to investigate the potential apoptotic and necrotic ef-
fects of tested flavonoid derivatives. Fig. 5 represents that Api, Pa
and Pa-iPro treatment caused only a minor decrease in the num-
ber of living cells and also just a slight elevation of apoptotic and
necrotic cells were observed. On the other hand 10-O-alkyl deriv-
atives caused a significant decrease in living cell number and a
considerable increase in both apoptotic and necrotic cell fractions
were observed. These results clearly demonstrate that a longer
aliphatic side-chain leads to a considerable increase in apoptotic
and necrotic effects; but interestingly Pa-Pro, Pa-PIII and Pa-But
show almost the same impact. Furthermore Annexin V/PI assay
also supports that Pa-All exerts much less antitumor activity than
Pa-Pro or Pa-PIII. Our results strongly suggest that both apoptotic
and necrotic effects play a key role in the mode of action of Pa-
derivatives.
3.4. Effects on cell cycle
Finally impacts of Pa-derivatives on cell cycle were also exam-
ined. In the case of Api the elevation in the number of G2/M phase
cells was observed on the other hand Fig. 6 suggests that 24 h
treatment with 10 lM Pa results in both S and G2/M phase cell cy-
cle arrest. Pa-iPro treatment supports again the previously experi-
enced no significant impacts. All 10-O-alkyl Pa derivatives (with the
exception of Pa-iPro) show a SubG1 peak which is one of the reli-
able biochemical markers of apoptosis [24]; this effect is the high-
est in the case of Pa-Et and Pa-Me derivatives. Pa-All shows again
weaker impact but the SubG1 phase is also visible. These results
are in good agreement with the data obtained for the Annexin V/
PI assay. Besides induction of SubG1 phase Pa-Et, Pa-Pro, Pa-But
and Pa-PIII show the most strongest G2/M phase cell cycle arrest.
4. Discussion
In order to get deeper insight into the biological behavior of the
flavonoid protoapigenone and its 10-O-alkyl derivatives albumin
binding properties and several biological effects on HepG2 cells
were investigated. In our experiments results obtained from calcu-
lation of stability constants (using Hiperquad2006 software and
also Stern–Volmer equation) for protoapigenone and its deriva-
tives were completed with the data on competitive investigations
with ochratoxin A. Application of Stern–Volmer plot suggests a sta-
tic quenching of fluorescence intensity of HSA by Pa-derivatives
(results in Table 1). After 24-h treatment of HepG2 cells with
10 lM flavonoid derivatives ATP and total protein levels were
quantified, cell number was counted, calcein and Annexin V/PI via-
bility assays were done furthermore effects on cell cycle were also
Fig. 6. Effect of 10 lM apigenin and Pa-derivatives on cell cycle of HepG2 cells after a 24-h treatment with a single dose of flavonoid (SD values did not exceed 6%).
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investigated. Our results represent well that stability constants of
Pa derivative – HSA complexes and competing capacities of differ-
ent alkyl derivatives show major differences among the studied
flavonoids. Furthermore it can also be stated that by increasing
the length of the carbon chain a considerable increase in stability
constants is observed, these results are in good accordance with
the competing capacity of the studied substances against OTA.
Our findings show that protoapigenone treatment causes a ma-
jor decrease in cell viability, and a similar tendency was observed
in the case of 10-O-alkyl derivatives with the exception of isopropyl
derivative representing much less effects (the allyl derivative also
exerts milder impacts). 10 lM of Pa almost halved the number of
living cells, cell viability and intracellular ATP levels, moreover, to-
tal protein concentrations fell down to 46% of the control. Treat-
ment with 10-O-alkylated derivatives, again with the exceptions
of Pa-iPro and Pa-All, resulted in similar or slightly stronger effects.
On the other hand Annexin V/PI assay and cell cycle analyses show
major differences between Pa-derivatives: the longer aliphatic
side-chain causes significantly stronger impacts on HepG2 cells,
the primarily most effective derivatives are Pa-Pro, Pa-But and
Pa-PIII.
Our investigation proves that changing the lipophilicity and
plasma protein binding properties causes a consequent alteration
in the pharmacokinetic behavior of Pa without decreasing its phar-
macodynamic effect. Moreover, parallel with the structural modifi-
cations additional minor or major increase in the biological effects
were also detectable. These latter findings are in good agreement
with our previously suggested structure–activity relationships for
the 10-O-alkylated Pa derivatives, namely a longer, aliphatic side-
chain might lead to an increase in anticancer activity, while a
branching side-chain, as in case of Pa-iPro can considerably de-
crease it [17]. Moreover, the alkylated pharmacophore B-ring rep-
resents much higher chemical stability as compared to that of the
non-substituted one, such as in the case of protoflavonoid Pa. Since
current studies suggest that the described anticancer effects show
tumor selective property [8,11,13,14] some of these compounds
might become first-line candidates in the ongoing development
of a practically novel class of anticancer agents. Investigating the
in vivo significance of albumin binding in the pharmacokinetics
of these compounds is certainly an urgent need in this process,
such experiments are going to be performed and reported in the
near future.
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a b s t r a c t
Xanthine oxidase (XO) is a key enzyme in purine metabolism with an important role in various pathol-
ogies. Several flavonoids have been reported for their capacity to inhibit this enzyme, and, for these com-
pounds, the ability to adopt a planar 3D structure has been accepted as fundamental prerequisite for such
activity. Here we report the in vitro investigation of a series of non-planar protoflavone derivatives as XO
inhibitors, among which protoapigenone 10-O-propargyl ether was found to be an efficient competitive
inhibitor of the enzyme with an IC50 value of 3.61 lM, significantly (p <0.001) stronger than the anti-gout
drug allopurinol (IC50 = 8.72 lM). Methoxy substitution at C-7, however, resulted in complete loss of
activity. In silico docking supported the observed structure–activity relationships, based on which a ‘pla-
nar structure’ itself can no longer be considered as a criterion for flavonoid-type inhibitors of XO.
 2013 Elsevier Ltd. All rights reserved.
Xanthine oxidase (XO), a molybdenum-containing metalloen-
zyme, is well known for its key role in the catabolism of purines,
during which hypoxanthine and xanthine are transformed into uric
acid. Elevated levels of uric acid lead to various pathological events
including gout and the related formation of kidney stones. More-
over, although uric acid is the most abundant antioxidant in the
human body, high XO activity makes a major contribution to oxi-
dative stress by also producing reactive oxygen species (ROS)
according to the following equations:1
Xanthine + H2O + O2? Uric acid + H2O2
Xanthine + H2O + O2? Uric acid + O2 + 2H+
Possibly related to its role in oxidative stress, XO inhibition also
seems to have benefits in many pathological conditions including
tissue injuries of various types and inflammatory diseases, and
might also decrease cardiovascular risk.2,3 Despite their various
problematic adverse effects, the purine derivative allopurinol and
its active metabolite, oxipurinol, have long been nearly the exclu-
sive choices for therapeutic XO inhibition. Thanks to the significant
efforts on the search for new, non-purine type XO inhibitors,
several different classes of compounds have been revealed as pos-
sible alternatives,4,5 a number of which have also been patented.6
Febuxostat [2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thia-
zole-5-carboxylic acid], a non-competitive inhibitor of the enzyme,
is probably the most important example to mention due to its
recent approval by the FDA.7
Another prospective class of non-purine type XO inhibitors is
the flavonoids, many of which have long been described as efficient
inhibitors of the enzyme.8 In fact, this enzyme-inhibiting activity is
also related to their well-known antioxidant action in vivo,9
potentially contributing to the widely accepted, generally positive
0040-4039/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.tetlet.2013.09.087
⇑ Corresponding author. Tel.: +36 62546456; fax: +36 62545704.
E-mail address: hunyadi.a@pharm.u-szeged.hu (A. Hunyadi).
Tetrahedron Letters 54 (2013) 6529–6532
Contents lists available at ScienceDirect
Tetrahedron Letters
journal homepage: www.elsevier .com/ locate/ tet le t
effect of flavonoids on human health. A large body of scientific lit-
erature on flavonoids as XO inhibitors has been published. All
established structure–activity relationships (SAR) of these com-
pounds are highly consistent with the following conclusions: (i)
the structures of efficient inhibitors allow them to take a planar
shape (i.e., no sp3 carbons are present; flavones are far more active
than flavanones), (ii) OH-groups at C-5 and C-7 are important for
strong activity, and (iii) flavonols, isoflavones and anthocyanodins
are less active than flavones.10–14 The structures of apigenin, a
well-known, highly potent flavone-type XO inhibitor, and naringe-
nin, an inactive flavanone, are shown in Figure 1, as well as that of
quercetin, another efficient inhibitor of the enzyme, whose 3D
structure has recently been revealed within the active center of XO.
Protoflavones are rare and unusual flavonoid derivatives having
a non-aromatic B-ring; in Nature they can most typically be found
in certain genera of ferns, for example, Pseudophegopterys or The-
lypteris.15 These compounds have become a focus of biomedical re-
search, and some are currently under development as promising
anticancer agents.15 As part of our ongoing research, we have
started a thorough investigation on the redox properties of protof-
lavone derivatives synthesized previously.16,17 Screening their
capacity for XO inhibition led to surprising results that partially
re-write the accepted SAR of flavonoids in this regard (Fig. 2), as
presented and discussed below.
The genkwanin derivatives (group B) were inactive, whilst weak
inhibition was found for some of the naphthoflavone derivatives
(group C), and weak to moderate activity was observed for most
of the protoapigenone analogs (group A). However, compound 7,
protoapigenone 10-O-propargyl ether, was found to inhibit the
enzyme almost completely at the tested concentration. The
dose–effect curve was subsequently determined for this compound
and compared to those of allopurinol and apigenin (Fig. 3).
In order to investigate thoroughly the inhibition mechanism of
7, the enzyme kinetics were studied. The kinetic curve was found
to be characteristic of substrate inhibition (Fig. 4), that is, increas-
ing the amounts of the substrate (here: xanthine) could also exert
mild inhibition. Such a situation has already been described for
XO.18 Furthermore, a global model with identical Vmax values for
each curve was found (1.376 nM s1) at p <0.05, while no solutions
were found when curve fitting criterion of a common Km value was
set for all curves. Based on these thorough analyses, compound 7
was strongly suggested to be a competitive inhibitor of the
enzyme.
The binding mode of 7 into the enzyme was investigated by in
silico docking, using the 3NVY structure, corresponding to the
crystal structure of XO in complex with quercetin (www.pdb.org).
In this structure, quercetin is bound near the active center of the
enzyme within the channel dedicated to the substrate. Since 7 is
described here as a competitive inhibitor similar to quercetin, the
XO/quercetin complex appears as a relevant model for further
docking, that is, replacing quercetin by 7 and using the same active
site for the docking procedure. iGEMDOCK, a recently released
docking and virtual screening tool utilizing the GEMDOCK scoring
function was used,19,20 which conveniently combines an automatic
preparation of the macromolecule around the bound ligands with
docking and post-analysis. Re-docking the experimental ligand
into the binding site resulted in a root mean square deviation
(RMSD) value as low as 0.9149 Å for the best-fit pose, which repre-
sented the most favorable van der Waals interactions. The results
of this experiment and the best docking pose of 7, as well as its
interactions with the enzyme are shown in Figure 5.
Figure 1. Structures of apigenin, naringenin and quercetin. Apigenin has strong XO
inhibitor activity, while naringenin is practically inactive; the only difference
between them is the presence or absence of the 2,3-double bond that allows
flavones and flavonols to adopt a planar shape practically depending on the torsion
of the 2,10 bond only.
Figure 2. Structures of compounds 1–23 and their XO inhibition activities at
0.1 mM. A, B and C represent the corresponding basic skeleton. n.a.: not available.
Apigenin, genkwanin and 40-OH-b-naphthoflavone, that is, the starting materials for
the synthesis of these three groups of compounds, exhibited 98.3%, 33.3% and 26.0%
inhibition at 0.1 mM, respectively, while allupurinol, used as positive control,
inhibited the enzyme by 97.78% at 0.1 mM.
Figure 3. Dose–effect curves and IC50 values of compound 7, apigenin, and
allopurinol. Max. inh.: maximum inhibition, ⁄⁄⁄: significant (p <0.001) difference
of the IC50 value with respect to that of allopurinol.
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Of the ten possible solutions found in the docking study of 7, the
best four represented very similar positions, with binding energies
of 126.88, 126.33, 118.68 and 117.50 kcal/mol, respectively.
In the case of the fifth best solution, the A and C rings of 7 almost
perfectly overlapped with those of quercetin within the X-ray
structure, resulting in a somewhat less favorable binding energy
(95.37 kcal/mol). The remaining five solutions showed much
weaker binding to 3NVY (68.11 to 16.73 kcal/mol).
In the most stable orientation of 7 in the XO active site, several
H-bonds were observed (Fig. 5B), which differed from those exist-
ing in the presence of quercetin (Fig. 5A). This difference is mainly
attributed to the flipped orientation of 7 with respect to that of
quercetin, which modifies the H-bonding possibilities with resi-
dues of the active site. Interestingly, due to these flip–flop orienta-
tions, the 5-OH and 7-OH groups have inverted roles in quercetin
and compound 7. Concerning quercetin, the 5-OH group forms a
H-bond with the oxygen of the molybdopterin (MOS) residue, thus
blocking its function. However, the 5-OH group of flavonoids is
known to form a strong intramolecular H-bond with the keto
group at C-4,21 which consequently weakens the intermolecular
H-bond with molybdopterin. In the case of compound 7, the
7-OH group forms this intermolecular H-bond, which enhances
effectively the binding to molybdopterin, and therefore the
blocking of its function. This highlights the crucial role of the
7-OH group, fully rationalizing the dramatic loss of activity, for
example, from 7 to 15 (Fig. 2).
The orientation of 7 in the XO active site is also stabilized by
p–p interactions between the A and C rings of the flavonoid and
the aromatic ring of the Phe914 residue (Fig. 5B); these interac-
tions are similarly observed for quercetin (Fig. 5A).
The most stable orientations found for 7 in the XO active site
suggest a reasonable explanation for the importance of the propar-
gyl side-chain: it fits perfectly into the hydrophobic pocket formed
by the Leu648, Phe649, Asp872, Leu873 and His875 residues.
Moreover, this orientation is also stabilized by a H-bond between
the ether oxygen and Ser876. On the other hand, when the butyl
ether derivative 6 was docked into 3NVY, its docking scores and
positions could not explain its much lower activity compared to
7. Similar binding energies and orientations were found for these
two compounds, and even the longer butyl ether side-chain was
able to fit into the aforementioned pocket and form a H-bond with
Ser876 at the same time. Side-chain length, on the other hand,
might still be a limiting factor for these compounds to reach the ac-
tive site through its relatively narrow access channel. This might
explain the gradually decreasing XO inhibitor activity from the
methyl to butyl derivatives (compounds 2–6) when tested at
0.1 mM.
Nevertheless, the previously detailed interactions anchor the
inhibitor inside the channel through which the ligand can
approach the molybdenum active center. Based on our results, the
‘planar structure’ criterion no longer appears as amajor prerequisite
for efficient XO inhibitor activity of flavonoid derivatives; unlike the
case of flavanones, if loss of the p-conjugation from the B- to the C-
ring occurs at C-10, the activity does not necessarily decrease as
compared to flavones. Although the structure of protoapigenone
10-O-propargyl ether certainly represents a rather special case
among flavonoids, revision of this globally accepted structure–
activity relationship might open novel directions for designing
potent and safe XO inhibitors from this compound class. The planar-
ity of the A and Cmoiety appearsmandatory to favor intermolecular
p–p stacking, but flexibility is permitted for the moiety attached to
C-2. For example, enhancing the binding to the Leu648–Phe649–
Asp872–Leu873–His875 hydrophobic pocket is a relevant strategy
to improve selectivity of flavonoid-type XO-inhibitors.
Figure 4. Enzyme kinetics study on the XO inhibition by compound 7. Curve-fitting
was performed by using the substrate inhibition nonlinear model of GraphPad
Prism 5.0; the concentrations of 7 are given in lM.
Figure 5. Results of the docking study. (A) Overlapping of the re-docked quercetin residue (turquoise) with its experimental position (yellow, interactions shown to this
position). (B) Best docked position of 7 (turquoise) along with the hydrophobicity surface around the ligand at a probe radius of 1.1 Å. In A and B, the viewing angles are
identical, and H-bonds and p–p interactions are shown in green and orange, respectively. (C) 2D Interpretation of the ligand–residue interactions between 3NVY and 7
including the distances of the H-bonds in Å.
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Abstract Protoflavones represent a less widespread,
unique class of natural flavonoids with a non-aromatic
B-ring and a hydroxyl group at C-10. Due to their
recently discovered anticancer activity, these com-
pounds have gotten into the focus of biomedical
research during the past few years. The present review
aims to give a brief summary on the available
literature data on this special class of flavonoids,
including their occurrence in plants and their
bioactivity. A special emphasis is given on the
anticancer potential of these compounds. Attempts
for the development of certain synthetic/semi-syn-
thetic protoflavone analogs as anticancer drugs, and
structure–activity relationships are also discussed.
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Introduction
Flavonoids, polyphenolic compounds abundant in the
Plant Kingdom, have long been recognized to play an
important role in prevention and/or treatment of many
pathological conditions (Di Carlo et al. 1999; Le
Marchand 2002). Their chemical structure allows
these compounds to participate in various redox
reactions including free radical scavenging, while
due to their typically phenolic characteristics they can
also specifically interact with several biochemical
processes on various levels (Tapas et al. 2008). The
common belief, which considers flavonoids in general
as beneficial and healthy-to-consume plant metabo-
lites, is certainly based on a large body of scientific
evidence. Most common members of this compound
family are present in fruits and vegetables, and they
even have been suggested to be vitamins (vitamin P,
coming from ‘‘permeability’’) by the group of the
Nobel-laureate Albert Szent-Gyo¨rgyi (Bentsa´th et al.
1936). Although they finally withdrew this theory,
nowadays, more than 75 years later it is of no doubt
that most typical dietary flavonoids have a generally
positive impact on human health. One has to note,
however, that several classes of flavonoids can exert
very well defined, specific, sometimes strong bioac-
tivities: isoflavones and prenylflavones are for exam-
ple well known from their phytoestrogenic effect
(Ososki and Kennelly 2003), and certain methoxylated
flavones have been identified as potent antiviral agents
(Hayashi et al. 1997). The present review focuses on
the occurrence, chemistry and bioactivity of an
unusual class of flavonoids, protoflavones, and aims
to give a brief summary on the current trends in the
research and development of protoflavone derivatives
as potential anticancer agents.
Protoflavones: chemistry and occurrence in nature
Protoflavones are relatively oxidated flavonoids, bear-
ing an unusual, non-aromatic B-ring with a hydroxyl
group at C-10. Although this nomenclature has not
been explained, trivial names of protoflavones keep
deriving from the corresponding 40-hydroxyflavones
in a way that a ‘‘proto-’’ prefix is added in case a 40-
hydroxy group is present (as in protogenkwanin), and
an additional ‘‘-one’’ ending shows if it is oxidized to
an oxo group (as in protogenkwanone). First member
of this class of flavonoids, 2-(4-b-D-glucosyloxy-1-
hydroxy-2,5-cyclohexadienyl)-5-hydroxy-7-methox-
ychromone (14), was isolated from the fertile sprouts
of Equisetum arvense and called protogenkwanin 40-
glucoside (Hauteville et al. 1980). This was soon
followed by reporting isolation of its aglycone,
protogenkwanin (13), from the same source (Haute-
ville et al. 1981). The two hydroxyl groups of this
compound on the B-ring at positions 10 and 40 were
found to be trans oriented by means of X-ray
crystallography (Stomberg et al. 1991), and similar
orientation was found both for the partially (Klaus-
Peter 1999) and the completely saturated B-ring
containing protogenkwanin analogs (Wada et al.
1987). On the other hand, existence of the 10,40-cis
form in the dihydroprotogenkwanin series was also
argued by Pouny et al. (2011). Structures of the known
natural protoflavones are shown in Fig. 1; occurrence
of these compounds in plant species is summarized in
Table 1.
As seen from the table, protoflavones are typical for
certain genera of ferns, and, till now, Apium appears to
be the only non-fern plant genus where such com-
pounds were detected. Although biosynthesis of these
compounds has not been investigated, a possible way
for their production was suggested from the corre-
sponding 40-hydroxyflavone (i.e. apigenin or genkw-
anin) by oxidation. This step would then be followed
by reduction of the 40-oxo group and/or saturation of
either one or both double bond(s) in the already non-
aromatic B-ring (Lin et al. 2007a). Interestingly, the
formation of derivatives with further hydroxylation on
a partially saturated B-ring seems to occur via a non-
specific way: 20-hydroxy-20,30-dihydroprotoapigenone
(3) was isolated from Equisetum fluviatile as a
racemate (Pouny et al. 2011), and both enantiomers
were also found to be present in Thelypteris torresiana
(Fang et al. 2011; Liu et al. 2012). Such data on the
enantiopurity of the related methoxy derivatives are,
however, not available.
Bioactivity of protoflavones
In several cases, the isolation of new natural protof-
lavones was reported together with bioactivity data
typically against various cancer cell lines. To date,
however, protoapigenone (1) is far the most deeply
studied among them. This compound and a number of
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its analogs were shown to exert strong cytotoxic
activity in a wide variety of cancer cells including
breast, ovarian, cervical, prostate, lung, liver, etc. (Lin
et al. 2005, 2007a, b; Chang et al. 2008a, b; Chiu et al.
2009; Hunyadi et al. 2011; Danko et al. 2012). Chang
et al. (2008a) also showed that protoapigenone (1)
exerted strong cytotoxicity on ovarian cancer cell lines
MDAH-2774 and SKOV3 but not on immortalized
non-cancer ovarian epithelial cells. Moreover, several
studies showed that this compound induces apoptosis
both in vitro and in vivo, without significantly
damaging healthy tissues in the latter case (Chang
et al. 2008a, b; Wang et al. 2012). Cytotoxicity of
protoapigenone (1) was recently also correlated with
phenotypic changes in HeLa cells: impaired centro-
somal c-tubulin labeling was observed both in mitotic
and interphasic cells (Pouny et al. 2011).
Concerning the mechanism of action, several
pathways were found to be involved in the anticancer
activity of protoflavones, and mainly of protoapige-
none (1). Apoptosis induction was shown to be
mitogen-activated protein kinase (MAPK)-dependent
in both human prostate (Chang et al. 2008a) and breast
cancer cells (Chen et al. 2011a), also involving the
activation of c-Jun NH2-Terminal Kinase (JNK).
Related apoptotic pathways were also identified using
ovarian cancer cell lines (Chang et al. 2008b):
activation of caspase-3, cleavage of PARP and
decreasing of Bcl-xL and Bcl-2 protein levels were
found, accompanied by membrane alterations and
nuclear fragmentations at different stages of the cell
cycle. Protoapigenone (1) was also shown to interfere
with the cell cycle inducing its arrest at S and G2/M
phases (Chang et al. 2008a, b; Chiu et al. 2009). Both
in human ovarian (Chang et al. 2008a) and prostate
(Chang et al. 2008b) cancer cells, the cell cycle arrest
was correlated with alterations in the expression level
of Cdk2, Cyclin B1 and Cdc25C, well known cell
cycle regulators that actually lead to a higher cytotoxic
effect of protoapigenone (1) at this stages of the cell
cycle. In human breast cancer cells (Chen et al. 2011a)
loss of the mitochondrial membrane potential was also
observed and linked with the persistent activation of
MAPK upon treatment with protoapigenone (1).
DNA damage in lung (Chiu et al. 2009) and prostate
cancer cell lines (Chen et al. 2011b) treated by
protoapigenone or one of its synthetic analogs
(WYC0209, see section on synthetic/semi-synthetic
derivatives) was also observed. Damage of DNA is an
important and frequent outcome during cancer treat-
ment. In fact, inhibition of DNA damage response
mechanisms is an attracting novel target for enhancing
tumor chemosensitivity (Lapenna and Giordano 2009;
Bolderson et al. 2009). Remarkably, a recent study
showed that protoapigenone (1) and WYC0209 can
significantly interact with the ATR-dependent signal-
ing pathways by inhibiting the phosphorylation of
Chk2 and Chk1 kinases (Wang et al. 2012) that play a
Fig. 1 Structures of natural protoflavones isolated from plants. Glu b-D-glucopyranoside. From 3, both the (?)cis-10R,60S and the
(-)cis-10S,60R stereoisomers were isolated, as well as the racemate. Natural origin or artifact nature of 20 is unclear
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Table 1 Occurrence of protoflavones in plants
Plant species Protoflavones identifieda References
Equisetum arvense Protogenkwanin 40-O-b-D-glucoside (14) Hauteville et al.
(1980)
Protogenkwanin (13) Hauteville et al.
(1981)
Pseudophegopteris hirtirachis Protogenkwanone (2); tetrahydroprotogenkwanone (10);
tetrahydroprotogenkwanin (19); protogenkwanin 40-O-b-D-
glucoside (14)
Wada et al. (1987)
Pseudophegopteris subaurita Protogenkwanone (2); tetrahydroprotogenkwanone (10);
protogenkwanin 40-O-b-D-glucoside (14); protogenkwanin
40-O-(2-O-acetyl)-b-D-glucoside (15); protogenkwanin
40-O-(6-O-acetyl)-b-D-glucoside (16)
Wada et al. (1987)
Pseudophegopteris bukoensis Protogenkwanin 40-O-b-D-glucoside (14); protogenkwanin
40-O-(2-O-acetyl)-b-D-glucoside (15); protogenkwanin
40-O-(6-O-acetyl)-b-D-glucoside (16)
Wada et al. (1987)
Equisetum fluviatile Protoapigenin 40-O-b-D-glucoside (12) Veit et al. (1995)
20,30-Dihydroprotogenkwanone (6); (±)20-hydroxy-20,
30-dihydroprotoapigenoneb (3)
Pouny et al. (2011)
Equisetum debile Protoapigenone (1) Pouny et al. (2011)
Cyclosorus falcilobus Protoapigenin (11); protoapigenin 40-O-b-D-glucoside (12) Pouny et al. (2011)
Cyclosorus parasiticus Protoapigenone (1) Pouny et al. (2011)
Phegopteris decursive-pinnata Protogenkwanone (2); 50,60-dihydroprotogenkwanone (6);
negative for 1
Pouny et al. (2011)
Phegopteris connectilis 50,60-Dihydroprotogenkwanin (8) Klaus-Peter (1999)
Thelypteris or Macrothelypteris
torresianac
Protoapigenin (11); protoapigenin 40-O-b-D-glucoside (12);
protoapigenone (1); 20-methoxy-20,30-dihydroprotoapigenone (4)
Lin et al. (2005)
Flavotorresin (20) Lin et al. (2007a)
20-Hydroxy-20,30-dihydroprotoapigenone acetonide (7) Tang et al. (2009)
20,60-Dimethoxy-tetrahydroprotoapigenone (9) Tang et al. (2010)
Tetrahydroprotoapigenine (17); (?)20-hydroxy-20,
30-dihydroprotoapigenone (3)
Fang et al. (2011)
(-)20-Hydroxy-20,30-dihydroprotoapigenone (3) Liu et al. (2012)
Macrothelypteris oligophlebia Protoapigenone (1); protoapigenin 40-O-b-D-glucoside (12) Wu et al. (2011)
Macrothelypteris viridifrons Protoapigenone (1); protoapigenin (11); protoapigenin
40-O-b-D-glucoside (12); 20-hydroxy-20,30-dihydroprotoapigenone
acetonide (7); 20,60-dimethoxy-tetrahydroprotoapigenone (9)
Wei et al. (2011a)
7-Ethoxy-20-hydroxy-20,30-dihydroprotoapigenone (5) Wei et al. (2011b)
Tetrahydroprotoapigenin (17); tetrahydroprotoapigenin 40-O-
b-D-glucoside (18); 20-hydroxy-20,30-dihydroprotoapigenone (3);
20-methoxy-20,30-dihydroprotoapigenone (4)
Wei et al. (2012)
Apium graveolens Protoapigenin 40-O-b-D-glucoside (12) Nikolic et al. (2011)
a Several compounds listed in this table were reported with their IUPAC names; for a more clear interpretation here they are
presented according to the classical nomenclature of protoflavones
b OH or OCH3 groups present at C-2
0 in derivatives with partially saturated B-ring are cis to the 10-OH group
c Depending on the botanical definition of Thelypteridaceae, the species can be assigned to different genera; both names were used in
protoflavone related publications
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crucial role in DNA damage response (Smith et al.
2010). According to this, it was shown that these
protoflavones themselves apparently do not directly
damage DNA, the underlying mechanism is rather a
specific inhibition of its repair. As expected, this
inhibition could effectively sensitize the cancer cells
to the DNA damaging anticancer drug cisplatin,
resulting in significantly stronger combined activities
as compared to those of the compounds administered
alone (Wang et al. 2012). These results suggest that
future development of protoflavones might reasonably
be re-directed towards the optimization of this highly
promising chemo-sensitizing activity, in order to
obtain valuable new options for combination chemo-
therapy. Particular emphasis should be given to
WYC0209, which was as much as 10 times stronger
than protoapigenone (1) in some of the aforemen-
tioned activities.
Based on the chemical structure of the p-quinol
B-ring, protoflavones seem to be capable for partic-
ipating in various redox reactions. Indeed, apoptosis
induced by protoapigenone (1) and other synthetic
analogs were shown to be correlated with the induc-
tion of oxidative stress within the cancer cells by
generating reactive oxygen species (ROS) (Chen et al.
2011a, b; Wei et al. 2011a, b; Liu et al. 2012). In
connection to this, inhibition of the enzyme glutathi-
one S-transferase p was also observed, even though it
is still to be determined if this was a direct effect on the
enzyme or rather a result of the increase in ROS within
the cell (Chen et al. 2011a). Studies on breast cancer
cells showed that protoapigenone treatment led to
increased levels of ROS, required for activation of
MAPK involved in the mitochondria-mediated apop-
tosis induced by this compound (Chen et al. 2011a).
Similar observations were made when other protofl-
avonoids, WYC0209 (Chen et al. 2011b), DHEC (Wei
et al. 2011a, b) and DEDC (Liu et al. 2012) were tested
for their apoptotic effect on DU145 postate cancer,
human colon HT-29 cancer and human neuroblastoma
SH-SY5Y cell lines, respectively. In fact, WYC0209
was shown to increase intracellular generation of
ROS, followed by DNA damage induction and
activation of Chk1/Chk2 which led to cell cycle arrest
at S and G2/M phases (Chen et al. 2011b), and resulted
in a stronger cytotoxic effect than that of protoapige-
none (1) (Chang et al. 2008a). Due to the important
role of ROS in the activity of protoflavones, it is
currently hard to make a sound judgment on which of
the previously mentioned pathways are subject to
specific changes and which would be non-specifically
affected by the oxidative stress; further research will
be necessary to clarify such questions.
In addition to its anti-tumor activity, a very
interesting anti-angiogenic effect was recently
described for a protoflavone containing extract of
Macrothelypteris viridifrons (see Table 1) (Wei et al.
2012). The same experiment was however not pre-
sented with the purified protoflavones—based on the
crucial role of angiogenesis in tumor growth, biolog-
ical significance of this important information should
be explored in the near future.
Last but not the least, protoapigenone (1) was
shown to inhibit the expression of Epstein-Barr virus
(EBV) lytic proteins in P3HR1 cells, preventing EBV
lytic proliferation at doses well below those which
exerted cytotoxic activity on the host cells (Tung et al.
2011). This study also shows that the use of protof-
lavones is not limited to their anticancer activity; these
unique flavonoids apparently represent a class of
bioactive compounds with several further potential
effects yet to be discovered.
Development of synthetic/semi-synthetic
protoflavone derivatives
Based on its obvious structural relationship to apigenin,
a well known natural chemopreventive agent (Patel
et al. 2007), it is no wonder that the discovery of
protoapigenone (1) and its promising anticancer activity
(Lin et al. 2005) was rapidly followed by a raise of
serious efforts for developing it as a new anticancer
drug. First a total synthetic procedure was reported by
our group, which, regardless of its limitations on the
large-scale production of protoapigenone, allowed
extending the known structure–activity relationships
and led to the discovery of the strongest synthetic
derivative till now, WYC0209 (Lin et al. 2007b). This
compound, originated from 40-hydroxy-b-naphthoflav-
one, has become one of the most promising lead for
further development. The structure of WYC0209,
together with a selection of further prospective protof-
lavone analogs, is shown in Fig. 2.
After an optimization of the critical step of the total
synthesis, namely the oxidative de-aromatization of
the B-ring, it has been revealed that a semi-synthetic
production of protoapigenone (1) is also possible
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directly from apigenin (Hunyadi et al. 2011). By
allowing large-scale synthesis, this finding was a
breakthrough for the in-depth pharmacological and
toxicological investigation of protoapigenone (1)
in vivo.
Considering current trends, there is also an effort to
synthesize further promising derivatives with
improved pharmacological properties at all possible
levels. Based on the available data on structure–
activity relationships, the presence of a symmetric and
non-substituted p-quinol structure on the B-ring seems
to be the most important moiety for a strong pro-
apoptotic activity: none of the partly or completely
saturated, nor the 40-hydroxy compounds including
their glycosides were found as potent in this regard as
protoapigenone (1) (Lin et al. 2005, 2007b; Fang et al.
2011; Pouny et al. 2011; Wei et al. 2011a). Interest-
ingly, the rule for the need of a free 10-OH group is not
general: although a methoxy group at C-1’ definitely
decreases cytotoxic activity, in case of protoapigenone
analogs, a longer, non-branching aliphatic side-chain
(n-propyl or n-butyl) can restore or even increase
activity as compared to that of the parental compound
(Hunyadi et al. 2011). This was however not true in
case of any other analogs including similar derivatives
of genkwanin (Hunyadi et al. 2011; Danko et al. 2012),
where the only difference to the 10-O-alkylated
protoapigenone series was the 7-methoxy group.
Polarity differences might reasonably explain this
phenomenon, but specific role of the 7-OH group can
also not be excluded on the basis of the available data.
Slightly (around 1.5-fold) selective cytotoxicity of
6-methyl protoflavone derivatives on multi-drug resis-
tant cancer cells as compared to the parental cell line
was recently reported, which opened another prospec-
tive research direction (Danko et al. 2012). This
finding seems to be of particular interest, since the
ABCB1 efflux pump that conferred resistance to the
tested cell line, is among the most prevalent MDR
transporters (Sharom 2008), hence it represents a
major reason for the common failure of chemotherapy.
Exploring the SAR behind this selectivity is of
particular importance, and has become a primary
objective of our on-going research program. On the
other hand, it is also noteworthy that none of the
protoflavone derivatives synthesized from apigenin,
b-naphthoflavone, genkwanin or 6-methoxyflavone
were found to exert different cytotoxic activity on the
MDR cell line as compared to its parental one (Danko
et al. 2012). This means tumors can most likely not
become resistant to protoflavones by over-expressing
the aforementioned efflux pump.
It has also been revealed, that presence of the
A-ring is not necessarily needed for a strong cytotoxic
effect (Yuan et al. 2011), which supports well the
original assumption that the pharmacophore of pro-
toapigenone is the p-quinol moiety on the B-ring (Lin
et al. 2005). The available structure–activity relation-
ships concerning the cytotoxic activity of natural,
semi-synthetic and synthetic protoflavone derivatives
are summarized in Fig. 3.
Conclusions and future prospects
Protoflavones indeed represent a unique class of
natural flavonoids, with a rather unexplained biosyn-
thesis. The occurrence of racemic derivatives in plants
is most unusual, and suggests the role of non-specific
oxidation processes. This does not sound likely to be
limited to certain plant species; investigation of further
species biosynthesizing large amounts of 40-
Fig. 2 A selection of the synthetic/semi-synthetic protoflavone
analogs which are the most promising for further development
against cancer. WYC0209: the strongest pro-apoptotic protof-
lavone to date; 21: similar or stronger than protoapigenone with
a much more stable B-ring; 22: stronger than protoapigenone
with a slight MDR selectivity not found for other derivatives;
23: similar or stronger than protoapigenone possessing the
smallest part of the pharmacophore to date
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hydroxyflavones for presence of protoflavonoids
would be particularly interesting in this point of view.
Above the aspects of basic research, protoflavones
also represent a class of valuable bioactive com-
pounds. First of all, on-going development of such
compounds as anticancer drugs seems to be highly
prospective; the emerging number of related patents
indicates well the high expectations and optimism
about this process (Wu et al. 2007, 2009; Lin et al.
2008; Yuan et al. 2010; Ruan et al. 2011). On the other
hand, less cytotoxic protoflavone derivatives, includ-
ing those with a partially or completely saturated
B-ring, 40-hydroxyl group containing compounds and
most of the 10-O-alkyl substituted ones, might have
other interesting bioactivities worthy for further
research. For example, some of the 10-O-alkylated
compounds show stronger antiviral effects as com-
pared to that of protoapigenone, certainly with a
significantly lower cytotoxicity (unpublished data;
publication in process). Based on this, one can
presume that certain bioactivities of protoflavones
are based on fundamentally different structure–activ-
ity relationships, which is going to extend research on
the biological importance of these unique flavonoids
and their derivatives in the near future.
Finally, some of these compounds seem to be on the
right path to become classical examples for natural
product based drug discovery. A number of semi-
synthetic or synthetic protoflavone derivatives are
prospective leads for further development by utilizing
the idea of a non-aromatic, p-quinol moiety in the
B-ring discovered in the natural, fern-derived protofl-
avonoids. Protoapigenone (1) and WYC0209 are the
first flavonoids described for their ability to inhibit
ATR related DNA damage response mechanisms both
in vitro and in vivo, based on which these compounds
or some of their analogs might have a real possibility to
establish a novel class of anticancer drugs in the future.
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of compound 5, 6-methylprotoflavone previously published 
and a new derivative, 6-bromoprotoflavone (compound 6), 
on the cell cycle distribution were evaluated, and 6 was also 
studied for its potential to regulate the intracellular antioxi-
dative capacity.
Results Protoflavones showed a significant cytotoxicity 
against all cancer cell lines and selectivity toward MDR 
cancer cells adapted to conventional chemotherapeutics. 
Inverse sensitivity versus MDR selectivity pattern was 
observed. Treatment with H2O2 showed that MDR cancer 
cells are more vulnerable to oxidative stress. Compounds 
5 and 6 significantly decreased the portion of MDR cells 
in the G1 phase. The levels of reactive oxygen and nitro-
gen species (ROS/RNS) between MDR and non-MDR cells 
significantly differed upon exposure to 6, accompanied by 
changes in the glutathione (GSH) levels and in the expres-
sion of manganese superoxide dismutase (MnSOD), glu-
tathione-S-transferase π (GST π) and hypoxia-inducible 
factor-1α (HIF-1α).
Conclusions Our results suggest that MDR cancer cells 
can be more vulnerable to the pro-oxidative activity of 
protoflavones due to an impaired antioxidative defense that 
might arise during the adaptation processes provoked by 
chemotherapy.
Keywords Multidrug resistance · P-glycoprotein · 
Protoflavones · Pro-oxidative activity · Reactive oxygen 
species · Collateral sensitivity
Introduction
Multidrug resistance (MDR) is the main reason for a 
non-successful chemotherapy in cancer. Still, chemother-
apy cannot be excluded as a treatment option along with 
Abstract 
Purpose Multidrug resistance (MDR) may develop due 
to a series of adaptive responses under a new stress condi-
tions, such as chemotherapy. Novel strategies are urgently 
needed to fight MDR in cancer, and chemotherapeutics 
that are selective for MDR cancer cells offer a promising 
approach. Certain protoflavones were previously found to 
have potential in this regard.
Methods Cytotoxicity of six protoflavones was assessed 
in different P-glycoprotein overexpressing MDR cancer 
cell lines and in their non-MDR counterparts. The impacts 
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surgical intervention and/or radiotherapy. The capacity of 
cancer cells to develop resistance to chemotherapeutics is a 
significant challenge for new treatment strategies [1]. There 
is a wide range of cellular alterations acquired during the 
development of MDR: (1) overexpression of membrane 
efflux transporters belonging to the ATP-binding cassette 
family (e.g., the P-gp transporter, also known as P-glyco-
protein or P-gp, which is the most prevalent among these 
so-called efflux pumps [2]), (2) extensively up-regulated 
DNA damage repair mechanisms, (3) impaired death sign-
aling, (4) enhanced drug detoxification (e.g., up-regula-
tion of glutathione-S-transferase enzymes), (5) lysosomal 
changes, (6) modification of drug molecular targets [3].
Collateral sensitivity (CS) could be explained as the 
ability of drug to be more efficient in MDR cancer cells 
than in their sensitive counterparts in the laboratory setting 
or as a phenomenon that may occur during the develop-
ment of resistance when resistance to one or more drugs 
confers greater sensitivity to another agent [4]. The under-
lying mechanisms of CS may differ and may depend on 
the cell type and/or the applied drug. Recently proposed 
mechanisms that lead to this situation involve pro-oxida-
tive effects and modification of intracellular redox status. 
According to available data, increased vulnerability to reac-
tive oxygen species (ROS) could be the reason for hyper-
sensitivity of certain MDR cells [5].
Compounds with a potential to overcome MDR by 
selective killing of such cancer cells have recently been 
reviewed [6]. Analogs of a flavonoid containing a non-
aromatic A-ring, desmosdumotin B, showed great promise 
against P-gp overexpressing MDR cell lines [7]. Moreover, 
several phenolic compounds, including xanthones and fla-
vonoids, have been reported to exert selective cytotoxicity 
against ABCC1 (MRP1) overexpressing cancer cells typi-
cally due to their intrinsic pro-oxidant properties accom-
panied by an ability to promote glutathione (GSH) efflux 
through this ABC transporter [6].
Protoflavones have recently emerged as a class of natu-
ral compounds with prospective anticancer potential [8]. 
These unique flavonoids express an unusual non-aromatic 
B-ring; this p-quinol moiety makes them much stronger 
pro-oxidants than typical flavones. As such, these com-
pounds can severely interfere with the redox homeostasis 
of cancer cells on multiple levels, leading to an oxidative 
stress-mediated apoptosis [9]. Based on protoapigenone 
(PA; compound 1), a natural protoflavone derived from 
apigenin, a set of prospective leads is under develop-
ment including the synthetic β-naphthoflavone derivative 
WYC0209 (compound 2) [10]. According to our previous 
results, these compounds are unlikely to be P-gp substrates; 
moreover, 6-methyl derivatives showed a mild selectivity 
against a murine cancer cell line transfected with this efflux 
transporter [11].
Here we report the anticancer effects of six protoflavone 
derivatives (Fig. 1) on four MDR/non-MDR cancer cell 
line pairs: three pairs of human cancer [12, 13] and a pair 
of rat glioma cell lines [14], each developed by adaptation 
to various chemotherapeutics. Besides their cytotoxic activ-
ity, pro-oxidative effects of protoflavones as well as their 
impact on the antioxidative defense system of cancer cells 
were assessed.
Materials and methods
Synthesis of protoflavones
Compounds 1–5 were synthesized as published before [11, 
15]. For compound 6, 5′-bromo-2′-hydroxyacetophenone 
was used as starting material. The flavonoid synthesis 
started with a Claisen-Schmidt condensation with benzy-
loxybenzaldehyde in a mixture of EtOH and aqueous solu-
tion of potassium hydroxide. The chalcone was cyclized 
with 1 equivalent (eq.) of iodine in DMSO, and the ben-
zyl protecting group was removed with TFA in dichlo-
romethane. The 6-bromo-4′-hydroxyflavone was dissolved 
in acetonitrile–water (9:1, v/v), and [bis(trifluoroacetoxy)
iodo]benzene (PIFA; 2 eq.) was added to the mixture. The 
Fig. 1  Chemical structures of compounds 1–5 (a) and total synthesis of compound 6 (b)
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reaction mixture was heated to 50 °C for 1 h by using an 
oil bath. After the mixture was cooled down, the solvent 
was evaporated under reduced pressure, and the dry resi-
due was re-dissolved in acetonitrile and purified by a Büchi 
flash chromatography system consisting of two C-606 
pump and a C-640 ultraviolet detector (Büchi Labortech-
nik AG, Switzerland) on a prepacked RP C18 EC car-
tridge (12 × 150 mm, 40–63 µm, Büchi Labortechnik AG, 
Switzerland) with a gradient of aqueous MeOH (0–100 % 
in 30 min) at a flow rate of 8 ml/min. For the chemical 
structures, see Fig. 1. All compounds were kept as 20 mM 
stocks in dimethyl sulfoxide (DMSO) at 4 °C in dark prior 
to bioactivity testing.
Structure elucidation of compound 6
Structure elucidation was carried out by means of nuclear 
magnetic resonance (NMR) spectroscopy and high-res-
olution mass (HRMS) spectroscopy. NMR spectra were 
obtained on a Bruker Avance DRX-500 NMR spectrometer 
in dimethyl sulfoxide-d6. HRMS spectra were taken on a 
Shimadzu LCMS-IT-TOF equipped with an ESI interface 
which was used in positive mode.
Chemicals
P-gp inhibitor–tariquidar (TQ) was kindly provided by Dr. 
Sven Rottenberg from the Netherlands Cancer Institute, 
Amsterdam. TQ was diluted in DMSO, and 10 µM aliquots 
were kept at −20 °C. Before treatment, TQ and compounds 
1–6 were freshly diluted in sterile water. RPMI 1640 
medium, minimum essential medium (MEM), Dulbecco’s 
modified Eagle’s medium (DMEM), fetal bovine serum 
(FBS), antibiotic–antimycotic solution, penicillin–strept-
omicin solution, l-glutamine and trypsin/EDTA were pur-
chased from PAA, Vienna, Austria. McCoy’s 5 A medium, 
heat-inactivated horse serum and DMSO were obtained 
from Sigma-Aldrich Chemie Gmbh, Germany. Propidium 
iodide (PI) was purchased from Roche Applied Science, 
Basel, Switzerland. RNAse A and dihydrorhodamine 123 
(DHR) were obtained from Molecular Probes®, Invitrogen, 
USA.
Cells and cell culture
NCI-H460 (human non-small cell lung carcinoma—
NSCLC), DLD1 (human colorectal carcinoma), U87 
(human glioma), C6 (rat glioma) and MRC-5 (human 
embryonal bronchial epithelial) cell lines were purchased 
from the American Type Culture Collection, Rockville, 
MD. HaCaT cell line (normal human keratinocytes) was 
obtained from CLS-Cell Lines Service, Eppelheim, Ger-
many. NCI-H460/R cells were selected originally from 
NCI-H460 cells after 3 months of doxorubicin selective 
pressure [12]. DLD1-TxR and U87-TxR cells were selected 
by continuous exposure to stepwise increasing concentra-
tions of paclitaxel (PTX) for a period of 10 and 9 months 
from DLD1 and U87 cells, respectively [13]. RC6 cells 
were selected from C6 cells after continuous exposure to 
stepwise increasing concentrations of carmustine (10–
300 µM) for a period of 9 months [14]. MDR cancer cell 
lines (NCI-H460/R and DLD1-TxR) and their sensitive 
counterparts were maintained in RPMI 1640 medium sup-
plemented with 10 % FBS, 2 mM l-glutamine and 10,000 
U/ml penicillin, 10 mg/ml streptomycin, 25 μg/ml ampho-
tericin B solution, while U87 and U87-TxR were grown in 
MEM with 10 % FBS, l-glutamine (2 mM) and 5000 U/
ml penicillin, 5 mg/ml streptomycin solution at 37 °C in 
a humidified 5 % CO2 atmosphere. C6, RC6, HaCaT and 
MRC-5 cells were cultured in DMEM supplemented with 
10 % FBS, 2 mM l-glutamine, 4.5 g/l glucose, 5000 U/ml 
penicillin and 5 mg/ml streptomycin solution at 37 °C in 
a humidified 5 % CO2 atmosphere. All adherent cell lines 
were subcultured at 72 h intervals using 0.25 % trypsin/
EDTA and seeded into a fresh medium at the following 
densities: 8000 cells/cm2 for NCI-H460, DLD1, DLD1-
TxR, C6 and RC6; 16,000 cells/cm2 for U87 and NCI-
H460/R; and 32,000 cells/cm2 for U87-TxR.
Cell growth inhibition by MTT assay
Cell viability was assessed by MTT assay (MTT, Sigma, 
St. Louis, MO, USA). Briefly, 4000 cells/well were 
seeded overnight in 96-well microplates and the follow-
ing day, treated with protoflavones (0.05–25 μM) or H2O2 
(0.1–2.5 mM), by replacing the medium of each well with 
drug-containing fresh media and incubated for 72 and 48 h, 
respectively. At the end of the incubation period, MTT 
was added to each well in a final concentration of 0.2 mg/
ml for 4 h. Formazan product was extracted from cells by 
DMSO, and the absorbance was measured at 540 nm using 
an automatic microplate reader (LKB 5060-006 Micro 
Plate Reader, Vienna, Austria). IC50 value was defined as 
a concentration of each drug that inhibited cell growth by 
50 %, and it was calculated by linear regression analysis 
using Excel software.
Flow cytometric analysis of cell cycle distribution
NCI-H460, NCI-H460/R, U87 and U87-TxR cells were 
plated in 25 cm2 flasks and incubated overnight. The effects 
of compounds 5 and 6 on cell cycle distribution were stud-
ied after 48 h. Briefly, the attached and floating cells were 
trypsinized and collected by centrifugation, washed in 
phosphate buffer saline (PBS) and fixed in 70 % ethanol 
for 48 h at −20 °C. After fixation, the cells were washed in 
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PBS and pretreated with 133 µg/ml of RNAse A at 37 °C 
for 15 min. Then, PI was added to final concentration of 
17 µg/ml. After 30 min of incubation, flow cytometric anal-
ysis was performed on the FACSCalibur flow cytometer 
(Becton–Dickinson, Oxford, UK). A minimum of 10,000 
events was collected and analyzed for each experimental 
sample. Cell cycle distribution was determined automati-
cally in Mod-FIT (Verity Software House, Inc.). The valid-
ity of the data analysis model was verified using the RCS 
value (reduced Chi-square, RCS <15 %).
RNA extraction and reverse transcription (RT) reaction
Total RNA was isolated from NCI-H460, NCI-H460/R, 
U87 and U87-TxR cells. The isolation was carried out 
using TRIzol® reagent (Invitrogen Life Technologies, 
USA) according to the manufacturer’s instructions. RNA 
was quantified by spectrophotometry, and quality was 
determined by agarose gel electrophoresis. RT reactions 
were performed using 2 µg of total RNA, with a high-
capacity cDNA reverse transcription kit (Applied Biosys-
tems, USA), following the manufacturer’s instructions.
Real‑time quantitative PCR
To determine GST π, MnSOD and HIF-1α mRNA expres-
sion level in NCI-H460, NCI-H460/R, U87 and U87-TxR 
cells, real-time PCR was performed using specific primers 
[16–18]. Prepared cDNAs were amplified using Maxima 
SYBR Green/ROX qPCR Master Mix (Thermo Scientific, 
USA), according to the recommendations of the manufac-
turer, in a total volume of 20 μl in an ABI PRISM 7000 
Sequence Detection System (Applied Biosystems, USA). 
Thermocycler conditions comprised of an initial step at 
50 °C for 5 min, followed by a step at 95 °C for 10 min 
and a subsequent 2-step PCR program at 95 °C for 15 s 
and 60 °C for 60 s for 40 cycles. The accumulation of PCR 
products was detected in real time, and the results were 
analyzed using the 7000 System Software (Applied Biosys-
tems, USA) and presented as 2 − ΔCt [19], where ΔCt is 
the difference between Ct values of specific genes and the 
endogenous control (β-actin) [20].
Colorimetric detection of GSH
U87 and U87-TxR cells grown in 25 cm2 flasks were 
trypsinized and counted. The same number of untreated 
or treated cells (1 × 106) was used for this experiment. 
Cells were pelleted by centrifugation and washed with 
ice-cold PBS. After that, cells were lysed in 80 µl ice-cold 
glutathione buffer (ApoGSHTM Glutathione Colorimet-
ric Detection Kit, BioVision Inc, USA) for 10 min on ice. 
Then, 20 µl of 5 % sulfosalicylic acid was added and the 
samples were centrifuged for 10 min at 4 °C. The superna-
tant was transferred to a fresh tube and used for GSH assay. 
For the detection of GSH, glutathione buffer was added 
to each well (96-well plate) at a volume of 160 µl. After-
ward, 20 µl of either prepared samples or standards was 
added. Finally, 20 µl of substrate solution was added and 
the absorbance of generated product (2-nitro-5-thioben-
zoic acid) was read at 405 nm (LKB 5060-006 Microplate 
Reader, Austria). The concentrations of GSH (µg/µl) were 
determined using the standard calibration curve. The detec-
tion was performed at least four times in three independent 
experiments.
Reactive oxygen/nitrogen species (ROS/RNS) detection
Flow cytometric analysis of dihydrorhodamine 123 (DHR) 
fluorescence intensity was performed to detect ROS/RNS 
levels (peroxynitrite anion formation through the reaction 
of the two free radicals superoxide and nitric oxide) in 
U87 and U87-TxR cells untreated and treated with 400 nM 
5 or 4 μM 6. Levels of hydrogen peroxide and peroxyni-
trite anion were assessed. U87 and U87-TxR cells were 
incubated overnight in adherent 6-well plates (100,000 
cells/well). Then, cells were treated with protoflavones 
for 72 h. Cells were harvested by trypsinization and incu-
bated in PBS with or without the P-gp inhibitor tariquidar 
(TQ) ranging concentration from 0.5 to 10 nM, in order to 
exclude the impact of P-gp transporter activity on DHR 
accumulation [21]. After 5 min, 1 µM DHR was added 
for another 30 min at 37 °C in the dark. Cells were subse-
quently washed twice in ice-cold PBS. DHR fluorescence 
was analyzed by flow cytometry in the FL1-H channel. A 
minimum of 10,000 events was assayed for each sample. 
The samples were analyzed on a FACSCalibur (Becton–
Dickinson, UK) flow cytometer.
Statistical analysis
Statistical analysis was performed by Statistica 6.0 and 
GraphPad Prism 6 Software. The differences between 
groups were tested by Student’s t test and were considered 
statistically significant if p < 0.05. Main effects of proto-
flavones in different cell lines were examined by two-way 
ANOVA and analyzed by multiple comparisons.
Results
Chemical properties of new 6‑bromoprotoflavone
A new protoflavone derivative, 6-bromoprotoflavone (6), 
was obtained by using a four-step total synthesis. The struc-
ture elucidation of this compound was straightforward: 
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HRMS confirmed the expected molecular formula of 
C15H10BrO4, and appearance of the characteristic p-qui-
nol moiety was evidenced from the 1H NMR spectrum, 
while the A-ring signals and the H-3 singlet of the parental 
6-bromo-4′-hydroxyflavone were retained. Experimental 
details of the new protoflavone derivative are as follows.
6-Bromoprotoflavone (6). Yellow, amorphous solid; 
HRMS: C15H10BrO4, calculated: 332.9762, found: 
332.9763; 1H NMR (500 MHz, DMSO-d6) δ 8.08 (1H, d, 
J = 2.35 Hz, H-5), 7.91 (1H, dd, J = 8.97, 2.40 Hz, H-7), 
7.41 (1H, d, J = 8.70 Hz, H-8), 7.02 (2H, d, J = 10 Hz, 
H-2′ and H-6′), 6.66 (1H, s, H-3), 6.35 (2H, d, J = 9.95 Hz, 
H-3′ and H-5′); 13C NMR (500 MHz, DMSO-d6) δ 185.39 
(C-4′), 174.12 (C-4), 167.77 (C-2), 146.09 (C-9), 140.85 
(C-2′, C-6′), 134.39 (C-7), 128.88 (C-5), 124.46 (C-3′, 
C-5′), 120.02 (C-10), 118.39 (C-6), 112.68 (C-8), 107.79 
(C-3), 68.28 (C-1′).
The structures of the previously known compounds 1–5 
as well as the synthesis of the new protoflavone 6 are pre-
sented in Fig. 1.
Cytotoxic effects of protoflavone derivatives
The effect of protoflavone derivatives on cell growth was 
evaluated by the MTT assay. The results are summarized in 
Table 1. The efficacy and selectivity of protoflavones varied 
between different cell lines. Sensitivity of NCI-H460/R and 
U87-TxR to protoflavones was significantly higher in com-
parison with their sensitive counterparts (NCI-H460 and 
U87, respectively). However, although the strongest cyto-
toxic activity for all tested compounds was observed on the 
DLD1 and DLD1-TxR cells, with IC50 values at nanomo-
lar levels, only 6 showed a significant selectivity toward 
DLD1-TxR. Compounds with a substituent at C6 such as 
5 and 6 showed higher selectivity toward the three human 
MDR cancer cell lines than 2, and the sensitivity of all 
tested cancer cell lines to 5 was greater than to 6. In con-
trast with the three human cancer cell line pairs, rat MDR 
glioma cells RC6, which developed a strong antioxida-
tive defense system during the course of resistance induc-
tion, were more resistant to all tested protoflavones than 
their corresponding sensitive C6 cells (Table 1). This fact 
prompted us to investigate the sensitivity of employed cells 
to H2O2, an inducer of intracellular oxidative stress. When 
compared to their sensitive counterparts, human MDR 
cancer cells were more susceptible to the effects of H2O2, 
while rat MDR glioma cells were more resistant (Table 1). 
Normal human cells were significantly less sensitive to 2, 
while sensitivity to 5 and 6 decreased in HaCaT (normal 
keratinocytes) and MRC-5 (embryonal bronchial epithe-
lial) cells, respectively (Table 1). The selectivity of 5 and 
6 toward human glioma cells was examined next to human 
normal cells (Fig. 2a). Efficacy of 5 was significantly low-
ered in HaCaT, while efficacy of 6 was significantly low-
ered in MRC-5 in comparison with both non-MDR and 
MDR glioma cells (Fig. 2a).
Analysis of cell cycle distribution after protoflavones 
treatments
Next, we examined whether the influence of compounds 5 
and 6 on the cell cycle is correlated with their selectivity 
toward NCI-H460/R and U87-TxR cells. The differences 
between cell cycle distribution on non-MDR (NCI-H460 
and U87) and MDR (NCI-H460/R and U87-TxR) can-
cer cells after 48 h treatment with 5 and 6 were assessed 
Table 1  Sensitivity of non-MDR and MDR cancer cells and normal human cells to six protoflavone derivatives and H2O2 (expressed as IC50 
values in μM)
n.d. not determined
* Statistically significant sensitivity of MDR cancer cells: * p < 0.05; ** p < 0.01
#  Statistically significant resistance of MDR cancer cells: # p < 0.05; ## p < 0.01; ### p < 0.001
$  Statistically significant resistance of normal cells: $ p < 0.05; $$ p < 0.01
1 2 3 4 5 6 H2O2
NCI-H460 0.83 0.10 0.92 2.89 0.22 8.94 226
NCI-H460/R 0.48* 0.07 0.90 1.05** 0.08** 3.85** 136*
DLD1 0.45 0.06 0.49 0.71 0.12 1.87 625
DLD1-TxR 0.39 0.04 0.41 0.56 0.09 0.91** 312*
U87 2.05 0.41 2.47 2.66 0.77 7.94 2375
U87-TxR 0.91** 0.34 1.38* 1.64* 0.35** 4.13** 1000*
C6 2.50 0.21 4.64 2.50 0.37 3.35 92
RC6 5.93## 0.76## 9.01# 11.79### 1.30## 10.00## 189#
HaCaT 0.22 3.99$$ 3.21 0.47 1.92$$ 9.41 n.d.
MRC-5 0.28 3.05$$ 2.17 1.00 0.48 10.58$ n.d.
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by flow cytometry (Fig. 2). IC50 concentrations of 5 and 
6 on MDR cells were used in this experiment. Decrease 
in G1 phase and increase in G2/M phase were observed 
after treatment with compound 5 in the MDR cancer 
cells (Fig. 2c), while non-MDR cells remained unaffected 
(Fig. 2b). Decrease in G1 phase caused by compound 6 was 
even greater than that of 5, while cell cycle arrest in G2/M 
was not obvious (Fig. 2c). Non-MDR cells did not respond 
to treatment with 6 (Fig. 2b) at the employed concentration 
with this experimental setup.
Antioxidative capacity of MDR and non‑MDR cells
The antioxidative capacity of NCI-H460, NCI-H460/R, 
U87 and U87-TxR was evaluated by comparing the sensi-
tivity to H2O2 and the expression of antioxidative enzymes 
(Fig. 3). Sensitivity profiles for H2O2 differed between 
NCI-H460 and NCI-H460/R cells (Fig. 3a) as well as 
between U87 and U87-TxR cells (Fig. 3b). Moreover, 
glioma cells (U87 and U87-TxR) showed a consider-
able resistance to H2O2 treatment reaching IC50 values in 
the millimolar range (Table 1; Fig. 3b). Expression of 
enzymes involved in the antioxidative defense and oxida-
tive stress, GST π, MnSOD and HIF-1α was evaluated by 
real-time qPCR (Fig. 3c, d). The expression of MnSOD and 
HIF-1α mRNA was twofold and fourfold lower in NCI-
H460/R than in NCI-H460 cells, respectively (Fig. 3c). The 
expression of GST π mRNA did not change significantly 
in NCI-H460/R cells (Fig. 3c), while in U87-TxR cells, it 
decreased threefold in comparison with the non-MDR U87 
cells (Fig. 3d). HIF-1α mRNA expression also significantly 
decreased in U87-TxR cells, while MnSOD level increased 
threefold compared to U87 (Fig. 3d).
Bioactivity of compounds 5 and 6
Effects of 5 and 6 on the GSH levels and on the ROS/RNS 
production in U87 and U87-TxR cells (Fig. 4a–d) were also 
Fig. 2  Selectivity toward normal human cells and changes in the 
cell cycle distribution in human NSCLC and glioma cell lines upon 
protoflavone treatment. Comparison of protoflavones efficacy in 
glioma and normal cells assessed by MTT (a). Presented concentra-
tions for 5 (0.1, 0.25 and 0.5 µM) and 6 (5, 10 and 25 µM). Statistical 
difference in main effect toward non-MDR (*) and MDR (#) glioma 
cells. Unsynchronized non-MDR (b) and MDR cancer (c) cells were 
incubated in complete medium and treated with 5 or 6 for 48 h. NCI-
H460 and NCI-H460/R cells were treated with 100 nM of 5 or 4 μM 
of 6, while U87 and U87-TxR cells were treated with 400 nM of 5 
or 4 μM of 6. Cell cycle analysis was performed by FACSCalibur 
flow cytometry, using Mod-FIT software. Y-axis: relative cell num-
bers. X-axis: DNA content by propidium iodide. The percents of cells 
in G1 and G2/M represent average change between untreated and 
treated samples calculated from three repeated experiments
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evaluated. Both compounds significantly elevated the level 
of GSH in U87 and U87-TxR cells (Fig. 4a). Because DHR 
(a dye for ROS/RNS detection) is a substrate of the P-gp 
transporter, its accumulation was evaluated in the presence 
of the P-gp inhibitor TQ (Fig. 4b). As expected, the differ-
ence between the DHR accumulation within non-MDR and 
MDR cells decreased upon TQ treatment. Maximum pump 
inhibition in U87-TxR cells was achieved with 5 nM TQ 
(Fig. 4b). Therefore, basal ROS/RNS production in U87 
and U87-TxR cells was considered when P-gp pump was 
inhibited by 5 nM TQ. Then, the effect of compounds 5 and 
6 on ROS/RNS production was studied in the presence of 
5 nM TQ (Fig. 4c, d). No detectable change in the ROS/
RNS production was observed in the U87 cells upon treat-
ment with 5 or 6 (Fig. 4c), while both compounds signifi-
cantly increased it in U87-TxR cells (Fig. 4d). According 
to the obtained results, compounds 5 and 6 share the same 
potential for the engagement of GSH detoxification sys-
tem and ROS/RNS production. Therefore, only the mecha-
nism of the new protoflavone derivative, 6, on the mRNA 
expression levels of antioxidant enzymes was investigated. 
Compound 6 significantly decreased the expression of GST 
π and HIF-1α by twofold in U87 cells (Fig. 4e). MnSOD 
expression was decreased by twofold in U87-TxR cells, 
while HIF-1α was negligibly detected after treatment of 
this cell line with compound 6 (Fig. 4e).
Fig. 3  Comparison of antioxidative capacity between non-MDR and 
MDR cancer cells. Cell growth inhibition assessed by MTT assay 
after 48 h H2O2 treatment (a, b). The average ± SD was obtained 
from four independent experiments (n = 4). Statistical signifi-
cance between treated samples of NSCLC (a) and glioma cells (b): 
*p < 0.05; ***p < 0.001. qRT-PCR analysis of GST π, MnSOD and 
HIF-1α mRNA expression in NSCLC (c) and glioma cells (d). Statis-
tical significance between non-MDR and MDR cells from three inde-
pendent experiments (n = 3): *p < 0.05; **p < 0.01; ***p < 0.001
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Discussion
The potential of certain protoflavone derivatives as MDR 
selective anticancer agents [11] encouraged us to test their 
activity in a panel of cancer cell lines with different lev-
els of resistance, from different origins. Notably, a much 
stronger collateral sensitivity toward protoflavones was 
found in human MDR cancer cell lines than observed pre-
viously in P-gp-transfected mouse T cell lymphoma cells 
[11]. Although human MDR cancer cell lines utilized in 
this study displayed the P-gp overexpression similar to 
P-gp-transfected mouse T cell lymphoma cells, a major 
difference is that MDR phenotype in these cell lines was 
obtained by adaptation to chemotherapeutics. The selec-
tivity of protoflavones toward the MDR cancer cell lines 
appeared to be independent from the origin of the cells 
as well as from the chemotherapeutic they were adapted 
to during the development of resistance. Importantly, 
compound 2 was selective toward cancer cells being sig-
nificantly less effective in two human normal cell lines. 
Sensitivity of normal keratinocytes (HaCaT) to compound 
5 was lower, while sensitivity of embryonal bronchial epi-
thelial cells (MRC-5) to 6 was decreased. Their ability to 
distinguish normal cells differs, and new studies should 
be conducted to develop derivatives less toxic to normal 
cells.
Fig. 4  Impact of protoflavone derivatives on intracellular antioxi-
dative defense systems in non-MDR and MDR glioma cells. Levels 
of GSH in U87 and U87-TxR cells after treatment with 5 or 6 (a). 
Comparison of mean DHR intensity (as an indicator of ROS/RNS 
production) in U87 and U87-TxR cells treated with P-gp inhibitor TQ 
(b). Changes in DHR fluorescence (ROS/RNS production) after treat-
ment with 400 nM of 5 or 4 μM of 6 in U87 (c) and U87-TxR cells 
(d). qRT-PCR analysis of changes in GST π, MnSOD and HIF-1α 
mRNA expression after treatment with 4 μM of 6 (e). Statistical sig-
nificance in respect to non-MDR glioma cells (U87) from three inde-
pendent experiments (n = 3): ** p < 0.01; *** p < 0.001. Statistical 
significance between untreated and treated MDR glioma cells (U87-
TxR) from three independent experiments (n = 3): ## p < 0.01; ### 
p < 0.001
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Even though studying the structure–activity relationships 
of protoflavone derivatives was not the scope of this work, 
it was observed that the 6-bromo-substituted compound 6 
was the only one among the tested derivatives to which all 
of our human MDR cancer cell lines showed a significant 
CS. In contrast to this, compound 5, differing from 6 only 
in its 6-methyl substitution, was not selectively cytotoxic 
toward the DLD1-TxR cell line, while a similar selectivity 
toward NCI-H460/R and U87-TxR cells was observed as 
in case of compound 6. Based on their single-substituent 
structural difference and on the overview of their selectivity 
pattern on the employed cell lines, these two compounds 
were chosen for further studies of their mechanism of 
action using two pairs of non-MDR and MDR cells (NCI-
H460 and NCI-H460/R, and U87 and U87-TxR).
In contrast with the above-outlined cases of the human 
cancer cell line pairs, however, it was also observed that 
rat MDR glioma cells (RC6) were more resistant to proto-
flavones in comparison with their non-MDR counterparts 
(C6), which resistance was particularly strong in case of 
compound 4. This MDR cell line strengthened its intracel-
lular antioxidative defense systems during the development 
of resistance [14].
Therefore, our data suggest that protoflavones might 
affect some of the mechanisms that were altered during the 
stepwise acquisition of P-gp-dependent resistance rather 
than the presence of the transporter itself. Considering that 
protoflavones have been described as pro-oxidants [8], our 
starting point was to examine whether the tested MDR can-
cer cells show different sensitivity to H2O2-induced oxida-
tive stress when compared to their susceptible counterparts. 
Observations of sensitivity or resistance in case of the dif-
ferent cell lines to this treatment correlated well with those 
made for the protoflavones: The three human MDR cancer 
cell lines showed CS, while the RC6 cells were resistant to 
H2O2.
Next, we analyzed the mRNA expression of enzymes 
involved in the intracellular detoxification in non-MDR and 
MDR human NSCLC and glioma cells. Both MDR cancer 
cell lines possess lower mRNA GST π and HIF-1α expres-
sion than their corresponding non-MDR cell lines. It was 
previously suggested that decreased level of GST π could 
be associated with MDR cells’ vulnerability to pro-oxi-
dants [22]. The MnSOD mRNA expression was decreased 
in NCI-H460/R cells, and it was elevated in U87-TxR 
cells. This suggests that NSCLC and glioma MDR cells 
developed different patterns of expression of antioxida-
tive enzymes. Indeed, MnSOD expression could stabilize 
HIF-1α protein levels [23], which in return may decrease 
its mRNA expression. We observed low MnSOD expres-
sion followed by low HIF-1α expression in NCI-H460/R 
cells. According to Wang et al. [24], moderate overexpres-
sion of MnSOD, such as that observed in U87-TxR cells 
(less than fivefold compared to parental U87 cells), may 
block HIF-1α protein accumulation. We assume that higher 
vulnerability to protoflavones is governed by lower GST 
π activity in U87-TxR cells, while in NCI-H460/R cells, 
this is due to the insufficient activity of MnSOD. Although 
both MDR cancer cell lines possess P-gp overexpression, 
the alterations developed during adaptation to doxoru-
bicin (NCI-H460/R) and paclitaxel (U87-TxR) differ [25]. 
Therefore, it is likely that the mechanisms behind lower 
antioxidative capacity in these two MDR cancer cell lines 
are distinct.
Importantly, we found that compounds 5 and 6 induced 
a decrease in G1 phase followed by arrest in G2/M phase 
of cell cycle in both NSCLC and glioma MDR cells. The 
same concentration of compounds did not affect the cell 
cycle in corresponding non-MDR cells. The effects of 
compounds 5 and 6 in MDR cells are in accordance with 
those observed previously in prostate, lung and colorectal 
carcinoma cell lines with protoapigenone (1) and its deriva-
tive WYC02-9 (2), which were shown to cause cell cycle 
perturbation and induce G2/M arrest [26–28]. Addition-
ally, compound 6 significantly increased ROS/RNS pro-
duction in glioma MDR cells and this was accompanied 
by a decrease in mRNA MnSOD and HIF-1α expression. 
Although the level of GSH was increased in glioma MDR 
cells after protoflavones treatment, the expression of GST 
π was considerably low which might have been insufficient 
to activate the GSH detoxification system. This is also in 
line with previous studies that revealed increased levels 
of ROS in prostate and breast cancer cells after treatment 
with 1 or 2 [9, 26]. Moreover, RY10-4, another synthetic 
protoflavone analog, was reported to down-regulate HIF-1α 
expression in breast cancer cell lines [29].
Other authors showed that MnSOD activity is the high-
est during G1 phase and changes in its activity can signifi-
cantly influence cellular redox status during the cell cycle 
[30]. Cellular redox state shifts toward a more oxidizing 
environment during S and G2/M phases. Following cell 
division, the cellular redox state resets to that observed in 
the G1 phase. Inhibition of this oxidation state prior to S 
phase may negatively influence DNA synthesis [31]. There-
fore, we assume that by lowering the portion of MDR 
cells in G1 phase and decreasing the MnSOD expression, 
compound 6 may induce accumulation of ROS during cell 
division and consequentially decrease the proliferation of 
MDR cells.
CS has been connected with hypersensitivity to oxida-
tive stress in ABCG2 (BCRP) overexpressing MDR can-
cer cells: Krzyzanowski et al. [22], for example, found 
that MDCKII-BCRP cells are more vulnerable to ROS. 
As a possible explanation for the lower antioxidant capac-
ity of these cells, lower glutathione (GSH) levels and 
decreased activities of glutathione-S-transferase (GST) 
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and glutathione reductase (GR) were described. Lorendeau 
et al. [32] have recently published a comprehensive study 
on “classical” (i.e., not proto-) flavonoids’ ability to selec-
tively kill ABCC1 (MRP1)-transfected cancer cells through 
GSH depletion; potential use of protoflavones against such 
MDR cells might also be hypothesized. In addition to the 
role of oxidative stress in CS connected to the above-men-
tioned efflux transporters, Hall et al. [1] demonstrated that, 
in P-gp overexpressing MDR cells obtained via adaptation, 
CS activity of the thiol-containing prescription drug tio-
pronin was mediated by ROS generation and the inhibition 
of glutathione peroxidase (GPx).
However, these results obtained in vitro may not reflect 
the clinical situation. Therefore, in vivo preclinical models 
of MDR cancers should be engaged to confirm the CS to 
protoflavones. Likewise, several in vivo experiments con-
firmed the antitumor activity of compounds 1 and/or 2. In 
nude mice, 1 inhibited the growth of ovarian (MDAH-2774) 
and prostate (LNCap) cancer xenografts [33, 34], while both 
compounds exerted such activity against cervical (HeLa) 
cancer xenografts [35, 36]. Compound 2 was active against 
colorectal (HCT116) cancer xenografts in nude mice [28], 
and it was able to chemosensitize MDA-MB-231 breast 
cancer xenografts toward cisplatin possibly via the inhibi-
tion of DNA repair [10]. Moreover, 2 inhibited microvascu-
larization in HeLa xenografts as well as in vivo angiogen-
esis both in zebrafish model and in nude mice [36].
In conclusion, we may argue that CS of MDR cancer 
cells to protoflavones is a non-P-gp-dependent ROS hyper-
sensitivity [37]. Although our results together with those 
we obtained previously on a transfected cell line [11] sug-
gest that the P-gp efflux pump itself plays little if any role 
in this phenomenon, development of MDR through P-gp 
overexpression led to the suppression of intracellular anti-
oxidative capacity. This is apparently not significant in 
MDR cells that overexpress this efflux pump due to trans-
fection with a vector containing P-gp, while the adaptation 
to a new stress situation (i.e., chemotherapeutic pressure) 
caused several further changes in addition to the P-gp over-
expression in the MDR cancer cell lines utilized in our 
study. Therefore, we suggest that CS to protoflavone deriv-
atives is mediated by hypersensitivity to ROS, which is not 
directly caused by P-gp overexpression, but other changes 
during the evolution of P-gp-mediated resistance. These 
results need to be confirmed in vivo on cancer models of 
MDR.
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Introduction
Cancer is among the leading causes of morbidity and mortality
worldwide. According to the World Cancer Report, 8.2 million
cancer-related deaths were registered in 2012, and it is expect-
ed that annual cancer cases will rise from 14 million in 2012 to
around 22 million within the next two decades.[1] Resistance to
chemotherapy and molecularly targeted therapies is a major
problem facing current cancer research.[2] Despite the availabil-
ity of a broad range of diverse anticancer compounds with
new mechanisms and molecular targets, cancer is often incura-
ble due to the development of drug resistance.[3] Resistance
can rapidly develop even in cases when the tumor initially re-
sponds to chemotherapy. Multi-drug resistance (MDR) can
emerge as a result of decreased uptake or increased efflux of
cytostatic agents—the latter is mediated by ATP-binding-cas-
sette (ABC) proteins, primarily by P-glycoprotein (P-gp; ABCB1)
and ABCG2, which confer resistance to a wide variety of com-
pounds.[4,5] There is a constant need for novel chemotherapeu-
tics with marked and selective antitumor activity that can over-
come resistance mediated by these transporters. The unfavora-
ble prognostic impact of P-gp expression in several cancers
has prompted overwhelming research efforts aimed at the clin-
ical development of high affinity efflux inhibitors that were
shown to overcome MDR in in vitro models. Unfortunately,
even after decades of intensive research, a clinically effective
inhibitor has not been identified. Recently, the discussion has
shifted to alternative strategies, either to bypass the transport-
There is a constant need for new therapies against multidrug-
resistant (MDR) cancer. Natural compounds are a promising
source of novel anticancer agents. We recently showed that
protoflavones display activity in MDR cancer cell lines that
overexpress the P-glycoprotein (P-gp) drug efflux pump. In this
study, 52 protoflavones, including 22 new derivatives, were
synthesized and tested against a panel of drug-sensitive paren-
tal cells and their MDR derivatives obtained by transfection
with the human ABCB1 or ABCG2 genes, or by adaptation to
chemotherapeutics. With the exception of protoapigenone,
identified as a weak ABCG2 substrate, all protoflavones bypass
resistance conferred by these two transporters. The majority of
the compounds were found to exhibit mild to strong (up to
13-fold) selectivity against the MCF-7Dox and KB-V1 cell lines,
but not to transfected MDR cells engineered to overexpress
the MDR transporters. Our results suggest that protoflavones
can overcome MDR cancer by evading P-gp-mediated efflux.
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ers or to exploit the collateral sensitivity (CS) of MDR cells.[6]
Recent discoveries have shown that it is possible to invert the
selective advantage of resistant cells to reverse the evolution
of resistance.[7] For example, MDR-selective compounds were
shown to specifically target ABC transporter overexpressing
MDR cancer cells by exploiting the Achilles’ heel conferred by
the overexpression of the transporters.[8–10]
Our review of the literature identified several natural com-
pounds that were reported to elicit preferential toxicity against
MDR cells.[6] For example, the 4’-hydroxyflavone apigenin was
identified in a screen as a specific killer of drug-selected H69AR
cells and MRP1-transfected HeLa cells.[11] Flavonoids are natu-
rally derived compounds that display both anti- and pro-oxi-
dant properties. Flavonoids have been used in cancer chemo-
prevention and chemotherapy. A particularly interesting, rare
group of natural flavonoids with a high antitumor potential is
that of protoflavones. Typically derived from ferns, protofla-
vones contain a nonaromatic, usually p-quinol B-ring or its di-
or tetrahydro derivative. Based on the most frequently occur-
ring chemical nomenclature, herein we refer to the flavone
skeleton containing a 1’-hydroxy group and a 2’,5’-dien-4’-one
moiety in its B-ring as the “protoflavone” skeleton. Protofla-
vones can formally be derived from 4’-hydroxyflavones, like
apigenin (1), and some, for example, protoapigenone (2), the
protoflavone analogue of 1, have been described as potent an-
ticancer agents in vitro and in vivo. We have recently reviewed
the chemistry and bioactivity of protoflavones.[12] The pro-
apoptotic activity of protoflavones is mediated by oxidative
stress[13] and the inhibition of ATR-dependent signaling.[14] We
have previously shown that 6-methylated protoflavone deriva-
tives exert mild selective cytotoxicity against a murine lympho-
ma cell line transfected with the human ABCB1 transporter,
while other protoflavones, derived from apigenin, genkwanin
or b-naphthoflavone, did not exhibit such selectivity.[15] Fur-
thermore, protoapigenone and its 1’-O-butyl- and propargy-
lether, the b-naphthoflavone analogue WYC0209, 6-methylpro-
toflavone and 6-bromoprotoflavone showed selective cytotox-
icity against certain MDR cancer cell lines, such as NCI-H460
human non-small cell lung carcinoma cells adapted to doxoru-
bicin, U87 human glioma and DLD1 human colorectal cells,
both adapted to paclitaxel.[16] On the other hand, cross-resist-
ance (CR) to protoflavones was observed in C6 rat glioma cells
adapted to carmustine, and CS/CR pattern appeared to be in
line with altered antioxidative capacity of the MDR cells rela-
tive to their parental cell lines.[16]
Based on these results our aim was to systematically explore
the cytotoxicity and antitumor potential of further protoflavone
derivatives. In particular, we characterized the anticancer activity
of a total of 52 compounds in a diverse panel of cancer cell
lines including MDR derivatives expressing ABCB1 or ABCG2.
Results
Thirty-seven protoflavones and protoflavone 1’-O-alkyl ethers
were synthesized from apigenin (1), genkwanin, 4’-hydroxy-6-
methylflavone, 4’-hydroxy-6-methoxyflavone and 4’-hydroxy-b-
naphthoflavone, based on the synthetic route we have previ-
ously published for compounds 2–9,[17] 11–24[15] and 31–38.[17]
Briefly, an oxidative de-aromatization was performed by
a common hypervalent iodine reagent, [bis(trifluoroacetoxy)io-
do]benzene (PIFA) in acetonitrile in the presence of water or
the alcohol to be coupled at position C1’. Among these com-
pounds, protoapigenone 1’-O-benzylether 10 and the 6-me-
thoxylated derivatives 25–30 were obtained as new protofla-
vones; the synthesis and structures of the compounds are pre-
sented in Scheme 1.
Total synthesis of a set of various 6-substituted protofla-
vones was achieved in four to six steps. To obtain starting ma-
terials (i.e. , 5’-ethyl-2’-hydroxyacetophenone, 41; and 5’-pentyl-
2’-hydroxyacetophenone; 42) for our 6-ethyl- and 6-pentyl-
substituted target compounds, the appropriate p-substituted
phenols were acetylated and subjected to Fries rearrangement
reaction under the condition of dry aluminum chloride in di-
chloromethane.[18] The resulting 2’-hydroxyacetophenones and
those commercially available with a 5’-ethoxy or 5’-bromo sub-
stituent (43 and 44, respectively) were used in Claisen–Schmidt
condensation reactions with p-benzyloxybenzaldehyde to yield
chalcones 45–48, which, after performing ring closure with
iodine in DMSO, yielded the corresponding 6-substituted 4’-
benzyloxyflavones 49–52. The 6-bromo-substituted compound
52 was subjected to Suzuki coupling to obtain the correspond-
ing 6-phenylflavone 53. Debenzylation of the flavonoids ob-
tained this way and subsequent oxidative de-aromatization of
the flavones 54–58 with PIFA, as described above, allowed us
to obtain the protoflavones with various substituents at posi-
tions C6 and C1’ (59–73). Scheme 2 summarizes the total syn-
thetic procedure.
In the first set of experiments, the cytotoxicity of com-
pounds 2–38 and 59–73 were tested in two drug-sensitive/
MDR cancer cell line pairs (parental L5178 mouse lymphoma
cells and L5178B1 cells engineered to overexpress the human
ABCB1 protein; parental MCF-7 breast cancer cells and the
doxorubicin resistant derivative MCF-7Dox, overexpressing P-
gp). The fraction of IC50 values obtained in P-gp negative vs.
positive cells served as a quantification of the MDR selective
effect (selectivity ratio, SR). Accordingly, SR,0.5 indicated that
the compound is subject to P-gp-mediated resistance, whereas
SR+2 suggested that the P-gp expressing cells demonstrate
collateral sensitivity against the tested protoflavone derivative.
Results of the cytotoxicity testing on the L5178 and MCF-7
models are summarized in Figure 1; detailed data are present-
ed in Supporting Information Table S1.
The above results indicate that the synthesized protoflavone
derivatives possess significant toxicity in the two cell line pairs.
Interestingly, MCF7 cells were in general more resistant. Where-
as the expression of ABCB1 did not modify the sensitivity of
L5178B cells in comparison with the parental L5178 cell line,
MCF-7Dox cells showed collateral sensitivity to several deriva-
tives, with SR values exceeding 5 in the case of compounds
16, 18–22, 37, 68–71, and 73.
To substantiate the role of ABC transporters in the MDR-se-
lective toxicity of the compounds, additional MDR models
were included in the study. The cytotoxic activity of com-
pounds 2–11, 18, 31–38, 66 and 68–73 were tested in four ad-
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ditional drug-sensitive/MDR cell line pairs, including A431,
A431B1, A431G2, MES-SA, MES-SA/Dx5, KB-3-1 and KB-V1. These
compounds represent a diverse sub-set of derivatives of the
naturally occurring protoapigenone (2) and protogenkwanone
(11), analogues of the synthetic WYC0209 (31) identified as
a potential lead in previous studies,[12] as well as 6-methyl, 6-
pentyl, and 6-phenyl derivatives (18, 66, and 68–73) aiming to
further explore structure–activity relationships (SAR) at C6. The
results are shown in Figures 2 and 3; detailed data are avail-
able as Supporting Information (Tables S2 and S3).
The tested protoflavone derivatives were equally toxic to
A431, A431G2 or A431B1 cells (IC50 values ranged from 0.60 to
7.27 mm), with the exception of protoapigenone (2), suggesting
that the compounds tested herein are able to bypass ABCB1
Scheme 1. Synthesis of protoflavones from commercially available 4’-hydroxyflavones: a) CH3CN/ROH 9:1, PIFA (2 equiv).
Scheme 2. Total synthesis of 6-substituted protoflavone derivatives: a) (CH3CO)2O, conc. H2SO4 ; b) AlCl3 ; c) EtOH, 4-benzyloxybenzaldehyde, 50% KOH/H2O;
d) I2, DMSO; e) phenylboronic acid, K2CO3, tetrakis(triphenylphosphine)palladium(0) ; f) 10% Pd/C, H2 ; g) TFA/CH2Cl2, reflux
[16] ; h) CH3CN/ROH 9:1, PIFA
(2 equiv).
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as well as ABCG2. Resistance of A431G2 cells to compound 2
was abolished in the presence of tariquidar, confirming that
protoapigenone is an ABCG2 substrate (Figure 2).
Finally, we tested the interaction of the compounds with P-
gp to reveal if any of the compounds inhibit drug efflux.
ABCB1 function was characterized using the calcein accumula-
tion assay.[21] Each derivative was assayed at two concentra-
tions in the presence of the fluorescent indicator. Except for
the 6-phenylprotoflavone series (68–73), which showed mod-
erate inhibition at 20 mm (14–46%; see Supporting Information
Table 4), none of the compounds inhibited the efflux of calcein
AM by P-gp (Figure 4).
Discussion
This work was initiated with the aim to explore relevant SAR of
protoflavones with various substituents at the A-ring and par-
ticularly at C6. Following the preparation of acetophenones 41
and 42, a straightforward total-synthetic strategy[22] was ap-
plied to obtain 6-substituted protoflavones. It is worth men-
tioning that, even though related publications typically de-
scribe the use of a catalytic amount of iodine for the ring clo-
sure to obtain the flavone skeleton, using a larger, one equiva-
lent amount is far more efficient. Structure elucidation of the
protoflavones was straightforward based on the mass and
1H NMR spectra. The expected change in the molecular mass,
and, in the case of the 1’-O-alkyl derivatives, the appearance of
the characteristic 1H NMR signals and coupling pattern of the
side chain proved the successful linking of water or alcohol.
The buildup of the protoflavone type B-ring was evidenced by
the change in the coupling constant of the two doublets of H-
3’/H-5’ and H-2’/H-6’ from ~8.8 Hz to ~10.0 Hz, together with
the remaining H-3 singlet and practically unchanged A-ring
signals in the 1H NMR spectrum.
According to their B-ring substitution, cytotoxicity of the
protoflavones on the used cell lines typically followed the pre-
viously observed SAR: in most cases, 1’-hydroxy-substituted
compounds were more toxic than those with 1’-alkoxy moiet-
ies and the isopropyl ethers were the least cytotoxic deriva-
tives. This, however, did not apply for protogenkwanone and
its analogues 11–17: protogenkwanone 1’-O-methylether 12
exerted a stronger activity on the mouse lymphoma cells than
11. Moreover, an at least two carbons, long side chain was nec-
essary for this series of compounds to be slightly toxic on
Figure 1. Cytotoxicity of protoflavones 2–38 and 59–73. pIC50 values were
derived from dose–response curves obtained from cell viability experiments
on A) L5178/L5178B1 mouse lymphoma cells and B) MCF-7/MCF-7Dox cells.
SR= selectivity ratio, calculated as IC50
non-MDR/IC50
MDR ; n=3–4; Dox: doxorubi-
cin.
Figure 2. A) Cytotoxic activity of selected protoflavones against A431 (paren-
tal) cell line and two MDR derivatives engineered to overexpress ABCB1
(A431B1) or ABCG2 (A431G2). SR= selectivity ratio, calculated as IC50
sensitive/
IC50
MDR ; n=3–4; Mx: mitoxantrone. B) IC50 values of 2 (protoapigenone) and
mitoxantrone in A431 and A431G2 cell lines in the presence and absence of
tariquidar (TQ, 1 mm), an ABCG2 efflux inhibitor ; *p<0.05, **p<0.01.
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MCF-7 cells. The presence of a non-branching propyl or butyl
ether side chain at C1’ of protoapigenone (as in compounds 5
and 7) was previously found to be preferable for strong cyto-
toxic activity.[17] This was also observed in the present study in
most cell lines with the exception of the L5178/L5178B1 and
the MCF-7/MCF-7Dox cell line pairs. Moreover, the introduction
of a 1’-benzyloxy moiety (as in compound 10) to protoapige-
none also resulted in an increased toxicity in the A431 cell line
and its MDR sub-cell lines, as well as in the KB-3-1 and KB-V1
cells. This provides further evidence for the importance of the
size and/or lipophilicity of the substituent at C1’ and suggests
that a larger branching and/or unsaturated alkyl side chain
might also lead to an increased cytotoxicity, despite the gener-
ally lower activity of the 1’-O-isopropyl-substituted derivatives
than those with linear alkyl chains.
Our attempt to increase the mild selective toxicity of 6-meth-
ylprotoflavones 18–24 previously observed in ABCB1 transfected
L5178 cells[15] by introducing various C6 substituents revealed
one single compound reaching our chosen threshold of rele-
vance against the L5178B1 cells, 6-methoxyprotoflavone 1’-O-ally-
lether 29. On the other hand, while all 6-methoxy compounds
also showed tendency for such selectivity, other new derivatives
showed decreased selective cytotoxicity against this cell line
(Table S1). Similarly, none of the tested compounds, including 6-
methylprotoflavone 18, showed selective toxicity against ABCB1
transfected cell lines, including A431B1 (Table S2) and MDCK-IIB1
(not shown). Despite the equal toxicity of the studied com-
pounds on parental and P-gp-transfected cell lines, several de-
rivatives proved selectively toxic against MDR cell lines overex-
pressing P-gp as a result of long-term drug selection. In particu-
lar, MCF-7Dox cells (adapted to doxorubicin) showed collateral
sensitivity to most compounds except for 4, 31, 35 and 59–65,
with structural differences of the A-ring clearly influencing activi-
ty (Table S1). Compound 68, 6-phenylprotoflavone, for example,
showed a remarkable, 13.2-fold selective cytotoxicity, while its b-
naphthoflavone analogue 31, where a fused aromatic ring is
connected to the A-ring at the C5/C6 position, was nonselective.
By comparing the selectivity ratios of compounds with different
C6 substituents, a clear SAR of the following order was ob-
served: Ph > Me > OMe & pentyl, while the ethoxy-substituted
protoflavones 59–64 and the ethyl-substituted compound 65
were nonselective. No such general SAR could be concluded for
the C1’ substituents, except for the lower selectivity observed
for the isopropyl ether derivatives 35 and 72. Interestingly, in
case of the MES-SA/MES-SA/Dx5 cell line pair where the MDR
Figure 3. pIC50 values measured in doxorubicin-selected MES-SA/Dx5
[19] and
vinblastine-selected KB-V1[20] cells relative to the pIC50 values of A) MES-SA
and B) KB-3-1 cells. Two compounds were selectively toxic against both
MES-SA/Dx5 and KB-V1 cells (2 and 66), and none of the protoflavones
showed substrate-like characteristics; Dox: doxorubicin, Vbl : vinblastine.
Figure 4. Relative inhibition of calcein AM efflux by A) compounds 2, 11, 18,
31, 65, 66, and 68 (where R=H refers to Schemes 1 and 2), and B) deriva-
tives of compound 68 (6-phenylprotoflavones). Relative inhibition was calcu-
lated from mean calcein intensities as: 100*[(sample)@(negative control)]/
[(positive control)@(negative control)] ; 20 mm verapamil was used as positive
control, corresponding to full inhibition (100%); results of single-point ex-
periments are presented.
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sub-cell line was also obtained by adaptation to doxorubicin,[19]
collateral sensitivity was observed only for the classical, 1’-hy-
droxy-containing protoflavones (2, 11 18 and 66, but SR was
below threshold for 31 and 68) and not for any of the 1’-O-alkyl-
protoflavones. Furthermore, the KB-V1 cell line, obtained from
KB-3-1 by adaptation to vinblastine,[20] also presented marginal
CS toward most of the protoflavones, although SR values for
several compounds fell just below the 2-fold threshold (Fig-
ure 3B, Table S3).
Statistical significance of the SAR was tested from two
angles. Compounds were grouped either according to their A-
rings or their substituents at C1’, and the SR values of these
groups were compared by one-way ANOVA1 followed by Bon-
ferroni’s post hoc test. No differences were observed for the
C1’ substituents on any of the cell lines, not even when the
data were normalized to the average of their corresponding
series (i.e. , analogues with the same A-ring). However, the dif-
ferent A-ring-containing protoflavone derivatives showed sig-
nificant differences in their SR values on the MCF-7/MCF-7Dox
cell line pair ; results are presented in Figure 5.
All tested compounds were found to be similarly cytotoxic
on the L5178 and the L5178B1 cell lines, with a strong correla-
tion between the two (Spearman r=0.9544). Interestingly, IC50
values on the MCF-7Dox cell line also showed a good correlation
to those on the parental mouse lymphoma cell line (Spearman
r=0.7691), while the same correlation for MCF-7 was much
weaker with several outliers (Spearman r=0.5812; without out-
liers, that is, compounds 8, 11–17, 19–24, 37, 68–71 and 73 :
r=0.7420). For a graphical interpretation of these correlations,
see Supporting Information Figure S1.
These results suggest that the SR associated with the com-
pounds on the MCF-7/MCF-7Dox is more a result of the resist-
ance of MCF-7 to protoflavones, than the sensitivity of MCF-
7Dox. MCF-7 cells appear to be particularly resistant to the 7-
methoxy group containing protogenkwanone derivatives 11–
17, 6-methylprotoflavones 19–24, 6-phenylprotoflavones 68–
71 and 73, and 1’-allyl-group-containing analogues 8 and 37,
in line with the results presented in Figure S1. As such, adapta-
tion of MCF-7 cells to doxorubicin has apparently resulted in
the loss of initial resistance to protoflavones as an evolutionary
cost of acquiring the MDR phenotype, and this manifested as
collateral sensitivity.
Collateral sensitivity is causally linked to the adaption of
MDR cells to a chemotherapeutic and may involve metabolic
modifications, the upregulation of receptors[23] or the modula-
tion of the redox homeostasis.[24] One limitation of studies rely-
ing on MDR cell lines is that the contribution of MDR pumps,
versus other acquired cellular alterations, cannot be delineat-
ed.[8, 9, 25] Collateral sensitivity of the MDR cell lines analyzed in
this study indicates that resistance to doxorubicin or vinblas-
tine may result in cellular alterations that render the cells sus-
ceptible to the protoflavone derivatives. However, in contrast
to MDR-selective compounds,[10] protoflavone derivatives do
not selectively target cells engineered to overexpress P-gp,
suggesting that the increased toxicity observed in the MDR
cells is not conferred by the efflux pumps. This was also sup-
ported by our observation that selectivity ratios did not de-
crease significantly when compounds 2, 11, and 18 were
tested on the MES-SA/MES-SA/Dx5 cell line pair in the pres-
ence of tariquidar (data not presented).
It is important to point out that the lack of CR to most pro-
toflavones in all MDR cell lines studied here indicates that
these compounds can overcome MDR through bypassing
efflux that is mediated by ABCB1 or ABCG2. SAR of the cyto-
toxic activity concerning the 6-substituents appears to differ
from cell line to cell line, for example an order of Me > Et &
Pent & Ph > Br > OEt > OMe can be recognized on L5178
and L5178B1, Pent > Ph & Me on KB-3-1 and KB-V1, while simi-
lar activities are exerted by 6-pentyl (66), 6-phenyl (68) and 6-
methyl (18) compounds on MES-SA and MES-SA/Dx5. From
a general overview, 6-alkyl-substituted protoflavones appear to
be somewhat more favorable anticancer agents over 6-alkoxy
compounds, even though nearly all compounds presented
here can be considered as valuable leads against resistant can-
cers. As an interesting exception to this, however, resistance to
protoapigenone (2) was observed in the ABCG2 transfected
A431G2 cell line, and a tendency for marginal resistance ap-
peared also to its 1’-O-alkyl ethers. Resistance of this cell line
to protoapigenone (2) markedly decreased in the presence of
tariquidar, strongly suggesting that compound 2 is an ABCG2
substrate. ABCG2 did not confer resistance toward any of the
other compounds including protogenkwanone (11), which dif-
fers from 2 only in its 7-methoxy group. This suggests that
a nonsubstituted phenolic hydroxy group at C7 is necessary
for protoflavones to be recognized by this transporter.
Figure 5. Selectivity ratio (SR) values for protoflavone analogues containing
the same A-rings on the MCF-7/MCF-7Dox cell line pair. Box-and-whisker plots
represent medians, first and third quartiles and ranges; SR+2.0 and SR,0.5
represent CS and CR, respectively; lower-case letters represent datasets with
statistically significant differences (i.e. , groups with overlap in their marking
are not significantly different) at p,0.05 by one-way ANOVA followed by
Bonferroni’s post-hoc test.
1 Each group containing at least seven data points passed the Shapiro–Wilk
normality test, suggesting the normal distribution of SR values under the in-
fluence of the presented chemical variations. Therefore, ANOVA is suitable for
the statistical evaluation of these datasets.
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Conclusions
Our in vitro studies on various A-ring and 1’-substituted proto-
flavones revealed 6-methoxyprotoflavone 1’-O-allyl ether 29 as
an antitumor agent with a mild MDR selectivity (SR=2.0) in
a murine lymphoma cell line transfected with the human
ABCB1 efflux transporter.
The ability of protoflavones to evade efflux-mediated MDR
was confirmed both in ABCB1 and ABCG2 expressing cell lines,
with the exceptions of protoapigenone (2) which was identi-
fied as an ABCG2 substrate. MDR selective cytotoxicity was ob-
served for most of the tested protoflavones in a breast cancer
cell line adapted to doxorubicin (MCF-7Dox) and SAR revealed
importance of the A-ring substitution, while in the uterine sar-
coma MES-SA/Dx5, another doxorubicin-selected cell line, only
the 1’-hydroxy-containing compounds showed relevant selec-
tivity. Because overexpression of ABCB1 did not sensitize cells,
we conclude that the MDR-selective cytotoxicity of protofla-
vones is connected to other changes accompanying acquired
drug resistance.
Experimental Section
Structure elucidation was carried out by NMR spectroscopy and
MS. NMR spectra were obtained on a Varian Gemini-2000 200 MHz
or Bruker Avance DRX-500 NMR spectrometer in CDCl3, CD3OD,
[D6]acetone, or [D6]DMSO. Mass spectra were taken on an API 2000
triple-quadrupole (Ab Sciex, USA) or LCMS-IT-TOF (Shimadzu,
Japan) with an ESI interface. Compounds were purified by rotation
planar chromatography on a chromatotron (Harrison Research,
USA) with adequately chosen eluents of n-hexane/EtOAc on silica
GF254 (Merck, Germany), or by flash chromatography on a Combi-
flash Rf+ (Teledyne Isco, USA) with eluents of n-hexane/EtOAc or
MeOH/CH2Cl2 on RediSep normal-phase silica flash columns (Tele-
dyne Isco, USA). All compounds possessed a purity of +95.0% as
determined by HPLC-DAD, except for compounds 51 and 55
(92.20 and 93.41%, respectively), which served as intermediates for
further synthesis and whose bioactivity was not tested. All chemi-
cals were obtained from Aldrich Inc. (USA).
Synthesis of 5’-ethyl- and 5’-pentyl-2’-hydroxyacetophenone (41
and 42): In the first step, 4-ethyl- and 4-pentylphenol acetate (39
and 40, respectively) were synthesized by adding acetic anhydride
(0.1 mol, 10.2 g) and one drop of ccH2SO4 to 4-ethyl or 4-pentyl-
phenol (0.1 mol) and stirring at room temperature (RT) for 20 min.
The mixture was then poured into H2O and extracted with EtOAc
(3V50 mL). The organic layer was evaporated under reduced pres-
sure, re-dissolved in CH2Cl2 and crystallized anhydrous AlCl3 was
added little by little under ice bed cooling. The mixture was held
at reflux for 10 h, then the reaction was stopped by adding
crushed ice. After filtration, the precipitate was purified on silica to
obtain 41 or 42.
General procedure for chalcone synthesis
The 5’-substituted 2’-hydroxyacetophenone (41–44) and 4-benzy-
loxybenzaldehyde (3.0 g, 14.3 mmol) were dissolved in 50% EtOH,
KOH/H2O solution (20 mL). The reaction was stirred at RT for 30 h,
and then the solvent was evaporated under reduced pressure. The
mixture was purified on silica gel (isocratic elution, n-hexane/
EtOAc, 6:1) to afford 45–48.
(E)-3-(4-benzyloxyphenyl)-1-(5-ethoxy-2-hydroxyphenyl)prop-2-
en-1-one (47): Orange solid; yield: 82.2%; NP-HPLC purity:
99.15%; 1H NMR (500 MHz, CDCl3) d=12.47 (1H, s, OH), 7.89 (1H,
d, J=15.35 Hz), 7.62 (2H, d, J=8.60 Hz), 7.47 (1H, d, J=15.55 Hz),
7.34–7.45 (6H, m), 7.12 (1H, dd, J=9.00 Hz, 2.80 Hz), 7.02 (2H, d,
J=8.55 Hz), 6.96 (1H, d, J=9.00 Hz), 5.13 (2H, s), 4.05 (2H, q, J=
6.95 Hz), 1.44 (3H, t, J=6.95 Hz) 7.91 (2H, d, J=8.45 Hz), 7.86 (1H,
d, J=Hz), 7.67 (1H, d, J=2.65 Hz), 7.4–7.38 (5H, br), 7.35 (1H, d,
J=7.25 Hz), 7.19 (1H, dd, J=2.70 Hz, 8.50 Hz), 7.11 (2H, d, J=
8.50 Hz), 6.92 (1H, d, J=9.00 Hz), 5.19 (2H, s), 4.07 (2H, q, J=
6.85 Hz), 1.34 ppm (3H, t, J=6.90 Hz); 13C NMR (125 MHz, CDCl3)
193.45, 161.32, 157.97, 151.11, 145.47, 136.46, 130.69, 128.83,
128.36, 127.72, 127.61, 124.29, 119.97, 119.31, 117.93, 115.53,
114.22, 70.29, 64,72, 15.06; ESIMS (m/z): 375.3 [M+H]+ .
General procedure for flavone synthesis
Chalcone (3 mmol, 45–48) was dissolved in DMSO (5 mL), and
iodine (1 equiv. , 76 mg, 0.3 mmol) was added. The solution was
stirred and heated at 110 8C. After 2 h, Na2S2O3 (10%, 50 mL) was
added to remove the iodine. The mixture was extracted with
EtOAc (3V50 mL) and then purified by column chromatography
on silica gel to afford compounds 49–52.
6-Ethoxy-4’-benzyloxyflavone (51): Yield: 85.2%; NP-HPLC purity:
92.20%, pale-yellow solid; 1H NMR (500 MHz, CDCl3) d=7.86 (2H,
d, J=8.80 Hz), 7.56 (1H, d, J=2.70 Hz), 7.48–7.38 (5H, benzyl), 7.35
(1H, d, J=7.1 Hz), 7.25 (1H, dd, J=2.85 Hz, 8.75 Hz), 7.08 (2H, d,
J=8.70 Hz), 6.72 (1H, s), 5.14 (2H, s), 4.13 (2H, q, J=6.95 Hz),
1.44 ppm (3H, t, J=6.95 Hz); 13C NMR (125 MHz, CDCl3) 178.44,
163.26, 161.61, 156.43, 151.06, 136.34, 131.02, 128.95, 128.87,
128.41, 128.11, 127.62, 124.68, 124.61, 124.05, 119.46, 115.48,
105.72, 70.36, 64.36, 14.86 ppm; ESIMS (m/z): 372.9 [M+H]+ .
Synthesis of compound 53 from 52 via Suzuki coupling
Compound 52 (407.26 mg, 1.0 mmol), phenylboronic acid
(1.2 equiv. , 146.3 mg, 1.2 mmol) and K2CO3 (2 equiv. , 276.42 mg,
2.0 mmol) were dissolved in H2O (7 mL), and propanol (25 mL) and
tetrakis(triphenylphosphine)palladium(0) (5 mmol) were subse-
quently added. The reaction was performed under N2 gas at 40 8C,
to afford 53 as a yellow solid.
6-Phenyl-4’-benzyloxyflavone (53): Yield: 30.0%; yellow solid;
1H NMR (200 MHz, CDCl3) d=8.45 (1H, s), 7.89 (3H, d, J=7.80 Hz),
7.67 (1H, d, J=7.20 Hz), 7.50–7.30 (11H, m), 7.25 (1H, s), 7.10 (2H,
d, J=8.40 Hz), 6.77 (1H, s), 5.15 ppm (2H, s) ; 13C NMR (50 MHz,
CDCl3) 177.35, 162.34, 160.55, 154.56, 138.32, 137.20, 135.16,
131.35, 127.91, 127.68, 127.35, 127.21, 127.00, 126.74, 126.41,
126.12, 125.66, 123.19, 122.48, 117.39, 114.33, 113.90, 105.18, 97.23,
69.17.
General procedure for benzyl group removal
A mixture of 4’-benzyloxyflavone (0.5 mmol, 49–53), dry Pd/C
(10%, 106 mg), and EtOAc (20 mL) was stirred at 25 8C under an at-
mosphere of hydrogen for 10 h. The mixture was filtered, washed
with EtOAc, concentrated under vacuum and purified by column
chromatography on silica gel to afford compounds 54–58.
6-Pentyl-4’-hydroxyflavone (55): Yield: 85.4%; NP-HPLC purity:
93.41%, pale-yellow solid; 1H NMR (500 MHz, [D6]DMSO) d=10.31
(1H, brs, OH), 7.95 (2H, d, J=8.65 Hz), 7.81 (1H, s), 7.66 (1H, d, J=
8.45 Hz), 7.64 (1H, dd, J=8.85 Hz, 1.85 Hz), 6.90 (2H, d, J=9.75 Hz),
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6.94 (2H, d, J=8.60 Hz), 6.84 (1H, s), 2.70 (2H, t, J=7.45 Hz), 1.61
(2H, quin, J=7.00 Hz), 1.38–1.21 (4H, m), 0.85 ppm (2H, t, J=
6.85 Hz); 13C NMR (125 MHz, [D6]DMSO) 176.97, 162.97, 160.96,
154.05, 139.67, 134.43, 128.34, 123.43, 123.07, 121.7, 118.26, 115.97,
104.72, 34.42, 30.79, 30.55, 21.96, 13.94; ESIMS (m/z): 309.5 [M+H]+ .
General procedure for protoflavone synthesis from 4’-
hydroxyflavones
Apigenin, genkwanin, 4’-hydroxy-6-methylflavone, 4’-hydroxy-6-
methoxyflavone, 4’-hydroxy-b-naphthoflavone (Indofine, Hillsbor-
ough, NJ, USA), or the synthesized 4’-hydroxyflavone (1 mgmL@1,
54–58) was dissolved in a mixture of acetonitrile and H2O (9:1 v/v
ratio) or the alcohol to be coupled at position C1’. Two equivalents
of [bis(trifluoroacetoxy)iodo]benzene were added to the mixture.
After stirring at 80 8C for 1 h, the mixture was cooled down, evapo-
rated under reduced pressure and purified by flash chromatogra-
phy to obtain compounds 2–9,[17] 10, 11–24,[15] 25–30, 31–38,[17] or
59–73. Compounds 10, 25–30 and 59–73 are reported here as
new protoflavones.
Protoapigenone 1’-O-benzyl ether (10): Light-brown solid; yield:
39,6%; RP-HPLC purity: 99.21%, 1H NMR (500 MHz, [D6]DMSO) d=
12.47 (1H, s, OH), 7.36–7.43 (4H, m), 7.32 (1H, t, J=6.90 Hz), 7.18
(2H, d, J=9.95 Hz), 6.57 (2H, d, J=9.95 Hz), 6.50 (1H, s), 6.18 (2H,
d, J=9.15 Hz), 4.57 ppm (2H, s) ; 13C NMR (125 MHz, [D6]DMSO)
184.29, 181.32, 165.44, 164.37, 161.41, 157.41, 145.78, 137.53,
132.22, 128.35, 127.84, 127.65, 107.37, 103.68, 99.43, 94.01, 74.22,
66.52; ESIMS (m/z): 377.2 [M+H]+ .
6-Methoxyprotoflavone (25): Pale-yellow solid; yield: 32.3%; NP-
HPLC purity: 98.95%, 1H NMR (500 MHz, [D6]acetone) d=7.46 (1H,
d, J=2.95 Hz), 7.44 (1H, d, J=9.35 Hz), 7.33 (1H, dd, J=9.07 Hz,
2.90 Hz), 7.05 (2H, d, J=10.00 Hz), 6.66 (1H, s), 6.33 (2H, d, J=
10.00 Hz), 6.11 (1H, s), 3.90 (3H, s) ; 13C NMR (125 MHz, CDCl3)
185.54, 179.13, 166.64, 157.4, 151.23, 147.00, 129.71, 124.57, 119.68,
107.97, 104.84, 69.85, 56.09; ESIMS (m/z): 285.4 [M+H]+ .
6-Methoxyprotoflavone 1’-O-methyl ether (26): Yellow solid;
yield: 41.3%; NP-HPLC purity: 98.93%, 1H NMR (500 MHz,
[D6]acetone) d=7.45 (1H, d, J=3.20 Hz), 7.43 (1H, d, J=8.7 Hz),
7.33 (1H, dd, J=9.15 Hz, 3.00 Hz), 7.01 (2H, d, J=10.05 Hz), 6.58
(1H, s), 6.54 (2H, d, J=10.15 Hz), 3.90 (3H, s), 3.44 ppm (3H, s);
13C NMR (125 MHz, [D6]DMSO) 184.27, 176.53, 163.86, 156.74,
150.26, 145.91, 132.42, 123.96, 123.53, 119.89, 108, 104.77, 74.3,
55.74, 52.34; ESIMS (m/z): 299.1 [M+H]+ .
6-Methoxyprotoflavone 1’-O-ethyl ether (27): Yellow solid; yield:
39.3%; NP-HPLC purity: 98.39%, 1H NMR (500 MHz, [D6]acetone)
d=7.45 (1H, d, J=2.90 Hz), 7.43 (1H, d, J=8.85 Hz), 7.33 (1H, dd,
J=10.00, 2.80 Hz), 7.03 (2H, d, J=10.00 Hz), 6.63 (1H, s), 6.51 (2H,
d, J=9.95 Hz), 3.90 (3H, s), 3.64 (2H, q, J=6.80 Hz) 1.28 ppm (1H,
t, J=6.90 Hz); 13C NMR (125 MHz, [D6]DMSO) 184.34, 176.55,
164.04, 156.73, 150.24, 146.39, 131.91, 123.96, 123.5, 119.88, 107.96,
104.78, 74.01, 60.3, 55.73, 15.56; ESIMS (m/z): 313.0 [M+H]+ .
6-Methoxyprotoflavone 1’-O-butyl ether (28): Yield: 46.3%; NP-
HPLC purity: 98.67%, light-brown solid; 1H NMR (500 MHz,
[D6]acetone) d=7.45 (1H, d, J=2.90 Hz), 7.43 (1H, d, J=8.80 Hz),
7.32 (1H, dd, J=9.15 Hz, 1.80 Hz), 7.02 (2H, d, J=10.25 Hz), 6.63
(1H, s), 6.51 (2H, d, J=9.85 Hz), 3.90 (3H, s), 3.59 (2H, t, J=
5.35 Hz) 1.65 (2H, q, J=6.20 Hz), 1.51–1.35 (2H, m), 0.94 ppm (3H,
t, J=7.20 Hz); 13C NMR (125 MHz, CDCl3) 184.93, 178.42, 164.14,
153.28, 149.20, 146.45, 132.77, 124.66, 124.25, 119.64, 108.89,
104.99, 74.65, 65.09, 56.11, 32.23, 19.43, 13.99; ESIMS (m/z): 341.1
[M+H]+ .
6-Methoxyprotoflavone 1’-O-allyl ether (29): Light-brown solid;
yield: 37.2%; NP-HPLC purity: 95.17%, 1H NMR (500 MHz,
[D6]acetone) d=7.44 (1H, d, J=2.85 Hz), 7.43 (1H, d, J=8.85 Hz),
7.30 (1H, dd, J=9.15 Hz, 2.95 Hz), 7.02 (2H, d, J=10.10 Hz), 6.61
(1H, s), 6.49 (2H, d, J=9.85 Hz), 5.24 (1H, octet, J=6.55 Hz), 4.61
(1H, d, J=17.2 Hz), 4.43 (1H, d, J=10.57 Hz), 3.37 (2H, d, J=
5.05 Hz), 3.86 ppm (3H, s); 13C NMR (125 MHz, CDCl3) 184.69,
178.25, 163.8, 157.37, 151.09, 145.81, 145.78, 133.75, 132.87,
124.24, 123.68, 119.6, 117.69, 108.98, 105.01, 74.83, 66.23, 56.09;
ESIMS (m/z): 325.2 [M+H]+ .
6-Methoxyprotoflavone 1’-O-proargyl ether (30): Light-brown
solid; yield: 37.7%; NP-HPLC purity: 95.32%, 1H NMR (500 MHz,
[D6]acetone) d=7.46 (1H, d, J=2.90 Hz), 7.44 (1H, d, J=8.85 Hz),
7.33 (1H, dd, J=9.07 Hz, 2.80 Hz), 7.10 (2H, d, J=9.90 Hz), 6.61
(1H, s), 6.50 (2H, d, J=9.90 Hz), 4.44 (2H, d, J=1.95 Hz), 3.90 (3H,
s), 3.10 ppm (1H, t, J=2.20 Hz); 13C NMR (125 MHz, [D6]DMSO)
184.17, 176.5, 163.24, 156.76, 150.27, 144.90, 132.26, 123.95,
123.57, 119.92, 108.17, 104.76, 80.17, 78.41, 74.40, 55.74, 53.27;
ESIMS (m/z): 322.9 [M+H]+ .
6-Ethoxyprotoflavone (59): Pale-yellow solid; yield: 35.3%; NP-
HPLC purity: 99.14%, 1H NMR (500 MHz, CD3OD) d=7.51 (1H, d,
J=2.90 Hz), 7.43 (1H, d, J=9.20 Hz), 7.36 (1H, dd, J=9.25 Hz,
3.00 Hz), 7,00 (2H, d, J=9.95 Hz), 6.79 (1H, s), 6.39 (2H, d, J=
10.10 Hz), 4.14 (2H, q, J=6.95 Hz), 1.44 ppm (3H, t, J=7.00 Hz);
13C NMR (125 MHz, CDCl3) 185.37, 178.99, 166.3, 156.73, 151.08,
146.77, 129.75, 124.79, 124.23, 119.58, 107.97, 105.45, 69.78, 64.40,
14.72; ESIMS (m/z): 299.3 [M+H]+ .
6-Ethoxyprotoflavone 1’-O-methyl ether (60): Yellow solid; yield:
42.0%; NP-HPLC purity: 99.21%, 1H NMR (500 MHz, CDCl3) d=7.48
(1H, d, J=2.90 Hz), 7.26 (1H, d, J=9.15 Hz), 7.20 (1H, dd, J=
9.15 Hz, 2.90 Hz), 6.79 (2H, d, J=10.00 Hz), 6.71 (1H, s), 6.54 (2H, d,
J=9.95 Hz), 4.09 (2H, q, J=7.00 Hz), 3.37 (3H, s), 1.41 ppm (3H, t,
J=7.15 Hz); 13C NMR (125 MHz, CDCl3) 184.64, 178.16, 163.66,
156.66, 150.94, 145.68, 133.18, 124.65, 124.47, 119.51, 108.83,
105.65, 75.01, 64.37, 52.88, 14.76; ESIMS (m/z, %): 313.5 [M+H]+ .
6-Ethoxyprotoflavone 1’-O-ethyl ether (61): Yellow solid; yield:
41.2%; NP-HPLC purity: 98.12%, 1H NMR (500 MHz, CDCl3) d=7.49
(1H, d, J=2.85 Hz), 7.26 (1H, d, J=9.25 Hz), 7.20 (1H, dd, J=
9.20 Hz, 2.90 Hz), 6.80 (2H, d, J=10.00 Hz), 6.78 (1H, s, H-3), 6.50
(2H, d, J=10.00 Hz), 4.09 (2H, q, J=7.00 Hz), 3.57 (2H, q, J=
6.85 Hz), 1.41 (3H, t, J=6.85 Hz), 1.27 ppm (3H, t, J=6.95 Hz);
13C NMR (125 MHz, CDCl3) 184.83, 178.54, 164.14, 156.71, 151.02,
146.25, 132.68, 124.64, 124.53, 119.55, 108.77, 105.59, 74.71, 64.39,
61.03, 15.78, 14.75; ESIMS (m/z, %): 327.6 [M+H]+ .
6-Ethoxyprotoflavone 1’-O-propyl ether (62): Yellow solid; yield:
45.8%; NP-HPLC purity: 99.20%, 1H NMR (500 MHz, CDCl3) d=7.49
(1H, d, J=2.85 Hz), 7.25 (1H, d, J=9.25 Hz), 7.20 (1H, dd, J=
9.20 Hz, 2.90 Hz), 6.79 (2H, d, J=9.80 Hz), 6.78 (1H, s, H-3), 6.51
(2H, d, J=10.10 Hz), 4.09 (2H, q, J=7.00 Hz), 3.46 (2H, t, J=
6.45 Hz), 1.65 (2H, sex, J=7.15 Hz), 1.41 (3H, t, J=6.90 Hz),
0.96 ppm (3H, t, J=7.40 Hz); 13C NMR (125 MHz, CDCl3) 184.85,
178.31, 163.97, 156.65, 150.95, 146.37, 132.68, 124.65, 124.45,
119.51, 108.84, 105.63, 74.59, 66.92, 64.37, 23.47, 14.77, 10.7; ESIMS
(m/z, %): 341.5 [M+H]+ .
6-Ethoxyprotoflavone 1’-O-isopropyl ether (63): Yellow solid;
yield: 43.1%; NP-HPLC purity: 98.20%, 1H NMR (500 MHz, CDCl3)
d=7.48 (1H, d, J=2.75 Hz), 7.25 (1H, d, J=9.00 Hz), 7.20 (1H, dd,
J=9.15 Hz, 2.85 Hz), 6.81 (2H, d, J=10.00 Hz), 6.80 (1H, s), 6.48
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(2H, d, J=9.95 Hz), 4.09 (2H, q, J=7.00 Hz), 3.84 (2H, quin, J=
6.15 Hz), 1.42 (3H, t, J=7.30 Hz), 1.21 ppm (6H, d, J=6.35 Hz);
13C NMR (125 MHz, CDCl3) 185.05, 178.35, 164.16, 156.64, 150.93,
146.72, 131.97, 124.64, 124.43, 119.51, 108.96, 105.62, 74.91, 68.93,
64.36, 24.82, 14.77; ESIMS (m/z): 341.5 [M+H]+ .
6-Ethoxyprotoflavone 1’-O-buthyl ether (64): Light-brown solid;
yield: 49.9%; NP-HPLC purity: 98.30%, 1H NMR (500 MHz, CDCl3)
d=7.49 (1H, br s), 7.26 (1H, d, J=9.10 Hz), 7.22 (1H, dd, J=
8.55 Hz, 2.85 Hz), 6.83 (1H, s), 6.79 (2H, d, J=9.55 Hz), 6.51 (2H, d,
J=9.60 Hz), 4.09 (2H, q, J=6.85 Hz), 3.84 (2H, t, J=6.05 Hz), 1.61
(2H, q, J=6.65 Hz), 1.45–1.32 (2H, m), 1.41 (3H, t, J=6.40 Hz),
0.92 ppm (3H, t, J=7.25 Hz); 13C NMR (125 MHz, CD3OD) 186.46,
166.74, 158.31, 152.45, 148.05, 133.64, 125.79, 125.36, 120.82,
109.11, 106.55, 75.99, 66.07, 65.45, 33.38, 20.46, 15.07, 14.32; ESIMS
(m/z): 355.2 [M+H]+ .
6-Ethylprotoflavone (65): Light-brown solid; yield: 41.0%; RP-
HPLC purity: 95.0%, 1H NMR (500 MHz, CDCl3) d=7.92 (1H, s), 7.48
(1H, d, J=8,55 Hz), 7.27 (1H, d, J=8,65 Hz), 6.95 (2H, d, J=
9,30 Hz), 6.86 (1H, s), 6.38 (2H, d, J=9,30 Hz), 2.72 (2H, q, J=
7.50 Hz), 1.25 ppm (3H, t, J=7.00 Hz); 13C NMR (125 MHz, CDCl3)
185.33, 179.31, 166.56, 154.82, 146.63, 142.31, 134.77, 129.89,
123.88, 123.37, 118.11, 108.68, 69.94, 28.44, 15.58; ESIMS (m/z):
283.3 [M+H]+ .
6-Pentylprotoflavone (66): Light-brown solid; yield: 42.3%; NP-
HPLC purity: 96.10%, 1H NMR (500 MHz, CDCl3) d=7.92 (1H, s),
7.46 (1H, dd, J=8.45 Hz, 1.25 Hz), 7.28 (1H, d, J=8.95 Hz), 6.90
(2H, d, J=9.75 Hz), 6.79 (1H, s), 6.38 (2H, d, J=9.80 Hz), 2,66 (2H,
t, J=7.60 Hz), 1.61 (2H, quin, J=6.90 Hz), 1.38–1.21 (4H, m),
0.85 ppm (3H, t, J=7.05 Hz); 13C NMR (125.7 MHz, CDCl3) 176.91,
162.93, 160.90, 154.00, 139.61, 134.37, 123.38, 118.20, 104.68, 34.37,
30.48, 20.73, 21.90, 13.88; ESIMS (m/z): 325.4 [M+H]+ .
6-Phenylprotoflavone (68): Yellow solid; yield: 38.1%; NP-HPLC
purity: 95.19%, 1H NMR (500 MHz, CDCl3) d=8.37 (1H, d, J=
1.40 Hz), 7.88 (1H, dd, J=9.00 Hz, 1.85 Hz), 7.62 (2H, d, J=7.55 Hz),
7.45 (2H, t, J=6.75 Hz), 7.41 (1H, d, J=8.95 Hz), 7.37 (1H, t, J=
7.65 Hz), 6.91 (2H, d, J=10.10 Hz), 6.82 (1H, s), 6.57 ppm (2H, d,
J=9.90 Hz); 13C NMR (50 MHz, CDCl3) d=145.07, 131.64, 128.27,
127.94, 127.42, 126.95, 126.10, 122.51, 122.51, 117.47, 108.50,
65.77 ppm; HRESIMS C21H15O4, calcd: 331.0970, found: 331.0973.
6-Phenylprotoflavone 1’-O-methyl ether (69): Yellow solid; yield:
50.2%; NP-HPLC purity: 97.74%, 1H NMR (500 MHz, CDCl3) d=8.37
(1H, d, J=1.50 Hz), 7.88 (1H, dd, J=8.35 Hz, 1.50 Hz), 7.66 (2H, d,
J=7.85 Hz), 7.45 (2H, t, J=7,10 Hz), 7.41 (1H, d, J=8.85 Hz), 7.37
(1H, t, J=7.00 Hz), 6.82 (2H, d, J=9.95 Hz), 6.77 (1H, s), 6.57 ppm
(2H, d, J=9.90 Hz), 3.41 (3H, s) ; 13C NMR (50 MHz, CDCl3) d=
144.39, 132.14, 131.81, 128.26, 127.94, 127.42, 127.26, 126.92,
126.10, 122.51, 121.72, 117.47, 108.49, 108.11, 51.71, 28.63 ppm;
HRESIMS C22H17O4, calcd: 345.1127, found: 345.1125.
6-Phenylprotoflavone 1’-O-ethyl ether (70): Yellow solid; yield:
48.2%; NP-HPLC purity: 98.10%, 1H NMR (500 MHz, CDCl3) d=8.37
(1H, d, J=1.50 Hz), 7.87 (1H, d, J=8.60 Hz), 7.62 (2H, d, J=
7.50 Hz), 7.44 (2H, t, J=7.20 Hz), 7.40 (1H, d, J=8.85 Hz), 7.36 (1H,
br t, J=6.75 Hz), 6.84 (1H, s), 6.83 (2H, d, J=10.10 Hz), 6.53 (2H, d,
J=9.80 Hz), 3.58 (2H, q, J=7.00 Hz), 1.28 ppm (3H, t, J=6.80 Hz);
13C NMR (50 MHz, CDCl3) d=144.84, 132.63, 131.78, 128.29, 127.96,
127.42, 127.24, 126.91, 126.10, 122.51, 121.70, 117.49, 108.52,
108.15, 59.85, 28.63, 14.60 ppm; HRESIMS C23H19O4, calcd:
359.1283, found: 359.1280.
6-Phenylprotoflavone 1’-O-propyl ether (71): Light-brown solid;
yield: 46.4%; NP-HPLC purity: 99.39%, 1H NMR (500 MHz, CDCl3)
d=8.37 (1H, d, J=1.40 Hz), 7.88 (1H, dd, J=8.85 Hz, 1.60 Hz), 7.62
(2H, d, J=7.50 Hz), 7.44 (2H, br t, J=6.45 Hz), 7.40 (1H, d, J=
8.70 Hz), 7.36 (1H, t, J=7.20 Hz), 6.84 (1H, s), 6.83 (2H, d, J=
9.95 Hz), 6.54 (2H, d, J=9.90 Hz), 3.48 (2H, t, J=6.25 Hz), 1.67 (2H,
sex, J=6.95 Hz), 0.98 ppm (3H, t, J=7.35 Hz); 13C NMR (50 MHz,
CDCl3) d=145.07, 131.64, 128.27, 127.94, 127.42, 126.95, 126.10,
122.51, 117.47, 108.50, 65.77, 30.89, 28.63, 22.27, 9.51 ppm; HRE-
SIMS C24H21O4, calcd: 373.1440, found: 373.1438.
6-Phenylprotoflavone 1’-O-isopropyl ether (72): Light-brown
solid; yield: 42.2%; NP-HPLC purity: 99.30%, 1H NMR (500 MHz,
CDCl3) d=8.37 (1H, br s), 7.88 (1H, dd, J=8.10 Hz, 1.25 Hz), 7.62
(2H, d, J=7.85 Hz), 7.45 (2H, br t, J=6.65 Hz), 7.41 (1H, d, J=
8.85 Hz), 7.37 (1H, t, J=7.00 Hz), 6.82 (2H, d, J=9.95 Hz), 6.77 (1H,
s), 6.57 (2H, d, J=9.90 Hz), 3,89 ppm (1H, sext, J=6.25 Hz);
13C NMR (50 MHz, CDCl3) d=145.44, 138.05, 132.61, 128.30, 127.96,
127.44, 127.24, 126.91, 126.10, 122.51, 121.70, 117.47, 108.62,
108.26, 97.24, 67.81, 28.63, 23.62 ppm; HRESIMS C24H21O4, calcd:
373.1440, found: 373.1439.
6-Phenylprotoflavone 1’-O-butyl ether (73): Light-brown solid;
yield: 50.1%; NP-HPLC purity: 95.4%; 1H NMR (200 MHz, CDCl3) d=
8.40 (1H, d, J=1.50 Hz), 7.89 (1H, dd, J=9.02 Hz, 2.00 Hz), 7.64 (2H,
d, J=8.00 Hz), 7.47 (2H, br t, J=6.60 Hz), 7.41 (1H, d, J=8.20 Hz),
7.39 (1H, t, J=7.00 Hz), 6.81 (1H, s), 6.56 (2H, d, J=10.00 Hz), 6.39
(2H, d, J=9.80 Hz), 3.54 (2H, t, J=5.80 Hz), 1.68–1.36 (4H, m),
0.95 ppm (3H, t, J=7.20 Hz); 13C NMR (50 MHz, CDCl3) d=145.01,
138.03, 132.63, 128.27, 127.96, 127.42, 127.24, 126.91, 126.10, 122.52,
121.72, 117.47, 108.52, 108.15, 63.89, 31.01, 28.63, 18.20 ppm; HRE-
SIMS C25H23O4, calcd: 387.1596, found: 387.1593.
Cell lines
L5178 mouse T-cell lymphoma cell line (ECACC cat. no. 87111908,
US FDA, Silver Spring, MD, USA), and its sub-cell line L5178B1, de-
rived from L5178 by transfection with pHa MDR1/A retrovirus,[26]
were cultured in McCoy’s 5A media supplemented with inactivated
horse serum. L5178B1 cell line was selected by culturing the infect-
ed cells with colchicine (60 mgL@1, Sigma). Breast cancer cell lines
MCF7 and its sub-cell line obtained by adaptation to doxorubicin,
MCF7Dox
[27] were cultured in EMEM media supplemented with non-
essential amino acids, Na-pyruvate (1 mm) and inactivated fetal
bovine serum (FBS, 10%; MCF7Dox was cultured in presence of dox-
orubicin (1 mm) each third passage). All above cell lines were cul-
tured at 37 8C and 5% CO2 ; all media contained Nystatin, l-gluta-
mine (2 mm), penicillin (100U) and streptomycin (0.1 mg), pur-
chased from Sigma. MES-SA human uterine sarcoma cell line and
the doxorubicin selected MES-SA/Dx5 were obtained from ATCC.
The human cervix carcinoma cell line KB-3-1 and its vinblastine se-
lected derivative KB-V1 were a kind gift from Dr. Michael M. Gottes-
man (US National Institutes of Health). A431 and the retrovirally
transduced A431B1 and A431G2 are human skin-derived, epidermoid
carcinoma cells were kind gifts from Dr. K. N8met. MES-SA, KB-3-1,
A431 and their derivative cell lines were maintained in DMEM com-
pleted with FBS (10%), glutamine (5 mm) and penicillin and strep-
tomycin 50 UmL@1, (Life Technologies).
Cytotoxicity assays
In the case of the mouse lymphoma cell lines L5178 and L5178B1,
2V104 cells per well were cultured in 96-wells microplates with dif-
ferent concentrations of the tested compound, in McCoy’s 5A
media, at 37 8C and 5% CO2, for 24 h. With respect to MCF7 and
MCF7Dox, 1V10
4 cells per well were seeded overnight (o/n) and
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serial dilutions of the compounds were added the following day
and incubated for 48 h. In all cases, after the incubation time, MTT
(10%) was added to each well and incubated for 4 h, when
sodium dodecyl-sulfate (SDS, 100 mm of 10%) dissolved in HCl
(0.01m) was added to each well. Results were read after o/n incu-
bation. Fifty per cent inhibitory concentrations (IC50) were calculat-
ed using nonlinear regression curve fitting of log (inhibitor) versus
normalized response with a variable slope and least squares (ordi-
nary) fit of GraphPad Prism 5 software, for three independent sam-
ples. In the case of A431 cell lines, MES-SA cell lines, KB-3-1 and
KB-V1 cell lines, 5V103 cells per well were cultured and incubated
o/n in 96-well microplates. Serially diluted drugs were then added,
and plates were incubated for additional 72 h. Cytotoxicity was
measured by Presto Blue cell viability reagent (Invitrogen) in a final
dilution of 5%.
FACS measurements
Calcein accumulation assay was performed as described earlier.[21]
Briefly, 250000 cells per tube were pre-incubated for 5 minutes in
the presence of verapamil (20 mm) or the test protoflavone com-
pounds. Calcein AM was added at a final concentration of 250 nm
and incubated for an additional 10 minutes. Samples were then
washed with ice-cold PBS and were kept on ice until measured by
an Attune Acoustic Focusing Cytometer.
Supporting information available
Cytotoxicity data on the studied cancer cell line pairs and corre-
sponding selectivity ratios, as well as data of the calcein accumula-
tion assay are presented as Tables S1–S4, and correlation of IC50
values on the L5178B1, MCF-7 and MCF-7Dox cell lines with those on
the L5178 cells as Figure S1.
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